<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Mol Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Mol Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Molecular Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1662-5099</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">37008787</article-id><article-id pub-id-type="pmc">10064073</article-id><article-id pub-id-type="doi">10.3389/fnmol.2023.1123955</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reden&#x00161;ek Trampu&#x0017e;</surname><given-names>Sara</given-names></name><xref rid="fn0001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/386614/overview"/></contrib><contrib contrib-type="author"><name><surname>Vogrinc</surname><given-names>David</given-names></name><xref rid="fn0001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1219824/overview"/></contrib><contrib contrib-type="author"><name><surname>Gori&#x0010d;ar</surname><given-names>Katja</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/1245162/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dol&#x0017e;an</surname><given-names>Vita</given-names></name><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/21502/overview"/></contrib></contrib-group><aff><institution>Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana</institution>, <addr-line>Ljubljana</addr-line>, <country>Slovenia</country></aff><author-notes><fn id="fn0002" fn-type="edited-by"><p>Edited by: Michael Maes, Chulalongkorn University, Thailand</p></fn><fn id="fn0003" fn-type="edited-by"><p>Reviewed by: Sy Duong-Quy, Lam Dong Medical College, Vietnam; Christian Barbato, National Research Council, Italy</p></fn><corresp id="c001">*Correspondence: Vita Dol&#x0017e;an, <email>vita.dolzan@mf.uni-lj.si</email></corresp><fn id="fn0001" fn-type="equal"><p><sup>&#x02020;</sup>These authors have contributed equally to this work and share first authorship</p></fn><fn id="fn0004" fn-type="other"><p>This article was submitted to Brain Disease Mechanisms, a section of the journal Frontiers in Molecular Neuroscience</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>3</month><year>2023</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>16</volume><elocation-id>1123955</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Reden&#x00161;ek Trampu&#x0017e;, Vogrinc, Gori&#x0010d;ar and Dol&#x0017e;an.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Reden&#x00161;ek Trampu&#x0017e;, Vogrinc, Gori&#x0010d;ar and Dol&#x0017e;an</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Development and worsening of most common neurodegenerative diseases, such as Alzheimer&#x02019;s disease, Parkinson&#x02019;s disease, and multiple sclerosis, have been associated with COVID-19 However, the mechanisms associated with neurological symptoms in COVID-19 patients and neurodegenerative sequelae are not clear. The interplay between gene expression and metabolite production in CNS is driven by miRNAs. These small non-coding molecules are dysregulated in most common neurodegenerative diseases and COVID-19.</p></sec><sec><title>Methods</title><p>We have performed a thorough literature screening and database mining to search for shared miRNA landscapes of SARS-CoV-2 infection and neurodegeneration. Differentially expressed miRNAs in COVID-19 patients were searched using PubMed, while differentially expressed miRNAs in patients with five most common neurodegenerative diseases (Alzheimer&#x02019;s disease, Parkinson&#x02019;s disease, Huntington&#x02019;s disease, amyotrophic lateral sclerosis, and multiple sclerosis) were searched using the Human microRNA Disease Database. Target genes of the overlapping miRNAs, identified with the miRTarBase, were used for the pathway enrichment analysis performed with Kyoto Encyclopedia of Genes and Genomes and Reactome.</p></sec><sec><title>Results</title><p>In total, 98 common miRNAs were found. Additionally, two of them (hsa-miR-34a and hsa-miR-132) were highlighted as promising biomarkers of neurodegeneration, as they are dysregulated in all five most common neurodegenerative diseases and COVID-19. Additionally, hsa-miR-155 was upregulated in four COVID-19 studies and found to be dysregulated in neurodegeneration processes as well. Screening for miRNA targets identified 746 unique genes with strong evidence for interaction. Target enrichment analysis highlighted most significant KEGG and Reactome pathways being involved in signaling, cancer, transcription and infection. However, the more specific identified pathways confirmed neuroinflammation as being the most important shared feature.</p></sec><sec><title>Discussion</title><p>Our pathway based approach has identified overlapping miRNAs in COVID-19 and neurodegenerative diseases that may have a valuable potential for neurodegeneration prediction in COVID-19 patients. Additionally, identified miRNAs can be further explored as potential drug targets or agents to modify signaling in shared pathways.</p><p>
<fig position="float" id="fig4"><label>Graphical Abstract</label><caption><p>Shared miRNA molecules among the five investigated neurodegenerative diseases and COVID-19 were identified. The two overlapping miRNAs, hsa-miR-34a and has-miR-132, present potential biomarkers of neurodegenerative sequelae after COVID-19. Furthermore, 98 common miRNAs between all five neurodegenerative diseases together and COVID-19 were identified. A KEGG and Reactome pathway enrichment analyses was performed on the list of shared miRNA target genes and finally top 20 pathways were evaluated for their potential for identification of new drug targets. A common feature of identified overlapping miRNAs and pathways is neuroinflammation. AD, Alzheimer&#x02019;s disease; ALS, amyotrophic lateral sclerosis; COVID-19, coronavirus disease 2019; HD, Huntington&#x02019;s disease; KEGG, Kyoto Encyclopedia of Genes and Genomes; MS, multiple sclerosis; PD, Parkinson&#x02019;s disease.</p></caption><graphic xlink:href="fnmol-16-1123955-g004" position="float"/></fig>
</p></sec></abstract><kwd-group><kwd>COVID-19</kwd><kwd>neurodegeneration</kwd><kwd>neuroinflammation</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Parkinson&#x02019;s disease</kwd><kwd>miRNA</kwd><kwd>biomarker</kwd></kwd-group><funding-group><award-group><funding-source id="cn1"><institution-wrap><institution>Slovenian Research Agency (ARRS)</institution><institution-id institution-id-type="doi">10.13039/501100004329</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn1">P1-0170</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="262"/><page-count count="24"/><word-count count="19718"/></counts></article-meta></front><body><sec sec-type="intro" id="sec5"><label>1.</label><title>Introduction</title><p>Increasing evidence suggests that neurological deficits may develop due to infection with SARS-CoV-2 in a substantial proportion of patients (<xref rid="ref94" ref-type="bibr">Heneka et al., 2020</xref>). These deficits may manifest acutely and sub-acutely, as well as within the long COVID-19 pathology, and are often referred to as neuro-COVID-19 (<xref rid="ref37" ref-type="bibr">Chiappelli, 2020</xref>). About 36% of cases develop neurological symptoms, such as headache, nausea, anosmia, ageusia, myalgia/fatigue, confusion, disorientation, and vomiting (<xref rid="ref107" ref-type="bibr">Jarrahi et al., 2020</xref>), of which 25% can be attributed to the direct involvement of the central nervous system (CNS; <xref rid="ref149" ref-type="bibr">Mao et al., 2020</xref>). SARS-CoV-2 infection causes neurodegeneration (<xref rid="ref51" ref-type="bibr">De Felice et al., 2020</xref>; <xref rid="ref93" ref-type="bibr">Hascup and Hascup, 2020</xref>; <xref rid="ref137" ref-type="bibr">Lippi et al., 2020</xref>; <xref rid="ref114" ref-type="bibr">Karuppan et al., 2021</xref>). The exact mechanism of how this is initiated is not known. One of the common features shared between neurodegeneration and COVID-19 is age. Age is the major risk factor for neurodegenerative diseases, while at the same time, older patients present with more severe symptoms and prolonged course of COVID-19 (<xref rid="ref233" ref-type="bibr">Verkhratsky et al., 2020</xref>).</p><p>There are several explanations, how SARS-CoV-2 virus could contribute to neurodegeneration. The virus can directly invade the brain <italic>via</italic> the olfactory bulb, retrograde axonal transport from peripheral nerve endings, <italic>via</italic> hematogenous or lymphatic routes, and across the blood&#x02013;brain barrier (<xref rid="ref57" ref-type="bibr">Dolatshahi et al., 2021</xref>; <xref rid="ref119" ref-type="bibr">Krasemann et al., 2022</xref>). Infection of the neurons combined with peripheral leukocyte activation results in the upregulation of pro-inflammatory cytokines, leading to neurodegenerative changes related to neuroinflammation (<xref rid="ref233" ref-type="bibr">Verkhratsky et al., 2020</xref>; <xref rid="ref57" ref-type="bibr">Dolatshahi et al., 2021</xref>; <xref rid="ref90" ref-type="bibr">Haidar et al., 2021</xref>; <xref rid="ref194" ref-type="bibr">Rosen et al., 2021</xref>). In severe cases, systemic inflammation can cause acute brain damage associated with psychiatric symptoms and cognitive impairment which is indicative of neurodegeneration (<xref rid="ref233" ref-type="bibr">Verkhratsky et al., 2020</xref>). Furthermore, acute respiratory distress syndrome and sepsis often seen in COVID-19 induce hypoxemia and hypoperfusion, leading to oxidative stress and neurodegeneration (<xref rid="ref233" ref-type="bibr">Verkhratsky et al., 2020</xref>; <xref rid="ref57" ref-type="bibr">Dolatshahi et al., 2021</xref>; <xref rid="ref90" ref-type="bibr">Haidar et al., 2021</xref>; <xref rid="ref194" ref-type="bibr">Rosen et al., 2021</xref>). All of the above implies that SARS-CoV-2 is capable of entering the CNS and causing neurodegeneration.</p><p>The prevalence of neurodegenerative disorders is increasing, mostly due to extensions in lifespan, but nowadays COVID-19 may be a contributing factor as well. Several neurodegenerative diseases such as Alzheimer&#x02019;s disease (AD), Parkinson&#x02019;s disease (PD), and multiple sclerosis (MS) have already been associated with COVID-19, both in terms of development and in terms of worse disease prognosis (<xref rid="ref70" ref-type="bibr">Ferini-Strambi and Salsone, 2021</xref>; <xref rid="ref98" ref-type="bibr">Hu et al., 2021</xref>). Although information about the link between Huntington&#x02019;s disease (HD) or amyotrophic lateral sclerosis (ALS) and COVID-19 is still scarce, some reports indicating that the virus affects the disease diagnosis, prognosis and patient care, have been published (<xref rid="ref98" ref-type="bibr">Hu et al., 2021</xref>; <xref rid="ref126" ref-type="bibr">Li and Bedlack, 2021</xref>; <xref rid="ref232" ref-type="bibr">Vavougios, 2021</xref>). Long before COVID-19 pandemics, it was reported that antibodies against coronaviruses can be found in the cerebrospinal fluid of PD patients (<xref rid="ref69" ref-type="bibr">Fazzini et al., 1992</xref>). Coronaviruses can enter the brain through the nasal cavity causing anosmia or hyposmia (<xref rid="ref8" ref-type="bibr">Antonini et al., 2020</xref>). The latter is one of the main prodromal features of PD and the &#x003b1;-synuclein deposition in the olfactory bulb, among other locations, is one of the main pathological hallmarks (<xref rid="ref112" ref-type="bibr">Kalia and Lang, 2015</xref>; <xref rid="ref70" ref-type="bibr">Ferini-Strambi and Salsone, 2021</xref>), which indicates a strong association between PD and COVID-19. Furthermore, some COVID-19 patients develop cognitive deficits after the primary infection, indicating, that there might be a link between COVID-19 infection and dementia pathogenesis (<xref rid="ref251" ref-type="bibr">Ye et al., 2020</xref>; <xref rid="ref60" ref-type="bibr">Douaud et al., 2022</xref>). MS may also occur in association with COVID-19 infection as there were case reports published reporting the MS-like demyelination after the SARS-CoV-2 infection (<xref rid="ref105" ref-type="bibr">Ismail and Salama, 2022</xref>).</p><p>Relation between COVID-19 and neurodegeneration has been shown in clinical setting observing a simultaneous or sequential development of COVID-19 and neurodegeneration, but perturbations on molecular level have been detected as well. A proteome study described the interactions of SARS-CoV-2 proteins with human proteins from several aging-related pathways, such as vesicle trafficking (NSP6, NSP7, NSP10, NSP13, NSP15, ORF3A, E, and ORF8), lipid modifications (Spike), RNA processing and regulation (NSP8, N), ubiquitin ligases (ORF10), and mitochondrial activity (NSP4, NSP8, and ORF9C; <xref rid="ref85" ref-type="bibr">Gordon et al., 2020</xref>; <xref rid="ref137" ref-type="bibr">Lippi et al., 2020</xref>). Moreover, infections with RNA viruses, also SARS-CoV-2 in particular, were already associated with increased production of &#x003b1;-synuclein (<xref rid="ref22" ref-type="bibr">Bouali-Benazzouz and Benazzouz, 2021</xref>; <xref rid="ref194" ref-type="bibr">Rosen et al., 2021</xref>) and amyloid-&#x003b2; (A&#x003b2;; <xref rid="ref220" ref-type="bibr">Sun et al., 2021</xref>). It has also been shown, that SARS-CoV-2 infection could facilitate the spread of aggregated tau protein <italic>via</italic> the secretion of extracellular vesicles (<xref rid="ref139" ref-type="bibr">Liu et al., 2021</xref>). Furthermore, it was reported that the transcriptomic perturbations are shared between COVID-19 and HD (<xref rid="ref232" ref-type="bibr">Vavougios, 2021</xref>). These findings indicate a strong molecular link between SARS-CoV-2 and neurodegeneration, in particular PD and AD as two most common neurodegenerative disorders.</p><p>MiRNAs are the most studied small noncoding RNAs. They are functional RNA molecules of approximately 22 nucleotides in length that lack protein-coding properties (<xref rid="ref212" ref-type="bibr">Siedlecki-Wullich et al., 2021</xref>). MiRNAs regulate gene expression on the post-transcriptional level. They bind to the 3-untranslated region of the target messenger RNA (mRNA) by a partially complementary sequence. A single miRNA can bind hundreds of different mRNA targets. The most frequent consequence of miRNA binding is translational repression (<xref rid="ref73" ref-type="bibr">Filipowicz et al., 2008</xref>; <xref rid="ref50" ref-type="bibr">Daugaard and Hansen, 2017</xref>).</p><p>Many miRNAs have already been associated with neurodegenerative pathologies and COVID-19 as biomarkers of the disease, either in terms of susceptibility or disease prognosis (<xref rid="ref184" ref-type="bibr">Ravnik-Glava&#x0010d; and Glava&#x0010d;, 2020</xref>; <xref rid="ref58" ref-type="bibr">Dong and Cong, 2021</xref>; <xref rid="ref121" ref-type="bibr">Kuo et al., 2021</xref>; <xref rid="ref174" ref-type="bibr">Pietrasik et al., 2021</xref>; <xref rid="ref212" ref-type="bibr">Siedlecki-Wullich et al., 2021</xref>; <xref rid="ref171" ref-type="bibr">Paul et al., 2022</xref>), but the overlap between COVID-19 and neurodegenerative diseases is unknown. Several miRNAs were repeatedly dysregulated in various neurodegenerative diseases, which functionally overlap in pathways related to A&#x003b2; genesis, regulation of AMPA receptor subunits, autophagy homeostasis, apoptosis, microglial activation, blood brain barrier maintenance, and neurogenesis (<xref rid="ref111" ref-type="bibr">Ju&#x0017a;wik et al., 2019</xref>). miRNAs involved in immune system regulation, more specifically NF-&#x003ba;B signaling, were frequently observed to be dysregulated in neurodegeneration processes as well (<xref rid="ref111" ref-type="bibr">Ju&#x0017a;wik et al., 2019</xref>). Such miRNAs involved in both immune and nervous system are called neurimmiRs and have already been suggested as potential drug targets in neurodegeneration (<xref rid="ref219" ref-type="bibr">Soreq and Wolf, 2011</xref>). Additionally, altered miRNA levels have been associated with the formation of reactive oxygen species (ROS) and mitochondrial dysfunction, which are both hallmarks of neurodegenerative diseases (<xref rid="ref29" ref-type="bibr">Catanesi et al., 2020</xref>). Similarly, many miRNAs are dysregulated in COVID-19 as it was shown that SARS-CoV-2 infection significantly alters plasma miRNA composition from an early stage of COVID-19 (<xref rid="ref71" ref-type="bibr">Fern&#x000e1;ndez-Pato et al., 2022</xref>).</p><p>Given the fact that miRNA seem to have a great potential as biomarkers of both neurodegenerative diseases and COVID-19, and that COVID-19 patients can present with clinical signs of neurodegeneration, we explored, whether miRNA could provide information on the shared pathways between neurodegeneration and COVID-19 pathogenesis. We have first performed a thorough literature screening and database mining to find the shared miRNA landscapes of SARS-CoV-2 and neurodegeneration. Next, we also identified shared pathways between the two pathologies and listed top miRNA candidates that could potentially serve as biomarkers of neurodegeneration in COVID-19 patients or as valuable treatment targets or agents to halt or prevent neurodegeneration in COVID-19 patients.</p></sec><sec sec-type="methods" id="sec6"><label>2.</label><title>Methods</title><p>Literature screening approach and database mining were combined in search for common miRNAs shared between neurodegenerative diseases and COVID-19. Pathway enrichment analysis was performed on the list of target genes of the overlapping miRNAs.</p><p>First, differentially expressed miRNA in body fluids or tissues of COVID-19 patients were extracted from literature. PubMed search for original articles was performed using broad keyword string &#x0201c;COVID-19 and miRNA&#x0201d; to include as many relevant articles as possible. PRISMA flow diagram is presented in the <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref> (Additional file 1). Following exclusion criteria, articles evaluating viral miRNAs, <italic>in vitro</italic> or <italic>in silico</italic> analyses, articles overlapping with other diseases and review articles, commentaries, preprints or articles not in English were not included in further analysis. The two authors (SRT and DV) independently reviewed all abstracts and articles to evaluate whether the study would meet criteria for inclusion in the analysis. If there was any disagreement between the authors about the inclusion of a study, a third author (KG) reviewed the study and made a decision. Furthermore, a list of miRNAs, associated with five most prevalent neurodegenerative diseases (AD, PD, MS, ALS and HD), was obtained from The Human microRNA Disease Database (HMDD, accessed on 21 .1. 2022; <xref rid="ref103" ref-type="bibr">Huang et al., 2019</xref>). As HMDD reports only mature miRNAs (without specifying the-5p or-3p forms), we used mature miRNA forms also for the COVID-19 miRNA list. Key miRNAs were defined as miRNAs associated with both COVID-19 and all five neurodegenerative diseases and miRNAs deregulated in at least four COVID-19 studies with the same direction of effect (up-or down-regulated) and also deregulated in at least one neurodegenerative disease.</p><p>In search for overlapping miRNAs (<xref rid="fig1" ref-type="fig">Figure 1</xref>), a list of unique COVID-19 miRNAs was then compared to a list of unique neurodegenerative diseases&#x02019; miRNAs. Venn diagrams were generated using Bioinformatics &#x00026; Evolutionary Genomics group webtool (accessed on 12. 2. 2022; <xref rid="ref229" ref-type="bibr">UGent, n.d.</xref>).</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Workflow of the analysis. Integration of literature and database screening to identify miRNAs associated with neurodegenerative diseases and COVID-19, their target genes and pathway enrichment analysis. AD, Alzheimer&#x02019;s disease; ALS, amyotrophic lateral sclerosis; COVID-19, coronavirus disease 2019; HD, Huntington&#x02019;s disease; HMDD, Human microRNA Disease Database; MS, multiple sclerosis; PD, Parkinson&#x02019;s disease.</p></caption><graphic xlink:href="fnmol-16-1123955-g001" position="float"/></fig><p>Next, common miRNAs were screened for gene targets using miRTarBase (accessed on 11. 2. 2022; <xref rid="ref101" ref-type="bibr">Huang et al., 2020</xref>). We chose miRTarBase due to the fact that it allows to screen for experimentally confirmed target genes with all three strong evidence generating methods (Reporter assay, Western blot and qPCR). Only those target genes were included in further analysis (<xref rid="fig1" ref-type="fig">Figure 1</xref>). However, we were not able to differentiate whether a miRNA is up-or down-regulated in COVID-19 patients, because different studies reported different directions of effect.</p><p>A list of identified unique target genes served as a template for pathway enrichment analysis (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Two different approaches were used; Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment was performed using The Database for Annotation, Visualization and Integrated Discovery (DAVID) Functional annotation tool (accessed on 11. 2. 2022; <xref rid="ref99" ref-type="bibr">Huang da et al., 2009a</xref>,<xref rid="ref100" ref-type="bibr">b</xref>), while Reactome (accessed on 12. 2. 2022) was used for Reactome pathway enrichment (<xref rid="ref211" ref-type="bibr">Sidiropoulos et al., 2017</xref>). <italic>p</italic>-values below 0.05 after false discovery rate (FDR) adjustment were considered statistically significant. Top twenty significant pathways were visualized with bubble plots using GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA).</p></sec><sec sec-type="results" id="sec7"><label>3.</label><title>Results</title><p>Between March 2020 and 20<sup>th</sup> January 2022, 29 articles investigated miRNA expression changes associated with SARS-CoV-2 infection, mostly in plasma, serum or blood cell samples. In total, 226 unique miRNAs were identified, while 62 (27.4%) miRNAs were reported in more than one study. In patients with COVID-19, 108 (47.8%) miRNAs were down-regulated, 78 (34.5%) were up-regulated and 40 (17.7%) were either up- or down-regulated (<xref rid="tab1" ref-type="table">Table 1</xref>). The most commonly identified miRNAs were hsa-miR-142, which was down-regulated in 3 studies (5p form) and up-regulated in 2 studies (3p form in 1 study, 5p in 1), hsa-miR-144, which was down-regulated in 3 studies (3p form in 2 studies, 5p in 1) and up-regulated in 2 studies (both 3p and 5p form in 1 study), and hsa-miR-320a, which was down-regulated in 2 studies (3p form in 1 study) and up-regulated in 3 studies (3p form in 2 studies). Additionally, hsa-miR-155 was upregulated in 4 studies. Among these, only hsa-miR-155 showed consistent direction of effect across the studies, which is why we highlighted it as a key miRNA.</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>miRNAs with changed expression levels in COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Reference</th><th align="left" valign="top" rowspan="2" colspan="1">Disease stages</th><th align="left" valign="top" rowspan="2" colspan="1">Sample type</th><th align="center" valign="top" colspan="6" rowspan="1">miRNA</th></tr><tr><th align="center" valign="top" colspan="3" rowspan="1">Up-regulated miRNA</th><th align="center" valign="top" colspan="3" rowspan="1">Down-regulated miRNA</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3" colspan="1">
<xref rid="ref223" ref-type="bibr">Tang et al. (2020)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Moderate vs.severe vs. HC</td><td align="left" valign="middle" rowspan="3" colspan="1">Red blood cell depleted whole blood</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3605-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-486-3p</td><td align="center" valign="middle" rowspan="3" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-146a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-31-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-342-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-15b-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-18a-3p</td><td rowspan="1" colspan="1">hsa-miR-486-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-21-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-99a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-181a-2-3p</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-142-5p</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref130" ref-type="bibr">Li et al. (2020)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Mild + moderate vs. HC</td><td align="left" valign="middle" rowspan="1" colspan="1">Peripheral blood</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-16-2-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6501-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-618</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-183-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-627-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-144-3p</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref30" ref-type="bibr">Centa et al. (2020)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Severe vs. HC</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic>Post mortem</italic> lung biopsies</td><td rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-26a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-29b-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-34a-5p</td></tr><tr><td align="left" valign="middle" rowspan="13" colspan="1">
<xref rid="ref259" ref-type="bibr">Zheng et al. (2020)</xref>
</td><td align="left" valign="middle" rowspan="13" colspan="1">Mild vs. moderate vs. severe</td><td align="left" valign="middle" rowspan="13" colspan="1">Peripheral blood mononuclear cells</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-100-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-26a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-374b-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-let-7e-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-328-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-671-3p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-10395-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-26b-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-374c-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-10399-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3615</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6772-3p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-138-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-32-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-376a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-10a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-423-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6842-3p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-144-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-338-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4,772-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-11400</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-423-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-7706</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-144-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-33a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4,791</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-1249-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-424-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-7977</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-181c-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-708-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-514a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-1273&#x02009;h-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4646-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-877-5p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-186-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-95-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-548w</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-130b-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4659b-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-92b-3p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6718-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-374a-5p</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-139-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-484</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-941-1</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-139-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-490-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-941-2</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-145-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-5193</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-941-3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-1908-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-584-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-941-4</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-195-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-625-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-941-5</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-320a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6501-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-942-5p</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref198" ref-type="bibr">Sabbatinelli et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tocilizumab treatment vs. HC</td><td align="left" valign="middle" rowspan="1" colspan="1">Serum</td><td align="center" valign="middle" colspan="3" rowspan="1">/</td><td align="center" valign="middle" colspan="3" rowspan="1">hsa-miR-146a-5p</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">
<xref rid="ref78" ref-type="bibr">Garg et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="2" colspan="1">Mechanically ventilated vs. HC</td><td align="left" valign="middle" rowspan="2" colspan="1">Serum</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-21</td><td align="center" valign="middle" rowspan="2" colspan="1">hsa-miR-208a</td><td align="center" valign="middle" rowspan="2" colspan="1">hsa-miR-499</td><td rowspan="2" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-155</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref12" ref-type="bibr">Bagheri-Hosseinabadi et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">COVID-19 vs. HC</td><td align="left" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" colspan="3" rowspan="1">/</td><td align="center" valign="middle" colspan="3" rowspan="1">hsa-miR-10b</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">
<xref rid="ref158" ref-type="bibr">Mi et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Osteogenicdifferentiation in COVID-19</td><td align="left" valign="middle" rowspan="2" colspan="1">Blood</td><td align="center" valign="middle" colspan="3" rowspan="2">hsa-miR-4485</td><td align="center" valign="middle" colspan="3" rowspan="2">/</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref249" ref-type="bibr">Yang et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">COVID-19 vs. HC</td><td align="left" valign="middle" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" colspan="3" rowspan="1">/</td><td align="center" valign="middle" colspan="3" rowspan="1">hsa-miR-451a</td></tr><tr><td align="left" valign="middle" rowspan="5" colspan="1">
<xref rid="ref128" ref-type="bibr">Li et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="5" colspan="1">COVID-19 vs. HC</td><td align="left" valign="middle" rowspan="5" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-16-2-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6501-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-505-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-183-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4521</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-18b-5p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-5695</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4659a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-125b-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-627-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-144-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3613-5p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-10399-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-142-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-618</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-21-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-199a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-29b-2-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-20a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-199b-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-32-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-18a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-96-5p</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref115" ref-type="bibr">Keikha et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="1" colspan="1">COVID-19 (grades 1&#x02013;5) vs. HC</td><td align="left" valign="middle" rowspan="1" colspan="1">Blood</td><td rowspan="1" colspan="1">hsa-miR-17-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-31-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-29a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-126-3p</td></tr><tr><td align="left" valign="middle" rowspan="5" colspan="1">
<xref rid="ref203" ref-type="bibr">Saulle et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="5" colspan="1">COVID-19 pregnant vs. uninfected pregnant women</td><td align="left" valign="middle" rowspan="5" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-21</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-29c</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-155</td><td rowspan="5" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-23b</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-98</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-150</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-28</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-326</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-146</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-29a</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-17</td><td rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-92</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-223</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="10" colspan="1">
<xref rid="ref65" ref-type="bibr">Farr et al. (2021)</xref>
</td><td align="left" valign="middle" rowspan="10" colspan="1">Moderate vs. severe vs. HC</td><td align="left" valign="middle" rowspan="10" colspan="1">Plasma</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-let-7e-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-1290</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4,742-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-766-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-5189-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3913-5p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-195-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-103a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-423-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-651-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6772-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-28-5p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-let-7a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-320b</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-320c</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-1275</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-145-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-551b-3p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-483-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-193a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-142-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3198</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-4772-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-let-7i-3p</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3125</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-206</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-92a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-627-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-1226-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-548&#x02009;k</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-30a-5p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-148a-3p</td><td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-6,721-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4662a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-589-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-18a-3p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-27a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-let-7f-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3684</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-210-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-491-5p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-2116-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-576-5p</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3617-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3115</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-6503-3p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-31-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-197-3p</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-500b-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-769-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3065-3p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-664b-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-873-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-150-5p</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">
<xref rid="ref59" ref-type="bibr">Donyavi et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="2" colspan="1">Acute and post-acute COVID-19 vs. HC</td><td align="left" valign="top" rowspan="2" colspan="1">Peripheral blood mononuclear cells</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-let-7b-3p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-146a-3p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-29a-3p</td><td rowspan="2" colspan="1">/</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-155-5p</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="7" colspan="1">
<xref rid="ref86" ref-type="bibr">Grehl et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="7" colspan="1">Mild vs. severe</td><td align="left" valign="top" rowspan="7" colspan="1">Plasma</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4,516</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320b</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-629-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-454-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-126-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-342-3p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-362-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320c</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-1180-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-625-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-146b-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-193b-3p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-548&#x02009;k</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320d</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-502-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-30b-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-30c-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-190a-5p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-185-5p</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-192-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-144-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-365b-3p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-451a</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-29a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-122b-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-197-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-363-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-122-3p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-29b-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-99a-5p</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="9" colspan="1">
<xref rid="ref35" ref-type="bibr">Chen et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="9" colspan="1">COVID-19 vs. HC</td><td align="left" valign="top" rowspan="9" colspan="1">Peripheral blood mononuclear cells</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-485-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3614-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-let-7d-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-548ar-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-514a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4521</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-1226-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-103a-2-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-652-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-125b-1-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-615-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-142-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-196a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-184</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-1291</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-34c-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-192-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4772-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-708-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-499a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-141-3p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-27a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-340-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3615</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-642a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-581</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-659-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-509-3-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3194-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-132-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-511-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4473</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref175" ref-type="bibr">Pimenta et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Non-hospitalized vs. hospitalized vs. severe vs. HC</td><td align="left" valign="top" rowspan="1" colspan="1">Saliva</td><td align="center" valign="top" colspan="3" rowspan="1">hsa-miR-200c-3p</td><td align="center" valign="top" colspan="3" rowspan="1">/</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">
<xref rid="ref52" ref-type="bibr">de Gonzalo-Calvo et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Hospitalized vs. ICUsurvivor vs. non-survivor</td><td align="left" valign="top" rowspan="2" colspan="1">Plasma</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-27a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-148a-3p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-491-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-16-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-150-5p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-486-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-27b-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-199a-5p</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-92a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-451a</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">
<xref rid="ref68" ref-type="bibr">Fayyad-Kazan et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="2" colspan="1">COVID-19 vs.HC</td><td align="left" valign="top" rowspan="2" colspan="1">Plasma</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-15a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-19b-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-92a-3p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-17-5p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-142-5p</td><td rowspan="2" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-19a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-23a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320a</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref153" ref-type="bibr">McDonald et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19 vs. HC</td><td align="left" valign="top" rowspan="1" colspan="1">Serum and urine</td><td align="center" valign="top" colspan="3" rowspan="1">hsa-miR-2392</td><td align="center" valign="top" colspan="3" rowspan="1">/</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref91" ref-type="bibr">Haroun et al. (2022)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19 vs. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Plasma</td><td align="center" valign="top" colspan="3" rowspan="1">hsa-miR-155</td><td align="center" valign="top" colspan="3" rowspan="1">/</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref1" ref-type="bibr">Agwa et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Mild vs. severe vs. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Blood</td><td align="center" valign="top" colspan="3" rowspan="1">hsa-miR-4257</td><td align="center" valign="top" colspan="3" rowspan="1">/</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">
<xref rid="ref89" ref-type="bibr">Gutmann et al. (2022)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Non-severe vs. severe vs. HC</td><td align="center" valign="top" rowspan="2" colspan="1">Plasma</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-122</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-133a</td><td rowspan="2" colspan="1"/><td align="center" valign="top" colspan="3" rowspan="2">/</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mild vs. moderate vs. severe</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref241" ref-type="bibr">Wu et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19 vs. HC</td><td align="left" valign="top" rowspan="1" colspan="1">Plasma</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-29b-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-1246</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-186-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-15a-5p</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">
<xref rid="ref156" ref-type="bibr">Meidert et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="2" colspan="1">Mild vs. severe vs. HC</td><td align="left" valign="top" rowspan="2" colspan="1">Extracellular vesicles from serum</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-193a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-197-3p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-206</td><td align="center" valign="top" colspan="3" rowspan="2">/</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-let-7&#x02009;g-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-20a-5p</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">
<xref rid="ref3" ref-type="bibr">Akula and Bolin (2022)</xref>
</td><td align="left" valign="top" rowspan="2" colspan="1">Moderate+severe vs. HC</td><td align="left" valign="top" rowspan="2" colspan="1">Blood</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3197</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-4690-5p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-1915-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-150-5p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-122-5p</td><td align="left" valign="top" rowspan="2" colspan="1">hsa-miR-494-3p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3652</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-375</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref140" ref-type="bibr">Liu et al. (2022)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Moderate vs. severe vs. HC</td><td align="left" valign="top" rowspan="1" colspan="1">Blood</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-130a-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-29b-3p</td><td rowspan="1" colspan="1"/><td align="center" valign="top" colspan="3" rowspan="1">/</td></tr><tr><td align="left" valign="top" rowspan="7" colspan="1">
<xref rid="ref169" ref-type="bibr">Parray et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="7" colspan="1">Asymptomatic vs. mild vs. severe</td><td align="left" valign="top" rowspan="7" colspan="1">Blood</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-1246</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3609</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3651</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3180-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-6805-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-8073</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4532</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-199a-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-1273&#x02009;h-3p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-let-7i-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-98-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4750-5p</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-145-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-139-5p</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-4632-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3185</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-6075</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3651</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-145-5p</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-6861-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-572</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-let-7i-5p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-6802-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-371b-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-1231</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-5196-5p</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-3180</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-885-3p</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-92b-5p</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref62" ref-type="bibr">Duecker et al. (2021)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Moderate vs. severe vs. HC</td><td align="left" valign="top" rowspan="1" colspan="1">Blood</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">/</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320a</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320b</td><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-320c</td></tr></tbody></table></table-wrap><p>Based on HMDD data, 114 unique miRNAs were dysregulated in AD, 88 miRNAs in MS, 83 miRNAs in PD, 20 miRNAs in HD and 63 miRNAs in ALS (Additional file 2: <xref rid="SM2" ref-type="supplementary-material">Supplementary Tables S1a</xref>&#x02013;<xref rid="SM2" ref-type="supplementary-material">e</xref>). The overlap of miRNAs between different neurodegenerative diseases is presented in a Venn diagram in <xref rid="fig2" ref-type="fig">Figure 2A</xref>. In total, 234 unique miRNAs were associated with at least one neurodegenerative disease.</p><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Venn diagrams. Venn diagrams showing the overlap between miRNAs associated with different neurodegenerative diseases separately <bold>(A)</bold> and the overlap between miRNAs associated with at least one neurodegenerative disease and COVID-19 <bold>(B)</bold>. AD, Alzheimer&#x02019;s disease; ALS, amyotrophic lateral sclerosis; COVID-19, coronavirus disease 2019; HD, Huntington&#x02019;s disease; MS, multiple sclerosis; PD, Parkinson&#x02019;s disease.</p></caption><graphic xlink:href="fnmol-16-1123955-g002" position="float"/></fig><p>Comparison between neurodegenerative disease- and COVID-19-related miRNAs identified 98 common differentially expressed miRNAs (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). Only two miRNAs, hsa-miR-34a and hsa-miR-132, were associated with all five investigated neurodegenerative disorders. Consequently, we added these two miRNAs to the list of key miRNAs.</p><p>For all 98 common miRNAs associated with at least one neurodegenerative disease and COVID-19, experimentally confirmed target genes were extracted from miRTarBase (Additional file 3: <xref rid="SM3" ref-type="supplementary-material">Supplementary Table S2</xref>). Screening resulted in 746 unique target genes confirmed with strong evidence. Target genes for common miRNAs hsa-miR-34a (47 genes) and hsa-miR-132 (10 genes) are presented in <xref rid="tab2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Experimentally confirmed hsa-miR-34a and hsa-miR-132 target genes, associated with five investigated neurodegenerative disorders and COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">miRNA</th><th align="left" valign="top" rowspan="1" colspan="1">Target genes</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-34a-3p</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic>LDHA</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-34a-5p</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>AXL</italic>, <italic>BCL2</italic>, <italic>BIRC5</italic>, <italic>CCND1</italic>, <italic>CD44</italic>, <italic>CDK4</italic>, <italic>CDK6</italic>, <italic>DLL1</italic>, <italic>E2F3</italic>, <italic>FOSL1</italic>, <italic>FUT8</italic>, <italic>GALNT7</italic>, <italic>GAS1</italic>, <italic>GFRA3</italic>, <italic>HDAC1</italic>, <italic>HNF4A</italic>, <italic>HOTAIR</italic>, <italic>INHBB</italic>, <italic>JAG1</italic>, <italic>KDM4A</italic>, <italic>KLF12</italic>, <italic>KLF4</italic>, <italic>L1CAM</italic>, <italic>MAGEA12</italic>, <italic>MAGEA2</italic>, <italic>MAGEA3</italic>, <italic>MAGEA6</italic>, <italic>MAP2K1</italic>, <italic>MAP3K9</italic>, <italic>MDM4</italic>, <italic>MET</italic>, <italic>MYB</italic>, <italic>MYC</italic>, <italic>MYCN</italic>, <italic>NOTCH1</italic>, <italic>NOTCH2</italic>, <italic>PDGFRA</italic>, <italic>PDGFRB</italic>, <italic>POU5F1</italic>, <italic>RICTOR</italic>, <italic>SIRT1</italic>, <italic>SIRT7</italic>, <italic>SNAI1</italic>, <italic>SRC</italic>, <italic>TCF7</italic>, <italic>YY1</italic></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hsa-miR-132-3p</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>ARHGAP32</italic>, <italic>CDKN1A</italic>, <italic>EGFR</italic>, <italic>FOXO1</italic>, <italic>HBEGF</italic>, <italic>HN1</italic>, <italic>KLHL11</italic>, <italic>MAPK1</italic>, <italic>RAF1</italic>, <italic>RB1</italic></td></tr></tbody></table></table-wrap><p>Pathway enrichment analysis revealed, that miRNA target genes were significantly enriched (FDR&#x02009;&#x0003c;&#x02009;0.05) in 112 KEGG pathways (Additional file 4: <xref rid="SM4" ref-type="supplementary-material">Supplementary Table S3a</xref>) and 608 Reactome pathways (Additional file 4: <xref rid="SM4" ref-type="supplementary-material">Supplementary Table S3b</xref>). Among the 20 most significant KEGG pathways (<xref rid="fig3" ref-type="fig">Figure 3A</xref>), 11 (55%) were associated with cancer, 6 (30%) with signaling, and 2 (10%) with infections and 1 (5%) with other biological processes. Among the 20 most significant Reactome pathways (<xref rid="fig3" ref-type="fig">Figure 3B</xref>), 10 (50%) were associated with signaling, 4 (20%) with transcription, 3 (15%) with immune system, 1 (5%) with cancer and 2 (10%) with other biological processes. Their association with neuroinflammation, neuroprotection, and cell senescence is further described in the discussion.</p><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Bubble plots showing most significant enriched pathways. Bubble plots showing 20 most significant enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) <bold>(A)</bold> and Reactome <bold>(B)</bold> pathways. The x-axis represents the percentage of 746 miRNA target genes associated with a specific pathway represented on the y-axis. Size of the bubble represents the number of genes associated with a specific pathway and the color of the bubble reflects the <italic>p</italic>-value after false discovery rate (FDR) adjustment.</p></caption><graphic xlink:href="fnmol-16-1123955-g003" position="float"/></fig></sec><sec sec-type="discussions" id="sec8"><label>4.</label><title>Discussion</title><p>Among miRNAs, dysregulated in patients with COVID-19, almost half were previously associated with at least one neurodegenerative disease. Three key miRNAs were identified as potential biomarkers of neurodegeneration in COVID-19: hsa-miR-34a, hsa-miR-132, and hsa-miR-155. Target genes of all shared miRNAs were enriched in several pathways associated with neurodegeneration, including neuroinflammation promoting signaling pathways, pathways related to neuroinflammation mediators, neuroprotective pathways, and cellular senescence pathway.</p><sec id="sec9"><label>4.1.</label><title>Interplay between COVID-19 and neurodegenerative diseases: Key miRNAs</title><p>Downregulation of hsa-miR-34a and hsa-miR-132 was associated with COVID-19 and all five investigated neurodegenerative diseases, whereas hsa-miR-155 was found to be upregulated in at least four COVID-19 expression studies and was also associated with several of the investigated neurodegenerative diseases. All listed COVID-19-related miRNAs were identified in human studies, whereas not all neurodegeneration-related miRNAs were identified in human samples. According to the HMDD, all three listed key miRNAs were confirmed to be associated with AD and MS in human studies. Furthermore, hsa-miR-132 was associated with PD and ALS in patients, while hsa-miR-34a was associated with ALS in patients as well. Other associations between one of the key miRNAs and a certain neurodegenerative disease were identified in other types of models. Expression of miRNA is spatiotemporally specific. It is affected by various factors, such as age, comorbidities, SARS-CoV-2 strain, COVID-19 vaccination status, time from SARS-CoV-2 infection, etc.(<xref rid="ref151" ref-type="bibr">Mart&#x000ed;nez-Fleta et al., 2021</xref>) The choice of tissue for expression analysis and also taking into account the listed factors is thus important. However, considering that COVID-19 may induce a systemic inflammatory response, which relates to disease severity (<xref rid="ref72" ref-type="bibr">Ferrara and Vitiello, 2021</xref>; <xref rid="ref182" ref-type="bibr">Ramos-Casals et al., 2021</xref>), choosing plasma as a readily accessible reservoir of miRNAs originating from different tissues is reasonable. In body fluids, signaling molecules, including miRNAs, have been found as extracellular vesicle&#x02019;s (EV) cargo. Understanding the role of EVs as important mediators of intercellular communication, their potential in miRNA associated gene regulation of COVID-19 patients has previously been studied (<xref rid="ref156" ref-type="bibr">Meidert et al., 2021</xref>; <xref rid="ref237" ref-type="bibr">Wang Y. et al., 2021</xref>). Furthermore, another potential mechanism for EV transfer to periphery can be associated with the breakdown of blood brain barrier, an overlapping feature of many neurodegenerative diseases and COVID-19 as well (<xref rid="ref96" ref-type="bibr">Hill, 2019</xref>; <xref rid="ref20" ref-type="bibr">Bonetto et al., 2022</xref>). To date, different miRNAs of neuronal origin have been found in blood plasma samples (<xref rid="ref206" ref-type="bibr">Serpente et al., 2020</xref>; <xref rid="ref20" ref-type="bibr">Bonetto et al., 2022</xref>).</p><p>Of note, we considered the identified miRNAs only as potential biomarkers of a certain phenotype, e.g., neurodegeneration in COVID-19 patients, meaning that they do not necessarily have to be of neuronal origin. However, we speculate that COVID-19 has similar effects on miRNA expression in both CNS and peripheral tissues. Studies on patients or human cell lines are emphasized with the hsa- prefix, whereas no prefix indicates different animal models.</p><sec id="sec10"><label>4.1.1.</label><title>Hsa-miR-34a</title><p>Hsa-miR-34a is one of the miRNAs associated with COVID-19 and all neurodegenerative diseases investigated in our study. Relative expression of hsa-miR-34a-5p was significantly down-regulated in <italic>post mortem</italic> lung biopsies of patients that died of COVID-19 compared to controls that died of other causes (<xref rid="ref30" ref-type="bibr">Centa et al., 2020</xref>).</p><p>Dysregulation of miR-34a was observed in ALS (<xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>; <xref rid="ref192" ref-type="bibr">Rizzuti et al., 2018</xref>; <xref rid="ref118" ref-type="bibr">Kmetzsch et al., 2021</xref>), PD (<xref rid="ref87" ref-type="bibr">Grossi et al., 2021</xref>; <xref rid="ref248" ref-type="bibr">Yang et al., 2022</xref>), AD (<xref rid="ref202" ref-type="bibr">Sarkar et al., 2016</xref>; <xref rid="ref44" ref-type="bibr">Cos&#x000ed;n-Tom&#x000e1;s et al., 2017</xref>; <xref rid="ref133" ref-type="bibr">Li et al., 2020</xref>; <xref rid="ref127" ref-type="bibr">Li and Cai, 2021</xref>), HD (<xref rid="ref191" ref-type="bibr">Reynolds et al., 2018</xref>), and MS (<xref rid="ref80" ref-type="bibr">Ghadiri et al., 2018</xref>). In AD, hsa-miR-34a was overexpressed in specific brain regions (<xref rid="ref202" ref-type="bibr">Sarkar et al., 2016</xref>; <xref rid="ref127" ref-type="bibr">Li and Cai, 2021</xref>), but downregulated in blood or CSF (<xref rid="ref44" ref-type="bibr">Cos&#x000ed;n-Tom&#x000e1;s et al., 2017</xref>; <xref rid="ref133" ref-type="bibr">Li et al., 2020</xref>). In PD, this miRNA was enriched in small EVs and associated with disease duration and clinical characteristics (<xref rid="ref87" ref-type="bibr">Grossi et al., 2021</xref>). Hsa-miR-34a was also associated with disease relapse in MS (<xref rid="ref80" ref-type="bibr">Ghadiri et al., 2018</xref>) and disease duration in ALS (<xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>), while upregulation in CSF of ALS patients was also observed (<xref rid="ref193" ref-type="bibr">Rizzuti et al., 2022</xref>). It was proposed as a negative regulator of <italic>C9ORF72</italic>, a gene commonly mutated in familial ALS (<xref rid="ref118" ref-type="bibr">Kmetzsch et al., 2021</xref>).</p><p>MiR-34a regulates multiple processes that can contribute to neurodegeneration, such as neuronal differentiation, synaptic plasticity, neurogenesis, cognitive function, brain aging and energy metabolism (<xref rid="ref56" ref-type="bibr">Dickson et al., 2013</xref>; <xref rid="ref202" ref-type="bibr">Sarkar et al., 2016</xref>; <xref rid="ref87" ref-type="bibr">Grossi et al., 2021</xref>). Specifically, miR-34a can regulate several genes important for AD pathogenesis, such as sirtuin 1 (<italic>SIRT1</italic>), ADAM metallopeptidase domain 10 (<italic>ADAM10</italic>), triggering receptor expressed on myeloid cells 2 (<italic>TREM2</italic>), and BCL2 apoptosis regulator (<italic>BCL2</italic>; <xref rid="ref164" ref-type="bibr">Nunomura and Perry, 2020</xref>). Hsa-miR-34a can directly decrease expression of tau protein, a key player in AD pathogenesis (<xref rid="ref56" ref-type="bibr">Dickson et al., 2013</xref>). Studies have also shown that miR-34a affects A&#x003b2; induced neurotoxicity through regulation of beta-secretase 1 (<italic>BACE1</italic>; <xref rid="ref133" ref-type="bibr">Li et al., 2020</xref>), as well as amyloid precursor protein (<italic>APP</italic>) processing and cognitive defects (<xref rid="ref44" ref-type="bibr">Cos&#x000ed;n-Tom&#x000e1;s et al., 2017</xref>; <xref rid="ref109" ref-type="bibr">Jian et al., 2017</xref>). Additionally, this miRNA was implicated in signaling pathways associated with endothelial dysfunction (<xref rid="ref30" ref-type="bibr">Centa et al., 2020</xref>) and acting as a tumor suppressor in different types of cancer (<xref rid="ref132" ref-type="bibr">Li et al., 2021</xref>). It may also affect ROS production and response to oxidative stress by regulating expression of nuclear factor erythroid 2-related factor 2 (NRF2, encoded by <italic>NFE2L2</italic>) and other genes (<xref rid="ref42" ref-type="bibr">Climent et al., 2020</xref>; <xref rid="ref164" ref-type="bibr">Nunomura and Perry, 2020</xref>). NRF2 is a transcription factor that plays an important role in various neurodegenerative diseases and was even proposed as a potential therapeutic target (<xref rid="ref199" ref-type="bibr">Saha et al., 2021</xref>).</p><p>Hsa-miR-34a target genes are overrepresented in pathways associated with viral infectious diseases (<xref rid="ref30" ref-type="bibr">Centa et al., 2020</xref>) and hsa-miR-34a was dysregulated in response to infection with various viruses, especially human papilloma virus and influenza A virus, where hsa-miR-34a was downregulated [reviewed in (<xref rid="ref145" ref-type="bibr">Lv et al., 2019</xref>)]. Several hsa-miR-34a target genes have already been found to be differentially expressed in RNA sequencing studies or protein levels were found to be changed due to SARS-CoV-2 infection, such as <italic>AXL</italic> (<xref rid="ref236" ref-type="bibr">Wang S. et al., 2021</xref>) <italic>BCL2</italic> (<xref rid="ref143" ref-type="bibr">Lorente et al., 2021</xref>), <italic>LDHA</italic> (<xref rid="ref245" ref-type="bibr">Xu et al., 2021</xref>), <italic>SIRT1</italic> (<xref rid="ref21" ref-type="bibr">Bordoni et al., 2021</xref>; <xref rid="ref49" ref-type="bibr">D'Agnillo et al., 2021</xref>), <italic>PDGFRB</italic> (<xref rid="ref113" ref-type="bibr">Kamp et al., 2022</xref>), and <italic>MYC</italic> (<xref rid="ref14" ref-type="bibr">Banaganapalli et al., 2021</xref>). AXL is involved in virus cell entry (<xref rid="ref162" ref-type="bibr">Naik et al., 2022</xref>), while BCL2 is an apoptosis inhibitor (<xref rid="ref250" ref-type="bibr">Yapasert et al., 2021</xref>). LDHA was upregulated on both mRNA (<xref rid="ref176" ref-type="bibr">Qi et al., 2021</xref>) and protein (<xref rid="ref245" ref-type="bibr">Xu et al., 2021</xref>) levels and shows potential as a distinguishing biomarker between healthy and SARS-CoV-2 infected people. Expression of SIRT1 mRNA, a major inhibitor of oxidative stress&#x02013;induced senescence in lung endothelial and epithelial cells, was shown to be decreased in COVID-19 (<xref rid="ref49" ref-type="bibr">D'Agnillo et al., 2021</xref>). All this shows, that downregulation of hsa-miR-34a in COVID-19 may be one of the factors contributing to the neurological complications in COVID-19 patients.</p></sec><sec id="sec11"><label>4.1.2.</label><title>Hsa-miR-132</title><p>Second miRNA associated with all investigated neurodegenerative diseases and COVID-19 was hsa-miR-132. Relative expression of hsa-miR-132-5p was significantly down-regulated in peripheral mononuclear cell samples of COVID-19 patients (<xref rid="ref35" ref-type="bibr">Chen et al., 2021</xref>).</p><p>MiR-132 is one of the most commonly dysregulated miRNAs in neurodegenerative diseases, particularly in AD (<xref rid="ref124" ref-type="bibr">Lau et al., 2013</xref>; <xref rid="ref146" ref-type="bibr">Ma et al., 2014</xref>; <xref rid="ref214" ref-type="bibr">Smith et al., 2015</xref>; <xref rid="ref200" ref-type="bibr">Salta and De Strooper, 2017</xref>; <xref rid="ref63" ref-type="bibr">El Fatimy et al., 2018</xref>; <xref rid="ref31" ref-type="bibr">Cha et al., 2019</xref>; <xref rid="ref127" ref-type="bibr">Li and Cai, 2021</xref>), but also PD (<xref rid="ref6" ref-type="bibr">Alieva et al., 2015</xref>; <xref rid="ref247" ref-type="bibr">Yang et al., 2019</xref>; <xref rid="ref210" ref-type="bibr">Shu et al., 2020</xref>; <xref rid="ref83" ref-type="bibr">Gong et al., 2022</xref>), ALS (<xref rid="ref234" ref-type="bibr">Vrabec et al., 2018</xref>), MS (<xref rid="ref159" ref-type="bibr">Miyazaki et al., 2014</xref>; <xref rid="ref187" ref-type="bibr">Regev et al., 2017</xref>) and HD (<xref rid="ref77" ref-type="bibr">Fukuoka et al., 2018</xref>). Hsa-miR-132 was consistently downregulated in AD, both in the brain and blood, including in neurally-derived EVs (<xref rid="ref122" ref-type="bibr">Lagos et al., 2010</xref>; <xref rid="ref214" ref-type="bibr">Smith et al., 2015</xref>; <xref rid="ref173" ref-type="bibr">Pichler et al., 2017</xref>; <xref rid="ref31" ref-type="bibr">Cha et al., 2019</xref>; <xref rid="ref224" ref-type="bibr">Tasker et al., 2021</xref>). On the other hand, upregulation of hsa-miR-132 was mostly observed in PD, where it was also associated with disease duration and severity and dopaminergic neurodegeneration (<xref rid="ref247" ref-type="bibr">Yang et al., 2019</xref>; <xref rid="ref83" ref-type="bibr">Gong et al., 2022</xref>), but downregulation was also reported by some studies (<xref rid="ref210" ref-type="bibr">Shu et al., 2020</xref>). Additionally, increased expression was observed after treatment (<xref rid="ref6" ref-type="bibr">Alieva et al., 2015</xref>).</p><p>MiR-132 is one of the most abundant brain miRNAs and it was proposed as a neuroprotective miRNA that regulates multiple processes in the nervous system, such as neuronal differentiation, survival and migration, synaptic plasticity, neurogenesis, apoptosis, memory, and cognitive function (<xref rid="ref214" ref-type="bibr">Smith et al., 2015</xref>; <xref rid="ref200" ref-type="bibr">Salta and De Strooper, 2017</xref>; <xref rid="ref255" ref-type="bibr">Zhang and Bian, 2021</xref>). Several miR-132 target genes were identified and many are also important in neurodegenerative diseases, such as <italic>BACE1</italic>, <italic>APP</italic>, <italic>SIRT1</italic>, acetylcholinesterase (<italic>ACHE</italic>), nitric oxide synthase 1 (<italic>NOS1</italic>), and mitogen-activated protein kinase (<italic>MAPK1</italic>; <xref rid="ref159" ref-type="bibr">Miyazaki et al., 2014</xref>; <xref rid="ref200" ref-type="bibr">Salta and De Strooper, 2017</xref>; <xref rid="ref179" ref-type="bibr">Qu et al., 2021</xref>; <xref rid="ref255" ref-type="bibr">Zhang and Bian, 2021</xref>). It also regulates signaling pathways, e.g., PI3K/AKT and Notch signaling (<xref rid="ref200" ref-type="bibr">Salta and De Strooper, 2017</xref>). Importantly, miR-132 exerts a neuroprotective effect against A&#x003b2; and glutamate excitotoxicity and decreases tau protein expression (<xref rid="ref56" ref-type="bibr">Dickson et al., 2013</xref>; <xref rid="ref214" ref-type="bibr">Smith et al., 2015</xref>; <xref rid="ref63" ref-type="bibr">El Fatimy et al., 2018</xref>; <xref rid="ref231" ref-type="bibr">Varma-Doyle et al., 2021</xref>). Several studies have proposed that it could be a potential treatment target as restoration of miR-132 expression improved cognitive function in animal models (<xref rid="ref179" ref-type="bibr">Qu et al., 2021</xref>; <xref rid="ref255" ref-type="bibr">Zhang and Bian, 2021</xref>).</p><p>Hsa-miR-132 also plays an important role in inflammation and immune response (<xref rid="ref200" ref-type="bibr">Salta and De Strooper, 2017</xref>). It represses inflammatory cytokines such as interleukin 1&#x003b2; (IL-1&#x003b2;), tumor necrosis factor (TNF&#x003b1;) and interleukin 6 (IL-6; <xref rid="ref200" ref-type="bibr">Salta and De Strooper, 2017</xref>; <xref rid="ref83" ref-type="bibr">Gong et al., 2022</xref>). Expression of hsa-miR-132 target genes, such as <italic>MAPK1</italic> (<xref rid="ref92" ref-type="bibr">Hasankhani et al., 2021</xref>), and <italic>FOXO1</italic> (<xref rid="ref108" ref-type="bibr">Jha et al., 2020</xref>), involved in neuroinflammation or neuroprotective mechanisms, respectively, was found to be affected in COVID-19 patients. Interestingly, hsa-miR-132 was previously upregulated in response to infection with different viruses (<xref rid="ref122" ref-type="bibr">Lagos et al., 2010</xref>; <xref rid="ref25" ref-type="bibr">Buggele et al., 2012</xref>; <xref rid="ref177" ref-type="bibr">Qi et al., 2014</xref>; <xref rid="ref256" ref-type="bibr">Zhang et al., 2019</xref>). Its upregulation decreased interferon response through interferon regulatory factor 1 (<italic>IRF1</italic>) in H1N1 influenza A virus infection (<xref rid="ref256" ref-type="bibr">Zhang et al., 2019</xref>). It was speculated that miR-132 might be associated with nervous system complications such as encephalitis after varicella-zoster virus infection (<xref rid="ref177" ref-type="bibr">Qi et al., 2014</xref>). All these findings suggest that hsa-miR-132 might be a factor contributing to neurological complications in COVID-19 patients and should be investigated in further studies.</p></sec><sec id="sec12"><label>4.1.3.</label><title>Hsa-miR-155</title><p>Hsa-miR-155 expression was upregulated in blood or peripheral blood mononuclear cells in four studies on COVID-19 (<xref rid="ref59" ref-type="bibr">Donyavi et al., 2021</xref>; <xref rid="ref78" ref-type="bibr">Garg et al., 2021</xref>; <xref rid="ref203" ref-type="bibr">Saulle et al., 2021</xref>; <xref rid="ref91" ref-type="bibr">Haroun et al., 2022</xref>). It was upregulated in both acute and post-acute patients and was further upregulated in severe or critically ill COVID-19 patients or patients that died (<xref rid="ref59" ref-type="bibr">Donyavi et al., 2021</xref>; <xref rid="ref78" ref-type="bibr">Garg et al., 2021</xref>; <xref rid="ref91" ref-type="bibr">Haroun et al., 2022</xref>). It could also differentiate between COVID-19 and influenza-associated acute respiratory distress syndrome (<xref rid="ref78" ref-type="bibr">Garg et al., 2021</xref>). Studies have therefore proposed hsa-miR-155 as a potential diagnostic biomarker for COVID-19 (<xref rid="ref59" ref-type="bibr">Donyavi et al., 2021</xref>; <xref rid="ref78" ref-type="bibr">Garg et al., 2021</xref>; <xref rid="ref91" ref-type="bibr">Haroun et al., 2022</xref>).</p><p>Previous studies have found that miR-155 plays an important role in several neurodegenerative diseases: ALS (<xref rid="ref47" ref-type="bibr">Cunha et al., 2018</xref>; <xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>), PD (<xref rid="ref27" ref-type="bibr">Caggiu et al., 2018</xref>; <xref rid="ref166" ref-type="bibr">Oliveira et al., 2020</xref>), AD (<xref rid="ref216" ref-type="bibr">Song and Lee, 2015</xref>; <xref rid="ref134" ref-type="bibr">Liang and Wang, 2021</xref>), and MS (<xref rid="ref142" ref-type="bibr">Lopez-Ramirez et al., 2014</xref>; <xref rid="ref146" ref-type="bibr">Ma et al., 2014</xref>; <xref rid="ref163" ref-type="bibr">Niwald et al., 2017</xref>; <xref rid="ref187" ref-type="bibr">Regev et al., 2017</xref>; <xref rid="ref16" ref-type="bibr">Baulina et al., 2018</xref>). It was consistently upregulated in most studies on AD, PD, MS, ALS (<xref rid="ref111" ref-type="bibr">Ju&#x0017a;wik et al., 2019</xref>; <xref rid="ref213" ref-type="bibr">Slota and Booth, 2019</xref>; <xref rid="ref261" ref-type="bibr">Zingale et al., 2021</xref>). In PD, hsa-miR-155 was increased in patients treated with L-dopa and was proposed as a disease progression biomarker and potential treatment target (<xref rid="ref27" ref-type="bibr">Caggiu et al., 2018</xref>). It was also associated with patients&#x02019; clinical characteristics in ALS and MS (<xref rid="ref163" ref-type="bibr">Niwald et al., 2017</xref>; <xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>). Recently, in CSF EVs, miR-155 was specifically expressed in patients with encephalitis (<xref rid="ref228" ref-type="bibr">Torii et al., 2022</xref>).</p><p>MiR-155 is widely regarded as a central proinflammatory miRNA in CNS, associated with numerous processes of neuroinflammation, including polarization, neurotoxicity, activation of different cell types and cell plasticity (<xref rid="ref142" ref-type="bibr">Lopez-Ramirez et al., 2014</xref>; <xref rid="ref79" ref-type="bibr">Gaudet et al., 2018</xref>; <xref rid="ref213" ref-type="bibr">Slota and Booth, 2019</xref>). It could serve as a negative regulator of blood&#x02013;brain barrier permeability through regulation of cell&#x02013;cell complex molecules and focal adhesion components (<xref rid="ref142" ref-type="bibr">Lopez-Ramirez et al., 2014</xref>). In different models, it was proposed as a potential therapeutic target in neurodegenerative diseases (<xref rid="ref183" ref-type="bibr">Rastegar-Moghaddam et al., 2022</xref>).</p><p>Hsa-miR-155 is also abundantly expressed in B-cells, T-cells, macrophages, and dendritic cells (<xref rid="ref254" ref-type="bibr">Zeng et al., 2015</xref>). It regulates T lymphocyte function: development and activation, cell&#x02013;cell interaction and interferon &#x003b3; signaling (<xref rid="ref216" ref-type="bibr">Song and Lee, 2015</xref>). MiR-155 is associated with proinflammatory cytokines IL-1&#x003b2;, TNF&#x003b1; and IL-6, as well as auto-immunity (<xref rid="ref142" ref-type="bibr">Lopez-Ramirez et al., 2014</xref>; <xref rid="ref226" ref-type="bibr">Thome et al., 2016</xref>; <xref rid="ref183" ref-type="bibr">Rastegar-Moghaddam et al., 2022</xref>). It was also associated with immune system disorders, infection, and cancer (<xref rid="ref42" ref-type="bibr">Climent et al., 2020</xref>).</p><p>Among most important targets of hsa-miR-155 are suppressor of cytokine signaling 1 (<italic>SOCS1</italic>), inositol polyphosphate-5-phosphatase D (<italic>SHIP1</italic>), and interleukin 13 receptor subunit alpha 1 (<italic>IL13RA1</italic>; <xref rid="ref79" ref-type="bibr">Gaudet et al., 2018</xref>; <xref rid="ref213" ref-type="bibr">Slota and Booth, 2019</xref>; <xref rid="ref261" ref-type="bibr">Zingale et al., 2021</xref>). In AD, it was also associated with AD-related genes such as phosphatidylinositol binding clathrin assembly protein (<italic>PICALM</italic>) and sortilin related receptor 1 (<italic>SORL1</italic>), and production of A&#x003b2; (<xref rid="ref183" ref-type="bibr">Rastegar-Moghaddam et al., 2022</xref>). In PD, it was associated with Parkinsonism associated deglycase (<italic>DJ-1</italic>) and inflammatory responses induced by &#x003b1;-synuclein (<xref rid="ref226" ref-type="bibr">Thome et al., 2016</xref>; <xref rid="ref183" ref-type="bibr">Rastegar-Moghaddam et al., 2022</xref>). It was also associated with response to oxidative stress, NRF2 and inducible NO synthase (<xref rid="ref42" ref-type="bibr">Climent et al., 2020</xref>).</p><p>A lot of studies have shown that hsa-miR-155 plays a crucial role in response to microbial infections and is upregulated in response to various viruses [reviewed in (<xref rid="ref254" ref-type="bibr">Zeng et al., 2015</xref>; <xref rid="ref106" ref-type="bibr">Jafarzadeh et al., 2021</xref>)]. Hsa-miR-155 is involved in both adaptive and innate antiviral immune response and it affects both inflammatory response and anti-virus response, e.g., viral clearance and persistence (<xref rid="ref106" ref-type="bibr">Jafarzadeh et al., 2021</xref>). Hsa-miR-155 was also upregulated in viral infection of the CNS (<xref rid="ref213" ref-type="bibr">Slota and Booth, 2019</xref>; <xref rid="ref261" ref-type="bibr">Zingale et al., 2021</xref>). In coronavirus-induced neurologic disease model, miR-155 enhanced T cell trafficking to the CNS and was associated with host defence by regulating cytolytic activity and cytokine secretion (<xref rid="ref55" ref-type="bibr">Dickey et al., 2016</xref>). In COVID-19 it was suggested to be associated with the signature cytokine storm (<xref rid="ref59" ref-type="bibr">Donyavi et al., 2021</xref>). Importantly, this miRNA was associated with susceptibility to virus-induced neurologic disease such as encephalitis (<xref rid="ref55" ref-type="bibr">Dickey et al., 2016</xref>). All these findings provide ample support that hsa-miR-155 regulation might be an important factor contributing to neurological complications in COVID-19 patients and should be investigated in further studies.</p></sec><sec id="sec13"><label>4.1.4.</label><title>Other miRNAs</title><p>Additionally, three miRNAs (hsa-miR-142, hsa-miR-144, and hsa-miR-320a) were dysregulated in blood or peripheral blood mononuclear cells in five studies on COVID-19 (<xref rid="ref130" ref-type="bibr">Li et al., 2020</xref>; <xref rid="ref223" ref-type="bibr">Tang et al., 2020</xref>; <xref rid="ref259" ref-type="bibr">Zheng et al., 2020</xref>; <xref rid="ref35" ref-type="bibr">Chen et al., 2021</xref>; <xref rid="ref62" ref-type="bibr">Duecker et al., 2021</xref>; <xref rid="ref65" ref-type="bibr">Farr et al., 2021</xref>; <xref rid="ref68" ref-type="bibr">Fayyad-Kazan et al., 2021</xref>; <xref rid="ref86" ref-type="bibr">Grehl et al., 2021</xref>; <xref rid="ref128" ref-type="bibr">Li et al., 2021</xref>). Even though the reported direction of effect was not consistent among studies, further studies could provide more insight regarding the role of these miRNAs, as they were also often implicated in neurodegeneration.</p><p>MiR-142 downregulation promotes inflammatory processes and affects response to oxidative stress by regulating NRF2 expression (<xref rid="ref218" ref-type="bibr">S&#x000f8;rensen et al., 2016</xref>; <xref rid="ref187" ref-type="bibr">Regev et al., 2017</xref>; <xref rid="ref223" ref-type="bibr">Tang et al., 2020</xref>; <xref rid="ref231" ref-type="bibr">Varma-Doyle et al., 2021</xref>). It plays an important role in hematopoesis, inflammation, lung development, and response to viral infections (<xref rid="ref209" ref-type="bibr">Shrestha et al., 2017</xref>). Changes in hsa-miR-142 expression were reported in ALS (<xref rid="ref152" ref-type="bibr">Matamala et al., 2018</xref>), PD (<xref rid="ref138" ref-type="bibr">Liu et al., 2019</xref>; <xref rid="ref15" ref-type="bibr">Barbagallo et al., 2020</xref>), AD (<xref rid="ref120" ref-type="bibr">Kumar et al., 2013</xref>; <xref rid="ref218" ref-type="bibr">S&#x000f8;rensen et al., 2016</xref>; <xref rid="ref215" ref-type="bibr">Song and Kim, 2017</xref>), and especially in MS (<xref rid="ref146" ref-type="bibr">Ma et al., 2014</xref>; <xref rid="ref189" ref-type="bibr">Regev et al., 2016</xref>, <xref rid="ref187" ref-type="bibr">2017</xref>, <xref rid="ref188" ref-type="bibr">2018</xref>; <xref rid="ref148" ref-type="bibr">Mandolesi et al., 2017</xref>; <xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>; <xref rid="ref53" ref-type="bibr">De Vito et al., 2022</xref>). It was also associated with disease progression in MS and ALS (<xref rid="ref189" ref-type="bibr">Regev et al., 2016</xref>; <xref rid="ref148" ref-type="bibr">Mandolesi et al., 2017</xref>; <xref rid="ref187" ref-type="bibr">Regev et al., 2017</xref>; <xref rid="ref152" ref-type="bibr">Matamala et al., 2018</xref>; <xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>; <xref rid="ref188" ref-type="bibr">Regev et al., 2018</xref>; <xref rid="ref53" ref-type="bibr">De Vito et al., 2022</xref>).</p><p>MiR-144 plays an important role in cancer, regulating cell proliferation, migration, apoptosis and other signaling pathways (<xref rid="ref260" ref-type="bibr">Zhou et al., 2020</xref>). MiR-144 can also promote oxidative stress, as it regulates NRF2 in cooperation with hsa-miR-34a (<xref rid="ref42" ref-type="bibr">Climent et al., 2020</xref>). It was identified as a negative regulator of host response to RNA viruses in mice models (<xref rid="ref195" ref-type="bibr">Rosenberger et al., 2017</xref>). Hsa-miR-144 was dysregulated in ALS (<xref rid="ref135" ref-type="bibr">Liguori et al., 2018</xref>; <xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>), PD (<xref rid="ref244" ref-type="bibr">Xing et al., 2020</xref>; <xref rid="ref253" ref-type="bibr">Zago et al., 2022</xref>), AD (<xref rid="ref36" ref-type="bibr">Cheng et al., 2013</xref>), and MS (<xref rid="ref196" ref-type="bibr">Roshani et al., 2021</xref>).</p><p>MiR-320a affects multiple processes associated with neurodegeneration and has been proposed as an important regulator of blood&#x02013;brain barrier permeability (<xref rid="ref205" ref-type="bibr">Sepramaniam et al., 2010</xref>; <xref rid="ref11" ref-type="bibr">Aung et al., 2015</xref>). Altered hsa-miR-320a expression was observed especially in MS, where it was associated with disease relapse (<xref rid="ref11" ref-type="bibr">Aung et al., 2015</xref>; <xref rid="ref189" ref-type="bibr">Regev et al., 2016</xref>; <xref rid="ref188" ref-type="bibr">Regev et al., 2018</xref>), but also in ALS and AD (<xref rid="ref54" ref-type="bibr">Denk et al., 2018</xref>; <xref rid="ref180" ref-type="bibr">Raheja et al., 2018</xref>; <xref rid="ref222" ref-type="bibr">Tan et al., 2021</xref>). Interestingly, hsa-miR-320a was previously associated with adenoviral infection in lung cells (<xref rid="ref258" ref-type="bibr">Zhao et al., 2015</xref>) and downregulated in HIV-1 patients suffering from mild cognitive impairment (<xref rid="ref66" ref-type="bibr">Fatima et al., 2017</xref>).</p></sec></sec><sec id="sec14"><label>4.2.</label><title>Interplay between COVID-19 and neurodegenerative diseases: Key pathways</title><p>Our Reactome and KEGG pathway enrichment analyses highlighted some of the most significant pathways that could link COVID-19 and neurodegenerative diseases.</p><p>Overall, the most enriched pathways within the Reactome top 20 list belong to various signaling processes. Some of them are very broad and rather unspecific, such as &#x000bb;Diseases of signal transduction by growth factor receptors and second messengers&#x000ab;, &#x000bb;Signaling by receptor tyrosine kinases&#x000ab;, &#x000bb;Intracellular signaling by second messengers&#x000ab;, and &#x000bb;Signal transduction&#x000ab;. Additionally, three of the pathways are very general transcription-related pathways, such as &#x000bb;Generic transcription pathway&#x000ab;, &#x000bb;RNA Polymerase II transcription&#x000ab;, and &#x000bb;Gene expression (Transcription)&#x000ab;. Also the &#x000bb;Developmental biology&#x000ab; pathway according to the Reactome database (<xref rid="ref211" ref-type="bibr">Sidiropoulos et al., 2017</xref>) presents processes taking place long before COVID-19 and its neurological consequences occur and is thus not further discussed. More than half of the pathways identified with the KEGG pathway enrichment analysis are associated with cancer (&#x0201c;Pathways in cancer,&#x0201d; &#x0201c;MicroRNAs in cancer,&#x0201d; &#x0201c;Proteoglycans in cancer,&#x0201d; &#x0201c;Pancreatic cancer,&#x0201d; &#x0201c;Prostate cancer,&#x0201d; &#x0201c;Chronic myeloid leukemia,&#x0201d; &#x0201c;Colorectal cancer,&#x0201d; &#x0201c;Melanoma,&#x0201d; &#x0201c;Small cell lung cancer,&#x0201d; &#x0201c;Bladder cancer&#x0201d; and &#x0201c;Non-small cell lung cancer&#x0201d;). This can indicate a strong overlap between COVID-19 disease and cancer pathways and can also have implications for cancer treatment (<xref rid="ref262" ref-type="bibr">Zong et al., 2021</xref>). Additionally, two other pathways, &#x0201c;Focal adhesion&#x0201d; and &#x0201c;Signaling pathways regulating pluripotency of stem cells,&#x0201d; are very broad and unspecific and are thus not discussed in this paper.</p><p>However, several identified pathways show an important relationship between COVID-19 pathogenesis and neurodegeneration. A lot of these pathways indicate that neuroinflammation is the key shared process. Pivotal shared neuroinflammation promoting entities are pathways related to phosphatidyl-inositol-3-kinase (PI3K)/protein kinase B (AKT) signaling and mitogen-activated protein kinase (MAPK) signaling, whereas shared neuroprotective mechanisms belong to pathways related to the class O of forkhead box transcription factors (FOXO) signaling. Thus, these pathways present overlapping pathogenic processes and could serve as relevant drug targets for prevention of post-COVID-19 neurodegeneration. However, miRNAs found to be dysregulated in COVID-19 patients belonging to the same enriched pathway do not always present the same direction of effect. Thus, and also due to the fact that multiple miRNAs are involved in one pathway, it is not possible to state based on miRNA data whether the pathway is activated or inhibited in COVID-19.</p><sec id="sec15"><label>4.2.1.</label><title>Neuroinflammation promoting signaling pathways</title><p>Inflammation is a feature of both, neurodegeneration and COVID-19. It has been proposed that weak chronic activation of neuroinflammation signaling pathways causes neurodegeneration (<xref rid="ref40" ref-type="bibr">Chu et al., 2021</xref>; <xref rid="ref129" ref-type="bibr">Li et al., 2021</xref>), whereas strongly activated neuroinflammation often causes acute disease progression similar to COVID-19 (<xref rid="ref129" ref-type="bibr">Li et al., 2021</xref>). Furthermore, external inflammation, such as SARS-CoV-2 infection, and consequential immune signaling can both activate PI3K/AKT, MAPK, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#x003ba;B), NLR family pyrin domain containing 3 (NLRP3), and mammalian target of rapamycin (mTOR) signaling as the core inflammation pathways (<xref rid="ref129" ref-type="bibr">Li et al., 2021</xref>; <xref rid="ref95" ref-type="bibr">Hensley et al., 2022</xref>; <xref rid="ref116" ref-type="bibr">Khezri et al., 2022</xref>).</p><p>&#x000bb;PI3K/Akt signaling pathway in cancer&#x000ab; and &#x0201c;PI3K-Akt signaling pathway&#x0201d; were among the top enriched pathways in Reactome and KEGG top 20 lists, respectively. Under the umbrella of PI3K/AKT signaling we can also include &#x000bb;PIP3 activates AKT signaling&#x000ab; and &#x000bb;PI5P, PP2A and IER3 regulate PI3K/AKT signaling&#x000ab; pathways from Reactome analysis. The PI3K/AKT pathway is a key signaling cascade in cell biology and is highly involved in inflammation molecular functions. Activation of serine/threonine and tyrosine kinases through PI3K regulates different major cellular processes such as protein synthesis, apoptosis and cell proliferation (<xref rid="ref75" ref-type="bibr">Franke et al., 1997</xref>; <xref rid="ref116" ref-type="bibr">Khezri et al., 2022</xref>). Additionally, ROS response to SARS-CoV-2 spike in human bronchial and microvascular cells leads to activation of inflammation and apoptosis through PI3K/AKT pathway inhibition (<xref rid="ref131" ref-type="bibr">Li et al., 2021</xref>). PI3K/Akt signaling specifically is over-activated in COVID-19 patients and could affect SARS-CoV-2 entry and replication in the host cells by regulating the clathrin-mediated endocytosis and glycolysis (<xref rid="ref116" ref-type="bibr">Khezri et al., 2022</xref>). Thus, it also presents a potential drug target for COVID-19 treatment (<xref rid="ref67" ref-type="bibr">Fattahi et al., 2022</xref>). The role of PI3K/AKT signaling in neurogenesis has also been proposed. Beneficial effect on survival of newly formed neurons during exercise elucidates the role of PI3K/AKT in neurogenesis and synaptic plasticity in a rat model (<xref rid="ref24" ref-type="bibr">Bruel-Jungerman et al., 2009</xref>). Additionally, this pathway has already been associated with all five investigated neurodegenerative diseases (<xref rid="ref147" ref-type="bibr">Mammana et al., 2018</xref>; <xref rid="ref186" ref-type="bibr">Recabarren-Leiva and Alarc&#x000f3;n, 2018</xref>; <xref rid="ref40" ref-type="bibr">Chu et al., 2021</xref>). In the context of neurodegeneration, more specifically in AD, perturbations in PI3K/AKT pathway induce changes in action of fibrillary A&#x003b2;, insulin signaling, autophagy, oxidative stress defense, and neuroinflammation (<xref rid="ref185" ref-type="bibr">Razani et al., 2021</xref>). A rare familial mutation in <italic>PS1</italic> can affect presenilin-1 (PS-1), an upstream PI3K regulator, and promote AD pathology by inhibiting PI3K/AKT signaling (<xref rid="ref13" ref-type="bibr">Baki et al., 2004</xref>). Furthermore, phosphatase and tensin homolog (PTEN) induced PI3K/AKT pathway activation decreases endoplasmic reticulum stress response and apoptosis shown in an AD mouse model (<xref rid="ref46" ref-type="bibr">Cui et al., 2017</xref>). PI3K/AKT signaling plays a crucial role in oxidative mechanisms in PD. Downregulation of PI3K/AKT, caused by SHC-transforming protein 3 (SHC3) silencing in PD rats can promote oxidative stress injury, leading to motor abnormalities (<xref rid="ref84" ref-type="bibr">Gong et al., 2018</xref>). AKT-controlled inhibition of NAD(P)H dehydrogenase quinone 1 (NQO1), an important antioxidant system, aggravated PD pathogenesis in a rat model (<xref rid="ref144" ref-type="bibr">Luo et al., 2019</xref>). Given that PI3K/AKT is important in both COVID-19 and neurodegenerative diseases, modulation of this pathway in specific cell types could present a relevant option for treatment of neurodegenerative diseases (<xref rid="ref40" ref-type="bibr">Chu et al., 2021</xref>; <xref rid="ref185" ref-type="bibr">Razani et al., 2021</xref>) and could open a window of opportunity to avoid neurodegenerative sequelae of COVID-19.</p><p>The MAPK signaling within two identified Reactome pathways (&#x000bb;MAPK family signaling cascades&#x000ab; and &#x000bb;MAPK1/MAPK3 signaling&#x000ab;) and one KEGG pathway (&#x0201c;MAPK signaling pathway&#x0201d;) may act either as a positive or negative regulator of viral replication. MAPK signaling integrates diverse stimuli signals and elicits multiple cellular responses, including cellular proliferation, differentiation, development, inflammatory responses and apoptosis (<xref rid="ref257" ref-type="bibr">Zhang and Liu, 2002</xref>). The viral secretory proteins can trigger the extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation, which is one of the MAP kinases (<xref rid="ref160" ref-type="bibr">Mohanta et al., 2020</xref>). MAPK has been associated with viral entry mechanisms as well, since SARS-CoV-2 spike protein activates MAPK signaling through angiotensin II receptor type 1 (AT1) or transmembrane protease, serine 2 (TMPRSS2) upregulation (<xref rid="ref170" ref-type="bibr">Patra et al., 2020</xref>; <xref rid="ref41" ref-type="bibr">Cioccarelli et al., 2021</xref>). Furthermore, activation of the MAPK pathways due to SARS-CoV-2 infection contributes to higher cytokine levels and hyper-inflammatory responses (<xref rid="ref172" ref-type="bibr">Peter et al., 2020</xref>). On proteomic level, MAPK was enriched in SARS-CoV-2 associated myocarditis as well (<xref rid="ref238" ref-type="bibr">Weckbach et al., 2022</xref>). Similarly, MAP kinases, such as c-Jun N-terminal kinase (JNK), ERK1/2 and p38 are involved in creating the pro-inflammatory environment in age-related neurodegenerative diseases, which means that they support the cytokine release in neurodegenerative diseases as well. This uncontrolled release of cytokines may produce a self-perpetuating feedback loop enhancing inflammation and contributing to neuronal damage and death (<xref rid="ref2" ref-type="bibr">Ahmed et al., 2020</xref>). There have been reports published stating the abnormal activation of MAP kinases in all five investigated neurodegenerative pathologies and MAPK has been linked to pathophysiological hallmarks of neurodegeneration (<xref rid="ref4" ref-type="bibr">Albert-Gasc&#x000f3; et al., 2020</xref>; <xref rid="ref225" ref-type="bibr">Ten Bosch et al., 2021</xref>; <xref rid="ref246" ref-type="bibr">Yadav et al., 2021</xref>). Important role of MAPK signaling in A&#x003b2; generation (<xref rid="ref61" ref-type="bibr">Du et al., 2019</xref>) and cognitive decline independent of amyloid pathology has been proposed in AD (<xref rid="ref110" ref-type="bibr">Johnson et al., 2022</xref>). Multiple levels of evidence support the TREM2-induced MAPK signaling in PD pathogenesis (<xref rid="ref102" ref-type="bibr">Huang et al., 2021</xref>; <xref rid="ref197" ref-type="bibr">Ruganzu et al., 2022</xref>). Microglial MAPK over-activity has been extensively studied in MS (<xref rid="ref225" ref-type="bibr">Ten Bosch et al., 2021</xref>), while the therapeutic potential of MAPK pathway inhibition in demyelination recovery has also been proposed (<xref rid="ref221" ref-type="bibr">Suo et al., 2019</xref>). Similarly, a therapeutic strategy for ALS, targeting MAPK-mediated axonal retrograde transport, has been studied (<xref rid="ref82" ref-type="bibr">Gibbs et al., 2018</xref>). Based on these reports, we can conclude that dysregulation of the MAPK signaling due to SARS-CoV-2 infection could foster neurodegeneration in COVID-19 patients. In addition, MAPK signaling pathway also presents a potential druggable target to prevent or alleviate inflammation after COVID-19 and neurodegeneration.</p></sec><sec id="sec16"><label>4.2.2.</label><title>Pathways related to mediators of neuroinflammation</title><p>At least three further pathways indicate a strong overlap between neurodegeneration, COVID-19 and inflammation, such as &#x000bb;Interleukin-4 and interleukin-13 signaling&#x000ab;, &#x000bb;Cytokine signaling in immune system&#x000ab;, and &#x000bb;Signaling by interleukins&#x000ab;. The latter pathways greatly overlap with the enriched pathways described above. Recent findings suggest that COVID-19 could inflict structural and metabolic damage in the CNS by upregulating inflammatory cytokines. This phenomenon is known as the cytokine storm syndrome (<xref rid="ref161" ref-type="bibr">Nagu et al., 2021</xref>), within which the glial cells induce neuroinflammation by the release of various pro-inflammatory cytokines, such as IL-6, TNF&#x003b1;, interleukin 5 (IL-5) and interleukin 2 (IL-2; <xref rid="ref19" ref-type="bibr">Bohmwald et al., 2018</xref>). Among other inflammatory mediators, interleukin 10 (IL-10) has also been shown to be increased in COVID-19 (<xref rid="ref204" ref-type="bibr">Savarraj et al., 2021</xref>). Recovered COVID-19 patients with long-term symptoms, mostly neurological complaints, have higher plasma levels of interleukin 4 (IL-4; <xref rid="ref220" ref-type="bibr">Sun et al., 2021</xref>). This is an anti-inflammatory cytokine released as a response to neuroinflammation, trying to re-establish the neuronal homeostasis. However, the same study showed that plasma IL-6 levels present a more specific biomarker of neurological deficits after COVID-19 since elevation of IL-6 was observed specifically in neuro-long COVID-19 as compared to long COVID-19 without neurological symptoms (<xref rid="ref220" ref-type="bibr">Sun et al., 2021</xref>). In general, SARS-CoV-2 infection leads to maladaptive innate immunity and overall inflammation with activated microglia and astrocytes contributing to neurodegenerative processes, including demyelination, blood brain barrier disruption, and aberrant activation of CNS (<xref rid="ref88" ref-type="bibr">Gupta and Weaver, 2021</xref>). In chronically present neuroinflammatory environment glial cells are in charge of cytokine release and release of other pro-inflammatory mediators. Their secretome activates neighboring cells including other microglia and astrocytes, regardless of their encounter with pathogens or damage. Consequently, the neuroinflammation exacerbates and supports neurodegeneration (<xref rid="ref81" ref-type="bibr">Ghosh et al., 2021</xref>). The role of interleukins and other cytokines in neurodegenerative diseases has been extensively studied. In meta-analyses, dysregulation of several cytokines was observed in blood or CSF samples. In particular, TNF&#x003b1;, IL-6 and IL-1&#x003b2; were consistently increased in AD, PD and ALS patients (<xref rid="ref178" ref-type="bibr">Qin et al., 2016</xref>; <xref rid="ref97" ref-type="bibr">Hu et al., 2017</xref>; <xref rid="ref123" ref-type="bibr">Lai et al., 2017</xref>; <xref rid="ref208" ref-type="bibr">Shen et al., 2019</xref>). Targeting specific interleukin release could potentially slow down the process of neurodegeneration in COVID-19 patients, especially later after their recovery.</p></sec><sec id="sec17"><label>4.2.3.</label><title>Neuroprotective pathways</title><p>A highly significant pathway according to our Reactome analysis is the &#x000bb;FOXO-mediated transcription&#x000ab; pathway. Interestingly, one of the prime regulators of FOXO activity is the PI3K/AKT pathway that was found to be enriched in our analysis as well. Generally, FOXO proteins promote neuronal health and viability (<xref rid="ref155" ref-type="bibr">McLaughlin and Broihier, 2018</xref>). They regulate neuronal apoptosis in response to ROS accumulation and are important in regulating neural cell fate and function and essential for preventing age-dependent axonal degeneration (<xref rid="ref201" ref-type="bibr">Santo and Paik, 2018</xref>). A&#x003b2; exposure in AD brain leads to FOXO3A dephosphorylation and mitochondrial dysfunction (<xref rid="ref201" ref-type="bibr">Santo and Paik, 2018</xref>). Furthermore, moderate FOXO3 overexpression is protective in &#x003b1;-synuclein overexpressing dopaminergic neurons and drives &#x003b1;-synuclein into insoluble aggregates, suggesting that FOXO3 induces autophagy (<xref rid="ref155" ref-type="bibr">McLaughlin and Broihier, 2018</xref>). The latter suggests that FOXO3A as a member of the FOXO family protects the brain against neurodegenerative assaults. FOXOs play an important role in response to viral infections as well. They upregulate various pro-inflammatory cytokines such as IL-1&#x003b2; and interleukin 9, Toll-like receptor (TLR) 1 and TLR4, etc., which not only regulate the host inflammatory response but also alter the innate immune response (<xref rid="ref34" ref-type="bibr">Cheema et al., 2021</xref>). FOXO mediators regulate the expression of many different genes, among them also Kelch-like ECH-associated protein 1 (Keap1) and haem oxygenase 1 (HO-1), which both aim to ameliorate inflammation (<xref rid="ref34" ref-type="bibr">Cheema et al., 2021</xref>). It has been proposed that repurposing FOXO activators for COVID-19 treatment (<xref rid="ref34" ref-type="bibr">Cheema et al., 2021</xref>) could perhaps prevent or decrease neurodegenerative sequelae.</p><p>&#x000bb;ESR-mediated signaling&#x000ab; was identified as an overlapping pathway between neurodegeneration and COVID-19 as well. Estrogens can exert different neuroprotective roles by acting as antioxidants, promoting DNA repair, inducing expression of growth factors, supporting synaptic plasticity, and modulating brain blood flow (<xref rid="ref26" ref-type="bibr">Bustamante-Barrientos et al., 2021</xref>). In support of this statements, a meta-analysis showed that a hormone replacement therapy in post-menopausal women protected against AD and PD (<xref rid="ref217" ref-type="bibr">Song et al., 2020</xref>). Furthermore, epidemiological studies showed that PD for example is more prevalent in men than in women, which could be explained by the protective effect of estrogens in the brain (<xref rid="ref23" ref-type="bibr">Bourque et al., 2019</xref>). Even before the COVID-19 pandemics it was already reported that ovariectomised or antioestrogen-treated female mice had more severe coronavirus infections than control mice (<xref rid="ref33" ref-type="bibr">Channappanavar et al., 2017</xref>). Similarly, women taking oral contraceptives had reduced COVID-19 risk (<xref rid="ref45" ref-type="bibr">Costeira et al., 2021</xref>). Furthermore, women with high levels of estradiol had a lower risk of developing severe symptoms and an even lower incidence of death due to COVID-19 (<xref rid="ref181" ref-type="bibr">Ram&#x000ed;rez-de-Arellano et al., 2021</xref>). Based on these findings repurposing the estrogen receptor modulator raloxifene was suggested as an option to treat COVID-19 (<xref rid="ref7" ref-type="bibr">Allegretti et al., 2022</xref>). All things considered, aberrant estrogen signaling could contribute to neurodegeneration in COVID-19 patients.</p><p>&#x0201c;HIF-1 signaling pathway&#x0201d; was identified in the KEGG enrichment analysis. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor functioning as a master regulator of oxygen homeostasis and plays a pivotal role in hypoxic environment. Multiple levels of evidence highlight the importance of HIF-1 in COVID-19 pathophysiology. Metabolic shift in immune cells of COVID-19 infected lungs is triggered by HIF-1&#x003b1;, which was observed on both transcriptomic and proteomic levels. This shift allows cells to survive in the hypoxic environment (<xref rid="ref43" ref-type="bibr">Codo et al., 2020</xref>). Severe COVID-19 cases had higher expression of HIF-1 target genes (<xref rid="ref9" ref-type="bibr">Appelberg et al., 2020</xref>). HIF-1&#x003b1; is constitutively expressed, but its expression can be increased upon PI3K/AKT and ERK activation as well (<xref rid="ref154" ref-type="bibr">McGettrick and O'Neill, 2020</xref>). Another expression study correlated induced HIF-1&#x003b1; expression after COVID-19 infection with elevated inflammatory parameters, such as IL-6, interleukin 10, and TNF&#x003b1; (<xref rid="ref227" ref-type="bibr">Tian et al., 2021</xref>). The role of HIF-1&#x003b1; in COVID-19 infection can be further elucidated with hypoxic induction of HIF-1&#x003b1; or with its pharmacological inhibition, showing that activation of oxygen-sensing pathways can hamper SARS-CoV-2 cell entry and viral replication (<xref rid="ref239" ref-type="bibr">Wing et al., 2021</xref>). In neurodegenerative diseases, HIF-1 is well studied in AD, PD and ALS. HIF-1 induction in AD mouse reduces clustering of amyloid associated microglia and correlates with amyloid neuropathology in human hippocampus (<xref rid="ref150" ref-type="bibr">March-Diaz et al., 2021</xref>). Although hypoxia has not been directly linked to PD, multiple shared genetic and metabolic features can be observed in HIF-1 signaling pathway and PD (<xref rid="ref125" ref-type="bibr">Lest&#x000f3;n Pinilla et al., 2021</xref>). In ALS mice, hypoxia has been associated with neuronal death, muscular and cognitive dysfunction (<xref rid="ref117" ref-type="bibr">Kim et al., 2013</xref>). All of the above indicates that HIF-1 could present a shared pathway between COVID-19 and neurodegeneration and should be further explored.</p><p>&#x0201c;Neurotrophin signaling pathway&#x0201d; was identified in the KEGG pathway analysis as well. Neurotrophins are a family of proteins, involved in control of survival, development and function of neurons in both the peripheral and the CNS (<xref rid="ref190" ref-type="bibr">Reichardt, 2006</xref>). Disrupted blood levels of &#x003b2;-nerve growth factor (&#x003b2;-NGF), an initial metabolite in neurotrophin signaling pathway, have been observed in mild SARS-CoV-2 patients (<xref rid="ref230" ref-type="bibr">Usai et al., 2021</xref>). Besides NGF, brain-derived neurotrophic factor (BDNF) is the most studied neurotrophin in neurodegeneration. BDNF has been linked to microglial activation in mice (<xref rid="ref242" ref-type="bibr">Wu et al., 2020</xref>). A causative <italic>BDNF</italic> rs6265 polymorphism is associated with cognitive decline and increased AD risk (<xref rid="ref18" ref-type="bibr">Belbin et al., 2019</xref>; <xref rid="ref136" ref-type="bibr">Lim et al., 2022</xref>). The same <italic>BDNF</italic> polymorphism was associated with PD and its symptoms (<xref rid="ref28" ref-type="bibr">Cagni et al., 2017</xref>; <xref rid="ref157" ref-type="bibr">Mercado et al., 2021</xref>), while precision medicine application was also suggested to personalize treatment of PD patients (<xref rid="ref74" ref-type="bibr">Fischer et al., 2020</xref>). Furthermore, serum BDNF was increased in MS patients (<xref rid="ref104" ref-type="bibr">Islas-Hernandez et al., 2018</xref>).</p><p>The enrichment of different neuroprotective pathways emphasizes the important role of mechanisms, involved in neuronal damage reduction. The interplay between neuroprotection and COVID-19 could also be further investigated in search for therapeutic applications.</p></sec><sec id="sec18"><label>4.2.4.</label><title>Viral infection pathways</title><p>The pathway of &#x0201c;Hepatitis B&#x0201d; has been enriched in the KEGG pathway analysis. The impaired liver function, although poorly understood, is an important clinically significant outcome after COVID-19 infection (<xref rid="ref48" ref-type="bibr">da Mata et al., 2021</xref>; <xref rid="ref252" ref-type="bibr">Yu et al., 2021</xref>). COVID-19 can also trigger hepatitis B reactivation, but no direct pathophysiological overlap between both diseases has been reported to date (<xref rid="ref5" ref-type="bibr">Aldhaleei et al., 2020</xref>; <xref rid="ref243" ref-type="bibr">Wu et al., 2021</xref>). Hepatitis B was also proposed as one of COVID-19 risk factors for severe disease outcome (<xref rid="ref235" ref-type="bibr">Wang J. et al., 2021</xref>). Interestingly, a hepatitis B derived protein has been proposed as a promising therapeutic inhibitor of COVID-19 induced inflammation in lungs (<xref rid="ref38" ref-type="bibr">Choi et al., 2021</xref>). Similarly, pathophysiological link between hepatitis B and neurodegenerative diseases remains unclear. Hepatitis B was proposed as increased risk factor for PD (<xref rid="ref167" ref-type="bibr">Pakpoor et al., 2017</xref>), while increased risk was not observed in AD (<xref rid="ref39" ref-type="bibr">Choi et al., 2021</xref>).</p><p>Another virus related pathway enriched in the KEGG analysis was the &#x0201c;HTLV-I infection&#x0201d; pathway. The human T-cell leukemia virus type I (HTLV-1) can cause several fatal diseases such as adult T-cell leukemia or HTLV-1 associated myelopathy/tropical spastic paraparesis. Although the majority of HTLV-1 carriers remain asymptomatic throughout their lives, they are at higher risk of acquiring different opportunistic infections (<xref rid="ref165" ref-type="bibr">Oli&#x000e8;re et al., 2011</xref>). A case report of COVID-19 infected HTLV-1 carrier raises attention to potential long-term steroid use for secondary infection prevention (<xref rid="ref64" ref-type="bibr">Enomoto et al., 2022</xref>). Although myelopathy can be a shared condition between HPTV-1 and MS, to date no solid evidence linking the diseases can be found.</p><p>Both viral infection pathways show significant enrichments in the pathway analysis. However, this could be due to the fact that similar pathways are activated upon viral infection and further studies will have to be conducted to establish their role in COVID-19 or neurodegeneration.</p></sec><sec id="sec19"><label>4.2.5.</label><title>Cellular senescence pathway</title><p>Cellular senescence was a significantly enriched pathway in the generated list of miRNA targets as well. Senescence is a phenomenon featuring discontinuation of cell divisions. Senescence is in its core a beneficial process, with the aim to get rid of the damaged cells by triggering the immune system and then replacing them. However, when this cell turnover system is inefficient, the senescent cells start accumulating, which contributes to the aging phenotype (<xref rid="ref141" ref-type="bibr">L&#x000f3;pez-Ot&#x000ed;n et al., 2013</xref>). Cells in senescent state accumulate in the aged tissue and particularly senescent astrocytes and microglia contribute to neurodegeneration. Some senescent cells can secrete cytokines and chemokines, which stimulate the neighboring cells to release ROS. Accumulation of such senescent cells increases the risk for developing a more severe COVID-19 and also a longer course of the disease with symptoms of neurodegeneration (<xref rid="ref240" ref-type="bibr">Wissler Gerdes et al., 2022</xref>). A specific mechanism of cell senescence in COVID-19 has been described. As viruses replicate more efficiently in iron-rich senescent cells, they act towards changing the cell&#x02019;s phenotype to make a more favourable environment for their replication. This predisposes the CNS to immune dysfunction and neurodegeneration (<xref rid="ref207" ref-type="bibr">Sfera et al., 2021</xref>). All of the above indicates that cellular senescence is an important pathway that could contribute to neurodegenerative consequences of COVID-19.</p></sec></sec></sec><sec id="sec20"><label>5.</label><title>Future perspectives</title><p>Since a significant amount of COVID-19 patients develop neurological symptoms, especially symptoms of neurodegenerative nature, it would be highly relevant to find biomarkers of neurodegenerative processes in COVID-19. The latter would enable identification of COVID-19 patients at increased risk of neurodegenerative diseases as a late COVID-19 consequence. Furthermore, elucidation of shared pathways between COVID-19 and neurodegeneration would open a window of opportunity for identification of novel drug targets within these pathways or drug repurposing to prevent or alleviate progression of COVID-19 to neurodegeneration.</p><p>Presented systematic search adopted a strategy of deploying miRNA molecules for identification of shared pathways between both pathologies and for identification of predictive biomarkers of neurodegeneration as a COVID-19 sequela. The procedure to obtain miRNAs and assess their expression in patient&#x02019;s plasma or serum would be rather non-invasive, fast, and cost-effective. The three identified miRNAs (hsa-miR-34a, hsa-miR-132, and hsa-miR-155) could also present novel drug targets or novel drug compounds to alleviate neurodegeneration with acting on signaling cascades within shared pathways. In this study we only focused on the five most prevalent neurodegenerative diseases, although neurodegeneration due to COVID-19 could presumably also be presented in other forms, such as HIV encephalitis, which is a type of a virus-induced neurocognitive impairment.</p><p>Similar to our results, it has already been suggested that serum and plasma biomarkers could support detection of persistent neuroinflammation and neurodegeneration in COVID-19 patients (<xref rid="ref220" ref-type="bibr">Sun et al., 2021</xref>; <xref rid="ref32" ref-type="bibr">Chandra and Johri, 2022</xref>).Elevated cytokines are general markers of inflammatory process, which is driven by SARS-CoV-2, and they have been associated with higher chance of neurological sequelae development (<xref rid="ref90" ref-type="bibr">Haidar et al., 2021</xref>; <xref rid="ref220" ref-type="bibr">Sun et al., 2021</xref>). The exact mechanism on how SARS-CoV-2 induces changes in the brain, leading to potential neurodegeneration, is not fully elucidated. However, the three identified miRNAs shared between COVID-19 and neurodegeneration could be used as screening biomarkers to identify COVID-19 patients with increased risk for neurodegeneration. If the risk for neurodegeneration would be elevated based on the screening test, then more specific tests to decipher between different neurodegenerative pathologies could be applied afterwards. Specific markers of neurodegeneration in plasma could be measured, such as total tau (t-tau), phosphorylated tau-181 (p-tau<sub>181</sub>), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxyterminal hydrolase L1 (UCHL1), and A&#x003b2; (A&#x003b2;<sub>40</sub>, A&#x003b2;<sub>42</sub>) for dementia-related disorders (<xref rid="ref76" ref-type="bibr">Frontera et al., 2022</xref>).</p><p>Together with dysregulated expression of individual miRNAs, the identification of neuroinflammation-related enriched pathways based on the shared miRNA targets between both pathologies further imply the importance of neuroinflammation in COVID-19. For more precise evaluation of their effect, future studies should also focus on distinct disease stages as well, since specific miRNAs can be regulated differently during disease progression. In the outline of our study, we focused on dysregulated miRNAs in neurodegenerative diseases in general. Stratification of pathologies to different stages of the disease could lead to more precise and targeted studies in the future. Additionally, miRNAs that remain dysregulated even after the recovery from COVID-19 infection could be of interest in potential follow-up studies in the same patient cohorts. Certain studies have already followed the miRNA expression longitudinally. Two studies did not report any miRNAs that remained differentially expressed even after the recovery (<xref rid="ref259" ref-type="bibr">Zheng et al., 2020</xref>; <xref rid="ref65" ref-type="bibr">Farr et al., 2021</xref>), while among others hsa-miR-155-5p remained upregulated in the post-acute phase of the disease in comparison to controls in one study (<xref rid="ref59" ref-type="bibr">Donyavi et al., 2021</xref>).</p><p>Additionally, expression of several target genes of identified miRNAs has been shown to be dysregulated in COVID-19 patients on both mRNA and protein levels, which further supports our findings. The top identified miRNAs and pathways could thus serve as a basis to search for novel drug targets for prevention of neurodegeneration in COVID-19 or to screen for existing compounds targeting these pathways (<xref rid="ref168" ref-type="bibr">Panda et al., 2022</xref>). The most promising enriched pathways, identified with our approach, could be the PI3K/AKT and MAPK signaling as neuroinflammation promoting pathways, and FOXO signaling as a neuroprotective pathway. Since host-derived miRNAs play essential role in limiting viral replication, they could potentially be utilized as drug compounds to normalize perturbations in signaling pathways due to the underlying pathology. Furthermore, compounds targeting the identified miRNAs and pathways could be studied as potential very specific anti-neuroinflammatory drugs, which consequently affect the development of neurodegeneration (<xref rid="ref10" ref-type="bibr">Arghiani et al., 2021</xref>; <xref rid="ref17" ref-type="bibr">Bautista-Becerril et al., 2021</xref>; <xref rid="ref168" ref-type="bibr">Panda et al., 2022</xref>). Presumably, these drugs would be administered after recovery from COVID-19, in case the identified neurodegeneration-related biomarkers would still be elevated.</p></sec><sec sec-type="conclusions" id="sec21"><label>6.</label><title>Conclusion</title><p>Deciphering the shared landscapes between COVID-19 and neurodegeneration could foster identification of COVID-19 patients with increased risk for AD, PD, ALS, MS, and HD development. It could also enable drug discovery or drug repurposing for prevention or delay of consequential neurodegeneration in COVID-19. Studying shared miRNA landscapes presents a promising approach to tackle this challenge as it serves us with potential specific neuronflammation-related markers of neurodegeneration. Further studies are needed to confirm these findings in a clinical setting of COVID-19 patients.</p></sec><sec sec-type="data-availability" id="sec22"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="sec26" ref-type="sec">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p></sec><sec id="sec23"><title>Author contributions</title><p>SR proposed the analysis workflow. SR, DV, and KG performed the literature, database research, and wrote the paper. DV and KG performed the database mining and the pathway enrichment analysis. SR designed the figures and the graphical abstract. VD supervised the writing, edited the final manuscript, and provided the funding. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="funding-information" id="sec24"><title>Funding</title><p>This work was supported by the Slovenian Research Agency (ARRS) (grant no. P1-0170).</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="sec100"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="sec26" sec-type="supplementary-material"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fnmol.2023.1123955/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnmol.2023.1123955/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Image_1.TIF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data"><media xlink:href="Table_1.XLSX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM3" position="float" content-type="local-data"><media xlink:href="Table_2.XLSX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM4" position="float" content-type="local-data"><media xlink:href="Table_3.XLSX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agwa</surname><given-names>S. H. A.</given-names></name><name><surname>Elghazaly</surname><given-names>H.</given-names></name><name><surname>Meteini</surname><given-names>M. S. E.</given-names></name><name><surname>Shawky</surname><given-names>S. M.</given-names></name><name><surname>Ali</surname><given-names>M.</given-names></name><name><surname>Abd Elsamee</surname><given-names>A. M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>In silico identification and clinical validation of a novel long non-coding RNA/mRNA/miRNA molecular network for potential biomarkers for discriminating SARS CoV-2 infection severity</article-title>. <source>Cells</source>
<volume>9</volume>:<fpage>3098</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10113098</pub-id>, PMID: <pub-id pub-id-type="pmid">34831321</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>T.</given-names></name><name><surname>Zulfiqar</surname><given-names>A.</given-names></name><name><surname>Arguelles</surname><given-names>S.</given-names></name><name><surname>Rasekhian</surname><given-names>M.</given-names></name><name><surname>Nabavi</surname><given-names>S. F.</given-names></name><name><surname>Silva</surname><given-names>A. S.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Map kinase signaling as therapeutic target for neurodegeneration</article-title>. <source>Pharmacol. Res.</source>
<volume>160</volume>:<fpage>105090</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phrs.2020.105090</pub-id>, PMID: <pub-id pub-id-type="pmid">32707231</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akula</surname><given-names>S. M.</given-names></name><name><surname>Bolin</surname><given-names>P.</given-names></name><name><surname>Cook</surname><given-names>P. P.</given-names></name></person-group> (<year>2022</year>). <article-title>Cellular miR-150-5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulating nsp10 gene</article-title>. <source>RNA Biol.</source>
<volume>19</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1080/15476286.2021.2010959</pub-id>, PMID: <pub-id pub-id-type="pmid">34904915</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert-Gasc&#x000f3;</surname><given-names>H.</given-names></name><name><surname>Ros-Bernal</surname><given-names>F.</given-names></name><name><surname>Castillo-G&#x000f3;mez</surname><given-names>E.</given-names></name><name><surname>Olucha-Bordonau</surname><given-names>F. E.</given-names></name></person-group> (<year>2020</year>). <article-title>MAP/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume>:<fpage>4471</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21124471</pub-id>, PMID: <pub-id pub-id-type="pmid">32586047</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldhaleei</surname><given-names>W. A.</given-names></name><name><surname>Alnuaimi</surname><given-names>A.</given-names></name><name><surname>Bhagavathula</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates</article-title>. <source>Cureu</source>
<volume>12</volume>:<fpage>e8645</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.8645</pub-id>, PMID: <pub-id pub-id-type="pmid">32550096</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alieva</surname><given-names>A.</given-names></name><name><surname>Filatova</surname><given-names>E. V.</given-names></name><name><surname>Karabanov</surname><given-names>A. V.</given-names></name><name><surname>Illarioshkin</surname><given-names>S. N.</given-names></name><name><surname>Limborska</surname><given-names>S. A.</given-names></name><name><surname>Shadrina</surname><given-names>M. I.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>miRNA expression is highly sensitive to a drug therapy in Parkinson's disease</article-title>. <source>Parkinsonism Relat. Disord.</source>
<volume>21</volume>, <fpage>72</fpage>&#x02013;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.10.018</pub-id>, PMID: <pub-id pub-id-type="pmid">25465742</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allegretti</surname><given-names>M.</given-names></name><name><surname>Cesta</surname><given-names>M. C.</given-names></name><name><surname>Zippoli</surname><given-names>M.</given-names></name><name><surname>Beccari</surname><given-names>A.</given-names></name><name><surname>Talarico</surname><given-names>C.</given-names></name><name><surname>Mantelli</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection</article-title>. <source>Cell Death Differ.</source>
<volume>29</volume>, <fpage>156</fpage>&#x02013;<lpage>166</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41418-021-00844-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34404919</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonini</surname><given-names>A.</given-names></name><name><surname>Leta</surname><given-names>V.</given-names></name><name><surname>Teo</surname><given-names>J.</given-names></name><name><surname>Chaudhuri</surname><given-names>K. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Outcome of Parkinson's disease patients affected by COVID-19</article-title>. <source>Mov. Disord.</source>
<volume>35</volume>, <fpage>905</fpage>&#x02013;<lpage>908</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.28104</pub-id>, PMID: <pub-id pub-id-type="pmid">32347572</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appelberg</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Svensson Akusj&#x000e4;rvi</surname><given-names>S.</given-names></name><name><surname>Ambikan</surname><given-names>A. T.</given-names></name><name><surname>Mikaeloff</surname><given-names>F.</given-names></name><name><surname>Saccon</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells</article-title>. <source>Emerg. Microbes Infect.</source>
<volume>9</volume>, <fpage>1748</fpage>&#x02013;<lpage>1760</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2020.1799723</pub-id>, PMID: <pub-id pub-id-type="pmid">32691695</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arghiani</surname><given-names>N.</given-names></name><name><surname>Nissan</surname><given-names>T.</given-names></name><name><surname>Matin</surname><given-names>M. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Role of microRNAs in COVID-19 with implications for therapeutics</article-title>. <source>Biomed. Pharmacother.</source>
<volume>144</volume>:<fpage>112247</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112247</pub-id>, PMID: <pub-id pub-id-type="pmid">34601190</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aung</surname><given-names>L. L.</given-names></name><name><surname>Mouradian</surname><given-names>M. M.</given-names></name><name><surname>Dhib-Jalbut</surname><given-names>S.</given-names></name><name><surname>Balashov</surname><given-names>K. E.</given-names></name></person-group> (<year>2015</year>). <article-title>MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a</article-title>. <source>J. Neuroimmunol.</source>
<volume>278</volume>, <fpage>185</fpage>&#x02013;<lpage>189</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jneuroim.2014.11.004</pub-id>, PMID: <pub-id pub-id-type="pmid">25468268</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagheri-Hosseinabadi</surname><given-names>Z.</given-names></name><name><surname>Ostad Ebrahimi</surname><given-names>H.</given-names></name><name><surname>Bahrehmand</surname><given-names>F.</given-names></name><name><surname>Taghipour</surname><given-names>G.</given-names></name><name><surname>Abbasifard</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>The relationship between serum levels of interleukin-2 and IL-8 with circulating microRNA-10b in patients with COVID-19</article-title>. <source>Iran. J. Immunol.</source>
<volume>18</volume>, <fpage>65</fpage>&#x02013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.22034/iji.2021.88780.1904</pub-id>, PMID: <pub-id pub-id-type="pmid">33787515</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baki</surname><given-names>L.</given-names></name><name><surname>Shioi</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>P.</given-names></name><name><surname>Shao</surname><given-names>Z.</given-names></name><name><surname>Schwarzman</surname><given-names>A.</given-names></name><name><surname>Gama-Sosa</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations</article-title>. <source>EMBO J.</source>
<volume>23</volume>, <fpage>2586</fpage>&#x02013;<lpage>2596</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.emboj.7600251</pub-id>, PMID: <pub-id pub-id-type="pmid">15192701</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banaganapalli</surname><given-names>B.</given-names></name><name><surname>Al-Rayes</surname><given-names>N.</given-names></name><name><surname>Awan</surname><given-names>Z. A.</given-names></name><name><surname>Alsulaimany</surname><given-names>F. A.</given-names></name><name><surname>Alamri</surname><given-names>A. S.</given-names></name><name><surname>Elango</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Multilevel systems biology analysis of lung transcriptomics data identifies key miRNAs and potential miRNA target genes for SARS-CoV-2 infection</article-title>. <source>Comput. Biol. Med.</source>
<volume>135</volume>:<fpage>104570</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.104570</pub-id>, PMID: <pub-id pub-id-type="pmid">34157472</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbagallo</surname><given-names>C.</given-names></name><name><surname>Mostile</surname><given-names>G.</given-names></name><name><surname>Baglieri</surname><given-names>G.</given-names></name><name><surname>Giunta</surname><given-names>F.</given-names></name><name><surname>Luca</surname><given-names>A.</given-names></name><name><surname>Raciti</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases</article-title>. <source>Cell. Mol. Neurobiol.</source>
<volume>40</volume>, <fpage>531</fpage>&#x02013;<lpage>546</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10571-019-00751-y</pub-id>, PMID: <pub-id pub-id-type="pmid">31691877</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baulina</surname><given-names>N.</given-names></name><name><surname>Kulakova</surname><given-names>O.</given-names></name><name><surname>Kiselev</surname><given-names>I.</given-names></name><name><surname>Osmak</surname><given-names>G.</given-names></name><name><surname>Popova</surname><given-names>E.</given-names></name><name><surname>Boyko</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission</article-title>. <source>J. Neuroimmunol.</source>
<volume>317</volume>, <fpage>67</fpage>&#x02013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jneuroim.2018.01.005</pub-id>, PMID: <pub-id pub-id-type="pmid">29325906</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista-Becerril</surname><given-names>B.</given-names></name><name><surname>P&#x000e9;rez-Dimas</surname><given-names>G.</given-names></name><name><surname>Sommerhalder-Nava</surname><given-names>P. C.</given-names></name><name><surname>Hanono</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;nez-Cisneros</surname><given-names>J. A.</given-names></name><name><surname>Zarate-Maldonado</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>miRNAs, from evolutionary junk to possible prognostic markers and therapeutic targets in COVID-19</article-title>. <source>Viruses</source>
<volume>14</volume>:<fpage>41</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v14010041</pub-id>, PMID: <pub-id pub-id-type="pmid">35062245</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belbin</surname><given-names>O.</given-names></name><name><surname>Morgan</surname><given-names>K.</given-names></name><name><surname>Medway</surname><given-names>C.</given-names></name><name><surname>Warden</surname><given-names>D.</given-names></name><name><surname>Cortina-Borja</surname><given-names>M.</given-names></name><name><surname>van Duijn</surname><given-names>C. M.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>The epistasis project: a multi-cohort study of the effects of BDNF, DBH, and SORT1 epistasis on Alzheimer's disease risk</article-title>. <source>J. Alzheimers Dis.</source>
<volume>68</volume>, <fpage>1535</fpage>&#x02013;<lpage>1547</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-181116</pub-id>, PMID: <pub-id pub-id-type="pmid">30909233</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohmwald</surname><given-names>K.</given-names></name><name><surname>G&#x000e1;lvez</surname><given-names>N. M. S.</given-names></name><name><surname>R&#x000ed;os</surname><given-names>M.</given-names></name><name><surname>Kalergis</surname><given-names>A. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Neurologic alterations due to respiratory virus infections</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>12</volume>:<fpage>386</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2018.00386</pub-id>, PMID: <pub-id pub-id-type="pmid">30416428</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonetto</surname><given-names>V.</given-names></name><name><surname>Pasetto</surname><given-names>L.</given-names></name><name><surname>Lisi</surname><given-names>I.</given-names></name><name><surname>Carbonara</surname><given-names>M.</given-names></name><name><surname>Zangari</surname><given-names>R.</given-names></name><name><surname>Ferrari</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations</article-title>. <source>Front. Immunol.</source>
<volume>13</volume>:<fpage>1070379</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.1070379</pub-id><pub-id pub-id-type="pmid">36591311</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordoni</surname><given-names>V.</given-names></name><name><surname>Tartaglia</surname><given-names>E.</given-names></name><name><surname>Sacchi</surname><given-names>A.</given-names></name><name><surname>Fimia</surname><given-names>G. M.</given-names></name><name><surname>Cimini</surname><given-names>E.</given-names></name><name><surname>Casetti</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients</article-title>. <source>Int. J. Infect. Dis.</source>
<volume>105</volume>, <fpage>49</fpage>&#x02013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2021.02.019</pub-id>, PMID: <pub-id pub-id-type="pmid">33578018</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouali-Benazzouz</surname><given-names>R.</given-names></name><name><surname>Benazzouz</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Covid-19 infection and parkinsonism: is there a link?</article-title>
<source>Mov. Disord.</source>
<volume>36</volume>, <fpage>1737</fpage>&#x02013;<lpage>1743</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.28680</pub-id>, PMID: <pub-id pub-id-type="pmid">34080714</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourque</surname><given-names>M.</given-names></name><name><surname>Morissette</surname><given-names>M.</given-names></name><name><surname>Di Paolo</surname><given-names>T.</given-names></name></person-group> (<year>2019</year>). <article-title>Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease</article-title>. <source>Neuropharmacology</source>
<volume>147</volume>, <fpage>37</fpage>&#x02013;<lpage>54</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.04.005</pub-id>, PMID: <pub-id pub-id-type="pmid">29649433</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruel-Jungerman</surname><given-names>E.</given-names></name><name><surname>Veyrac</surname><given-names>A.</given-names></name><name><surname>Dufour</surname><given-names>F.</given-names></name><name><surname>Horwood</surname><given-names>J.</given-names></name><name><surname>Laroche</surname><given-names>S.</given-names></name><name><surname>Davis</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Inhibition of PI3K-Akt signaling blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in the dentate gyrus</article-title>. <source>PLoS One</source>
<volume>4</volume>:<fpage>e7901</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0007901</pub-id>, PMID: <pub-id pub-id-type="pmid">19936256</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buggele</surname><given-names>W. A.</given-names></name><name><surname>Johnson</surname><given-names>K. E.</given-names></name><name><surname>Horvath</surname><given-names>C. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Influenza a virus infection of human respiratory cells induces primary microRNA expression</article-title>. <source>J. Biol. Chem.</source>
<volume>287</volume>, <fpage>31027</fpage>&#x02013;<lpage>31040</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M112.387670</pub-id>, PMID: <pub-id pub-id-type="pmid">22822053</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustamante-Barrientos</surname><given-names>F. A.</given-names></name><name><surname>M&#x000e9;ndez-Ruette</surname><given-names>M.</given-names></name><name><surname>Ortloff</surname><given-names>A.</given-names></name><name><surname>Luz-Crawford</surname><given-names>P.</given-names></name><name><surname>Rivera</surname><given-names>F. J.</given-names></name><name><surname>Figueroa</surname><given-names>C. D.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>The impact of estrogen and estrogen-like molecules in neurogenesis and neurodegeneration: beneficial or harmful?</article-title>
<source>Front. Cell. Neurosci.</source>
<volume>15</volume>:<fpage>636176</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2021.636176</pub-id>, PMID: <pub-id pub-id-type="pmid">33762910</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caggiu</surname><given-names>E.</given-names></name><name><surname>Paulus</surname><given-names>K.</given-names></name><name><surname>Mameli</surname><given-names>G.</given-names></name><name><surname>Arru</surname><given-names>G.</given-names></name><name><surname>Sechi</surname><given-names>G. P.</given-names></name><name><surname>Sechi</surname><given-names>L. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients</article-title>. <source>eNeurologicalScience</source>
<volume>13</volume>, <fpage>1</fpage>&#x02013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ensci.2018.09.002</pub-id>, PMID: <pub-id pub-id-type="pmid">30255159</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cagni</surname><given-names>F. C.</given-names></name><name><surname>Camp&#x000ea;lo</surname><given-names>C.</given-names></name><name><surname>Coimbra</surname><given-names>D. G.</given-names></name><name><surname>Barbosa</surname><given-names>M. R.</given-names></name><name><surname>J&#x000fa;nior</surname><given-names>L. G. O.</given-names></name><name><surname>Neto</surname><given-names>A. B. S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Association of BDNF Val66MET polymorphism with Parkinson's disease and depression and anxiety symptoms</article-title>. <source>J. Neuropsychiatr. Clin. Neurosci.</source>
<volume>29</volume>, <fpage>142</fpage>&#x02013;<lpage>147</lpage>. doi: <pub-id pub-id-type="doi">10.1176/appi.neuropsych.16040062</pub-id>, PMID: <pub-id pub-id-type="pmid">27852165</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catanesi</surname><given-names>M.</given-names></name><name><surname>d'Angelo</surname><given-names>M.</given-names></name><name><surname>Tupone</surname><given-names>M. G.</given-names></name><name><surname>Benedetti</surname><given-names>E.</given-names></name><name><surname>Giordano</surname><given-names>A.</given-names></name><name><surname>Castelli</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>MicroRNAs dysregulation and mitochondrial dysfunction in neurodegenerative diseases</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume>:<fpage>5986</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21175986</pub-id>, PMID: <pub-id pub-id-type="pmid">32825273</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centa</surname><given-names>A.</given-names></name><name><surname>Fonseca</surname><given-names>A. S.</given-names></name><name><surname>Ferreira</surname><given-names>S.</given-names></name><name><surname>Azevedo</surname><given-names>M. L. V.</given-names></name><name><surname>Vaz de Paula</surname><given-names>C. B.</given-names></name><name><surname>Nagashima</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Deregulated miRNA expression is associated with endothelial dysfunction in post-mortem lung biopsies of COVID-19 patients</article-title>. <source>Am. J. Phys. Lung Cell. Mol. Phys.</source>
<volume>320</volume>, <fpage>L405</fpage>&#x02013;<lpage>L412</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajplung.00457.2020</pub-id>, PMID: <pub-id pub-id-type="pmid">33651636</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>D. J.</given-names></name><name><surname>Mengel</surname><given-names>D.</given-names></name><name><surname>Mustapic</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Selkoe</surname><given-names>D. J.</given-names></name><name><surname>Kapogiannis</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>miR-212 and miR-132 are downregulated in Neurally derived plasma exosomes of Alzheimer's patients</article-title>. <source>Front. Neurosci.</source>
<volume>13</volume>:<fpage>1208</fpage>.<pub-id pub-id-type="pmid">31849573</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>A.</given-names></name><name><surname>Johri</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>A peek into Pandora's box: COVID-19 and neurodegeneration</article-title>. <source>Brain Sci.</source>
<volume>12</volume>:<fpage>190</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci12020190</pub-id>, PMID: <pub-id pub-id-type="pmid">35203953</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Ten Eyck</surname><given-names>P. P.</given-names></name><name><surname>Meyerholz</surname><given-names>D. K.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection</article-title>. <source>J. Immunol.</source>
<volume>198</volume>, <fpage>4046</fpage>&#x02013;<lpage>4053</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1601896</pub-id>, PMID: <pub-id pub-id-type="pmid">28373583</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheema</surname><given-names>P. S.</given-names></name><name><surname>Nandi</surname><given-names>D.</given-names></name><name><surname>Nag</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19</article-title>. <source>Open Biol.</source>
<volume>11</volume>:<fpage>210069</fpage>. doi: <pub-id pub-id-type="doi">10.1098/rsob.210069</pub-id>, PMID: <pub-id pub-id-type="pmid">34102081</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Construction of an autophagy interaction network based on competitive endogenous RNA reveals the key pathways and central genes of SARS-CoV-2 infection in vivo</article-title>. <source>Microb. Pathog.</source>
<volume>158</volume>:<fpage>105051</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micpath.2021.105051</pub-id>, PMID: <pub-id pub-id-type="pmid">34153417</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Yoshimura</surname><given-names>S.</given-names></name><name><surname>Hao</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10)</article-title>. <source>J. Biol. Chem.</source>
<volume>288</volume>, <fpage>13748</fpage>&#x02013;<lpage>13761</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M112.381392</pub-id>, PMID: <pub-id pub-id-type="pmid">23546882</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiappelli</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Towards neuro-CoViD-19</article-title>. <source>Bioinformation</source>
<volume>16</volume>, <fpage>288</fpage>&#x02013;<lpage>292</lpage>. doi: <pub-id pub-id-type="doi">10.6026/97320630016288</pub-id>, PMID: <pub-id pub-id-type="pmid">32773986</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y. M.</given-names></name><name><surname>Jeong</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>U.</given-names></name><name><surname>Cho</surname><given-names>N. H.</given-names></name><name><surname>Kim</surname><given-names>B. J.</given-names></name></person-group> (<year>2021</year>). <article-title>A hepatitis B virus-derived peptide can inhibit infection of human lung cells with SARS-CoV-2 in a Type-1 interferon-dependent manner</article-title>. <source>Viruses</source>
<volume>13</volume>:<fpage>1227</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13071227</pub-id>, PMID: <pub-id pub-id-type="pmid">34202029</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H. G.</given-names></name><name><surname>Soh</surname><given-names>J. S.</given-names></name><name><surname>Lim</surname><given-names>J. S.</given-names></name><name><surname>Sim</surname><given-names>S. Y.</given-names></name><name><surname>Lee</surname><given-names>S. W.</given-names></name></person-group> (<year>2021</year>). <article-title>Association between dementia and hepatitis B and C virus infection</article-title>. <source>Medicine (Baltimore)</source>
<volume>100</volume>:<fpage>e26476</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000026476</pub-id>, PMID: <pub-id pub-id-type="pmid">34398003</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>E.</given-names></name><name><surname>Mychasiuk</surname><given-names>R.</given-names></name><name><surname>Hibbs</surname><given-names>M. L.</given-names></name><name><surname>Semple</surname><given-names>B. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Dysregulated phosphoinositide 3-kinase signaling in microglia: shaping chronic neuroinflammation</article-title>. <source>J. Neuroinflammation</source>
<volume>18</volume>:<fpage>276</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-021-02325-6</pub-id><pub-id pub-id-type="pmid">34838047</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cioccarelli</surname><given-names>C.</given-names></name><name><surname>S&#x000e1;nchez-Rodr&#x000ed;guez</surname><given-names>R.</given-names></name><name><surname>Angioni</surname><given-names>R.</given-names></name><name><surname>Venegas</surname><given-names>F. C.</given-names></name><name><surname>Bertoldi</surname><given-names>N.</given-names></name><name><surname>Munari</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>IL1&#x003b2; promotes TMPRSS2 expression and SARS-CoV-2 cell entry through the p38 MAPK-GATA2 Axis</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>:<fpage>781352</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.781352</pub-id>, PMID: <pub-id pub-id-type="pmid">34950146</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Climent</surname><given-names>M.</given-names></name><name><surname>Viggiani</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Y. W.</given-names></name><name><surname>Coulis</surname><given-names>G.</given-names></name><name><surname>Castaldi</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>MicroRNA and ROS crosstalk in cardiac and pulmonary diseases</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume>:<fpage>4370</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21124370</pub-id>, PMID: <pub-id pub-id-type="pmid">32575472</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codo</surname><given-names>A. C.</given-names></name><name><surname>Davanzo</surname><given-names>G. G.</given-names></name><name><surname>Monteiro</surname><given-names>L. B.</given-names></name><name><surname>de Souza</surname><given-names>G. F.</given-names></name><name><surname>Muraro</surname><given-names>S. P.</given-names></name><name><surname>Virgilio-da-Silva</surname><given-names>J. V.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1&#x003b1;/glycolysis-dependent Axis</article-title>. <source>Cell Metab.</source>
<volume>32</volume>, <fpage>437</fpage>&#x02013;<lpage>46.e5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2020.07.007</pub-id>, PMID: <pub-id pub-id-type="pmid">32697943</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cos&#x000ed;n-Tom&#x000e1;s</surname><given-names>M.</given-names></name><name><surname>Antonell</surname><given-names>A.</given-names></name><name><surname>Llad&#x000f3;</surname><given-names>A.</given-names></name><name><surname>Alcolea</surname><given-names>D.</given-names></name><name><surname>Fortea</surname><given-names>J.</given-names></name><name><surname>Ezquerra</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Plasma miR-34a-5p and miR-545-3p as early biomarkers of Alzheimer's disease: potential and limitations</article-title>. <source>Mol. Neurobiol.</source>
<volume>54</volume>, <fpage>5550</fpage>&#x02013;<lpage>5562</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-016-0088-8</pub-id>, PMID: <pub-id pub-id-type="pmid">27631879</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costeira</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>K. A.</given-names></name><name><surname>Murray</surname><given-names>B.</given-names></name><name><surname>Christiansen</surname><given-names>C.</given-names></name><name><surname>Castillo-Fernandez</surname><given-names>J.</given-names></name><name><surname>Ni Lochlainn</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Estrogen and COVID-19 symptoms: associations in women from the COVID symptom study</article-title>. <source>PLoS One</source>
<volume>16</volume>:<fpage>e0257051</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0257051</pub-id>, PMID: <pub-id pub-id-type="pmid">34506535</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Inhibition of PTEN attenuates endoplasmic reticulum stress and apoptosis via activation of PI3K/AKT pathway in Alzheimer's disease</article-title>. <source>Neurochem. Res.</source>
<volume>42</volume>, <fpage>3052</fpage>&#x02013;<lpage>3060</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-017-2338-1</pub-id>, PMID: <pub-id pub-id-type="pmid">28819903</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>C.</given-names></name><name><surname>Santos</surname><given-names>C.</given-names></name><name><surname>Gomes</surname><given-names>C.</given-names></name><name><surname>Fernandes</surname><given-names>A.</given-names></name><name><surname>Correia</surname><given-names>A. M.</given-names></name><name><surname>Sebasti&#x000e3;o</surname><given-names>A. M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Downregulated glia interplay and increased miRNA-155 as promising markers to track ALS at an early stage</article-title>. <source>Mol. Neurobiol.</source>
<volume>55</volume>, <fpage>4207</fpage>&#x02013;<lpage>4224</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-017-0631-2</pub-id>, PMID: <pub-id pub-id-type="pmid">28612258</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Mata</surname><given-names>G. F.</given-names></name><name><surname>Fernandes</surname><given-names>D. E.</given-names></name><name><surname>Luciano</surname><given-names>E. P.</given-names></name><name><surname>Sales</surname><given-names>G. T. M.</given-names></name><name><surname>Riguetti</surname><given-names>M. T. P.</given-names></name><name><surname>Kirsztajn</surname><given-names>G. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV</article-title>. <source>J. Venom Anim. Toxins Incl. Trop. Dis.</source>
<volume>27</volume>:<fpage>e20200154</fpage>. doi: <pub-id pub-id-type="doi">10.1590/1678-9199-jvatitd-2020-0154</pub-id>, PMID: <pub-id pub-id-type="pmid">34381495</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Agnillo</surname><given-names>F.</given-names></name><name><surname>Walters</surname><given-names>K. A.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Sheng</surname><given-names>Z. M.</given-names></name><name><surname>Scherler</surname><given-names>K.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19</article-title>. <source>Sci. Transl. Med.</source>
<volume>13</volume>:<fpage>eabj7790</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.abj7790</pub-id>, PMID: <pub-id pub-id-type="pmid">34648357</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daugaard</surname><given-names>I.</given-names></name><name><surname>Hansen</surname><given-names>T. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Biogenesis and function of ago-associated RNAs</article-title>. <source>Trends Genet.</source>
<volume>33</volume>, <fpage>208</fpage>&#x02013;<lpage>219</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tig.2017.01.003</pub-id>, PMID: <pub-id pub-id-type="pmid">28174021</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>F. G.</given-names></name><name><surname>Tovar-Moll</surname><given-names>F.</given-names></name><name><surname>Moll</surname><given-names>J.</given-names></name><name><surname>Munoz</surname><given-names>D. P.</given-names></name><name><surname>Ferreira</surname><given-names>S. T.</given-names></name></person-group> (<year>2020</year>). <article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system</article-title>. <source>Trends Neurosci.</source>
<volume>43</volume>, <fpage>355</fpage>&#x02013;<lpage>357</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tins.2020.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">32359765</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Gonzalo-Calvo</surname><given-names>D.</given-names></name><name><surname>Ben&#x000ed;tez</surname><given-names>I. D.</given-names></name><name><surname>Pinilla</surname><given-names>L.</given-names></name><name><surname>Carratal&#x000e1;</surname><given-names>A.</given-names></name><name><surname>Moncus&#x000ed;-Moix</surname><given-names>A.</given-names></name><name><surname>Gort-Paniello</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients</article-title>. <source>Transl. Res.</source>
<volume>236</volume>, <fpage>147</fpage>&#x02013;<lpage>159</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.trsl.2021.05.004</pub-id>, PMID: <pub-id pub-id-type="pmid">34048985</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vito</surname><given-names>F.</given-names></name><name><surname>Musella</surname><given-names>A.</given-names></name><name><surname>Fresegna</surname><given-names>D.</given-names></name><name><surname>Rizzo</surname><given-names>F. R.</given-names></name><name><surname>Gentile</surname><given-names>A.</given-names></name><name><surname>Stampanoni Bassi</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis</article-title>. <source>Neuropathol. Appl. Neurobiol.</source>
<volume>48</volume>:<fpage>e12765</fpage>. doi: <pub-id pub-id-type="doi">10.1111/nan.12765</pub-id>, PMID: <pub-id pub-id-type="pmid">34490928</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denk</surname><given-names>J.</given-names></name><name><surname>Oberhauser</surname><given-names>F.</given-names></name><name><surname>Kornhuber</surname><given-names>J.</given-names></name><name><surname>Wiltfang</surname><given-names>J.</given-names></name><name><surname>Fassbender</surname><given-names>K.</given-names></name><name><surname>Schroeter</surname><given-names>M. L.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls</article-title>. <source>PLoS One</source>
<volume>13</volume>:<fpage>e0197329</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0197329</pub-id>, PMID: <pub-id pub-id-type="pmid">29746584</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickey</surname><given-names>L. L.</given-names></name><name><surname>Worne</surname><given-names>C. L.</given-names></name><name><surname>Glover</surname><given-names>J. L.</given-names></name><name><surname>Lane</surname><given-names>T. E.</given-names></name><name><surname>O'Connell</surname><given-names>R. M.</given-names></name></person-group> (<year>2016</year>). <article-title>MicroRNA-155 enhances T cell trafficking and antiviral effector function in a model of coronavirus-induced neurologic disease</article-title>. <source>J. Neuroinflammation</source>
<volume>13</volume>:<fpage>240</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-016-0699-z</pub-id>, PMID: <pub-id pub-id-type="pmid">27604627</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>J. R.</given-names></name><name><surname>Kruse</surname><given-names>C.</given-names></name><name><surname>Montagna</surname><given-names>D. R.</given-names></name><name><surname>Finsen</surname><given-names>B.</given-names></name><name><surname>Wolfe</surname><given-names>M. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Alternative polyadenylation and miR-34 family members regulate tau expression</article-title>. <source>J. Neurochem.</source>
<volume>127</volume>, <fpage>739</fpage>&#x02013;<lpage>749</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jnc.12437</pub-id>, PMID: <pub-id pub-id-type="pmid">24032460</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolatshahi</surname><given-names>M.</given-names></name><name><surname>Sabahi</surname><given-names>M.</given-names></name><name><surname>Aarabi</surname><given-names>M. H.</given-names></name></person-group> (<year>2021</year>). <article-title>Pathophysiological clues to how the emergent SARS-CoV-2 can potentially increase the susceptibility to neurodegeneration</article-title>. <source>Mol. Neurobiol.</source>
<volume>58</volume>, <fpage>2379</fpage>&#x02013;<lpage>2394</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-020-02236-2</pub-id>, PMID: <pub-id pub-id-type="pmid">33417221</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Cong</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>MicroRNAs in Huntington's disease: diagnostic biomarkers or therapeutic agents?</article-title>
<source>Front. Cell. Neurosci.</source>
<volume>15</volume>:<fpage>705348</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2021.705348</pub-id>, PMID: <pub-id pub-id-type="pmid">34421543</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donyavi</surname><given-names>T.</given-names></name><name><surname>Bokharaei-Salim</surname><given-names>F.</given-names></name><name><surname>Baghi</surname><given-names>H. B.</given-names></name><name><surname>Khanaliha</surname><given-names>K.</given-names></name><name><surname>Alaei Janat-Makan</surname><given-names>M.</given-names></name><name><surname>Karimi</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Acute and post-acute phase of COVID-19: analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC</article-title>. <source>Int. Immunopharmacol.</source>
<volume>97</volume>:<fpage>107641</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2021.107641</pub-id>, PMID: <pub-id pub-id-type="pmid">33895478</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douaud</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Alfaro-Almagro</surname><given-names>F.</given-names></name><name><surname>Arthofer</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>McCarthy</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>SARS-CoV-2 is associated with changes in brain structure in UK biobank</article-title>. <source>Nature</source>, <volume>604</volume>, <fpage>697</fpage>&#x02013;<lpage>707</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-022-04569-5</pub-id>, PMID: <pub-id pub-id-type="pmid">35255491</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Fu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>MKP-1 reduces A&#x003b2; generation and alleviates cognitive impairments in Alzheimer's disease models</article-title>. <source>Signal Transduct. Target. Ther.</source>
<volume>4</volume>:<fpage>58</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-019-0091-4</pub-id>, PMID: <pub-id pub-id-type="pmid">31840000</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duecker</surname><given-names>R. P.</given-names></name><name><surname>Adam</surname><given-names>E. H.</given-names></name><name><surname>Wirtz</surname><given-names>S.</given-names></name><name><surname>Gronau</surname><given-names>L.</given-names></name><name><surname>Khodamoradi</surname><given-names>Y.</given-names></name><name><surname>Eberhardt</surname><given-names>F. J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>The MiR-320 family is strongly downregulated in patients with COVID-19 induced severe respiratory failure</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>22</volume>:<fpage>10351</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms221910351</pub-id>, PMID: <pub-id pub-id-type="pmid">34638691</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Fatimy</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Mushannen</surname><given-names>T.</given-names></name><name><surname>Gongala</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways</article-title>. <source>Acta Neuropathol.</source>
<volume>136</volume>, <fpage>537</fpage>&#x02013;<lpage>555</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-018-1880-5</pub-id>, PMID: <pub-id pub-id-type="pmid">29982852</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enomoto</surname><given-names>T.</given-names></name><name><surname>Shiroyama</surname><given-names>T.</given-names></name><name><surname>Hirata</surname><given-names>H.</given-names></name><name><surname>Amiya</surname><given-names>S.</given-names></name><name><surname>Adachi</surname><given-names>Y.</given-names></name><name><surname>Niitsu</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>COVID-19 in a human T-cell lymphotropic virus type-1 carrier</article-title>. <source>Clin Case Rep.</source>
<volume>10</volume>:<fpage>e05463</fpage>. doi: <pub-id pub-id-type="doi">10.1002/ccr3.5463</pub-id>, PMID: <pub-id pub-id-type="pmid">35223018</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr</surname><given-names>R. J.</given-names></name><name><surname>Rootes</surname><given-names>C. L.</given-names></name><name><surname>Rowntree</surname><given-names>L. C.</given-names></name><name><surname>Nguyen</surname><given-names>T. H. O.</given-names></name><name><surname>Hensen</surname><given-names>L.</given-names></name><name><surname>Kedzierski</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection</article-title>. <source>PLoS Pathog.</source>
<volume>17</volume>:<fpage>e1009759</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1009759</pub-id>, PMID: <pub-id pub-id-type="pmid">34320031</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatima</surname><given-names>M.</given-names></name><name><surname>Prajapati</surname><given-names>B.</given-names></name><name><surname>Saleem</surname><given-names>K.</given-names></name><name><surname>Kumari</surname><given-names>R.</given-names></name><name><surname>Mohindar Singh Singal</surname><given-names>C.</given-names></name><name><surname>Seth</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Novel insights into role of miR-320a-VDAC1 axis in astrocyte-mediated neuronal damage in neuroAIDS</article-title>. <source>Glia</source>
<volume>65</volume>, <fpage>250</fpage>&#x02013;<lpage>263</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.23089</pub-id>, PMID: <pub-id pub-id-type="pmid">27761954</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattahi</surname><given-names>S.</given-names></name><name><surname>Khalifehzadeh-Esfahani</surname><given-names>Z.</given-names></name><name><surname>Mohammad-Rezaei</surname><given-names>M.</given-names></name><name><surname>Mafi</surname><given-names>S.</given-names></name><name><surname>Jafarinia</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy</article-title>. <source>Immunol. Res.</source>
<volume>70</volume>, <fpage>269</fpage>&#x02013;<lpage>275</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12026-022-09268-x</pub-id>, PMID: <pub-id pub-id-type="pmid">35107743</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fayyad-Kazan</surname><given-names>M.</given-names></name><name><surname>Makki</surname><given-names>R.</given-names></name><name><surname>Skafi</surname><given-names>N.</given-names></name><name><surname>El Homsi</surname><given-names>M.</given-names></name><name><surname>Hamade</surname><given-names>A.</given-names></name><name><surname>El Majzoub</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Circulating miRNAs: potential diagnostic role for coronavirus disease 2019 (COVID-19)</article-title>. <source>Infect. Genet. Evol.</source>
<volume>94</volume>:<fpage>105020</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.meegid.2021.105020</pub-id>, PMID: <pub-id pub-id-type="pmid">34343725</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazzini</surname><given-names>E.</given-names></name><name><surname>Fleming</surname><given-names>J.</given-names></name><name><surname>Fahn</surname><given-names>S.</given-names></name></person-group> (<year>1992</year>). <article-title>Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease</article-title>. <source>Mov. Disord.</source>
<volume>7</volume>, <fpage>153</fpage>&#x02013;<lpage>158</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.870070210</pub-id>, PMID: <pub-id pub-id-type="pmid">1316552</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferini-Strambi</surname><given-names>L.</given-names></name><name><surname>Salsone</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?</article-title>
<source>J. Neurol.</source>
<volume>268</volume>, <fpage>409</fpage>&#x02013;<lpage>419</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-020-10070-8</pub-id>, PMID: <pub-id pub-id-type="pmid">32696341</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Pato</surname><given-names>A.</given-names></name><name><surname>Virseda-Berdices</surname><given-names>A.</given-names></name><name><surname>Resino</surname><given-names>S.</given-names></name><name><surname>Ryan</surname><given-names>P.</given-names></name><name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>O.</given-names></name><name><surname>Per&#x000e9;z-Garc&#x000ed;a</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerg</article-title>. <source>Microbes Infect.</source>
<volume>11</volume>, <fpage>676</fpage>&#x02013;<lpage>688</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2022.2038021</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>F.</given-names></name><name><surname>Vitiello</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Efficacy of synthetic glucocorticoids in COVID-19 endothelites</article-title>. <source>Naunyn Schmiedeberg's Arch. Pharmacol.</source>
<volume>394</volume>, <fpage>1003</fpage>&#x02013;<lpage>1007</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00210-021-02049-7</pub-id>, PMID: <pub-id pub-id-type="pmid">33443616</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipowicz</surname><given-names>W.</given-names></name><name><surname>Bhattacharyya</surname><given-names>S. N.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group> (<year>2008</year>). <article-title>Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?</article-title>
<source>Nat. Rev. Genet.</source>
<volume>9</volume>, <fpage>102</fpage>&#x02013;<lpage>114</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrg2290</pub-id>, PMID: <pub-id pub-id-type="pmid">18197166</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>D. L.</given-names></name><name><surname>Auinger</surname><given-names>P.</given-names></name><name><surname>Goudreau</surname><given-names>J. L.</given-names></name><name><surname>Cole-Strauss</surname><given-names>A.</given-names></name><name><surname>Kieburtz</surname><given-names>K.</given-names></name><name><surname>Elm</surname><given-names>J. J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>BDNF rs6265 variant alters outcomes with levodopa in early-stage Parkinson's disease</article-title>. <source>Neurotherapeutics</source>
<volume>17</volume>, <fpage>1785</fpage>&#x02013;<lpage>1795</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13311-020-00965-9</pub-id>, PMID: <pub-id pub-id-type="pmid">33215284</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>T. F.</given-names></name><name><surname>Kaplan</surname><given-names>D. R.</given-names></name><name><surname>Cantley</surname><given-names>L. C.</given-names></name></person-group> (<year>1997</year>). <article-title>PI3K: downstream AKTion blocks apoptosis</article-title>. <source>Cells</source>
<volume>88</volume>, <fpage>435</fpage>&#x02013;<lpage>437</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81883-8</pub-id>, PMID: <pub-id pub-id-type="pmid">9038334</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frontera</surname><given-names>J. A.</given-names></name><name><surname>Boutajangout</surname><given-names>A.</given-names></name><name><surname>Masurkar</surname><given-names>A. V.</given-names></name><name><surname>Betensky</surname><given-names>R. A.</given-names></name><name><surname>Ge</surname><given-names>Y.</given-names></name><name><surname>Vedvyas</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia</article-title>. <source>Alzheimers Dement.</source>
<volume>18</volume>, <fpage>899</fpage>&#x02013;<lpage>910</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.12556</pub-id>, PMID: <pub-id pub-id-type="pmid">35023610</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuoka</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Fujita</surname><given-names>H.</given-names></name><name><surname>Chiyo</surname><given-names>T.</given-names></name><name><surname>Popiel</surname><given-names>H. A.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Supplemental treatment for Huntington's disease with miR-132 that is deficient in Huntington's disease brain</article-title>. <source>Mol. Ther. Nucleic Acids</source>
<volume>11</volume>, <fpage>79</fpage>&#x02013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.omtn.2018.01.007</pub-id>, PMID: <pub-id pub-id-type="pmid">29858092</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>A.</given-names></name><name><surname>Seeliger</surname><given-names>B.</given-names></name><name><surname>Derda</surname><given-names>A. A.</given-names></name><name><surname>Xiao</surname><given-names>K.</given-names></name><name><surname>Gietz</surname><given-names>A.</given-names></name><name><surname>Scherf</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Circulating cardiovascular microRNAs in critically ill COVID-19 patients</article-title>. <source>Eur. J. Heart Fail.</source>
<volume>23</volume>, <fpage>468</fpage>&#x02013;<lpage>475</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ejhf.2096</pub-id>, PMID: <pub-id pub-id-type="pmid">33421274</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudet</surname><given-names>A. D.</given-names></name><name><surname>Fonken</surname><given-names>L. K.</given-names></name><name><surname>Watkins</surname><given-names>L. R.</given-names></name><name><surname>Nelson</surname><given-names>R. J.</given-names></name><name><surname>Popovich</surname><given-names>P. G.</given-names></name></person-group> (<year>2018</year>). <article-title>MicroRNAs: roles in regulating Neuroinflammation</article-title>. <source>Neuroscientist</source>
<volume>24</volume>, <fpage>221</fpage>&#x02013;<lpage>245</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1073858417721150</pub-id>, PMID: <pub-id pub-id-type="pmid">28737113</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghadiri</surname><given-names>N.</given-names></name><name><surname>Emamnia</surname><given-names>N.</given-names></name><name><surname>Ganjalikhani-Hakemi</surname><given-names>M.</given-names></name><name><surname>Ghaedi</surname><given-names>K.</given-names></name><name><surname>Etemadifar</surname><given-names>M.</given-names></name><name><surname>Salehi</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients</article-title>. <source>Gene</source>
<volume>659</volume>, <fpage>109</fpage>&#x02013;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.gene.2018.03.035</pub-id>, PMID: <pub-id pub-id-type="pmid">29551498</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Ganeshpurkar</surname><given-names>A.</given-names></name><name><surname>Pokle</surname><given-names>A. V.</given-names></name><name><surname>Singh</surname><given-names>R. B.</given-names></name><name><surname>Singh</surname><given-names>S. K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Cellular and molecular influencers of neuroinflammation in Alzheimer's disease: recent concepts &#x00026; roles</article-title>. <source>Neurochem. Int.</source>
<volume>151</volume>:<fpage>105212</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuint.2021.105212</pub-id>, PMID: <pub-id pub-id-type="pmid">34656693</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>K. L.</given-names></name><name><surname>Kalmar</surname><given-names>B.</given-names></name><name><surname>Rhymes</surname><given-names>E. R.</given-names></name><name><surname>Fellows</surname><given-names>A. D.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Whiting</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS</article-title>. <source>Cell Death Dis.</source>
<volume>9</volume>:<fpage>596</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-018-0624-8</pub-id><pub-id pub-id-type="pmid">29789529</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Mechanism of miR-132-3p promoting Neuroinflammation and dopaminergic neurodegeneration in Parkinson's disease</article-title>. <source>eNeuro</source>
<volume>9</volume>. doi: <pub-id pub-id-type="doi">10.1523/ENEURO.0393-21.2021</pub-id>, PMID: <pub-id pub-id-type="pmid">34983831</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xia</surname><given-names>X. J.</given-names></name><name><surname>Liu</surname><given-names>Y. Y.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Lentiviral vector-mediated SHC3 silencing exacerbates oxidative stress injury in Nigral dopamine neurons by regulating the PI3K-AKT-FoxO signaling pathway in rats with Parkinson's disease</article-title>. <source>Cell. Physiol. Biochem.</source>
<volume>49</volume>, <fpage>971</fpage>&#x02013;<lpage>984</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000493228</pub-id>, PMID: <pub-id pub-id-type="pmid">30184529</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D. E.</given-names></name><name><surname>Jang</surname><given-names>G. M.</given-names></name><name><surname>Bouhaddou</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Obernier</surname><given-names>K.</given-names></name><name><surname>O'Meara</surname><given-names>M. J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing</article-title>. <source>Nature</source>, <volume>583</volume>, <fpage>459</fpage>&#x02013;<lpage>468</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>, PMID: <pub-id pub-id-type="pmid">32353859</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grehl</surname><given-names>C.</given-names></name><name><surname>Schulthei&#x000df;</surname><given-names>C.</given-names></name><name><surname>Hoffmann</surname><given-names>K.</given-names></name><name><surname>Binder</surname><given-names>M.</given-names></name><name><surname>Altmann</surname><given-names>T.</given-names></name><name><surname>Grosse</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Detection of SARS-CoV-2 derived small RNAs and changes in circulating small RNAs associated with COVID-19</article-title>. <source>Viruses</source>
<volume>13</volume>:<fpage>1593</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13081593</pub-id>, PMID: <pub-id pub-id-type="pmid">34452458</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossi</surname><given-names>I.</given-names></name><name><surname>Radeghieri</surname><given-names>A.</given-names></name><name><surname>Paolini</surname><given-names>L.</given-names></name><name><surname>Porrini</surname><given-names>V.</given-names></name><name><surname>Pilotto</surname><given-names>A.</given-names></name><name><surname>Padovani</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>MicroRNA-34a-5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: an exploratory study</article-title>. <source>Int. J. Mol. Med.</source>
<volume>47</volume>, <fpage>533</fpage>&#x02013;<lpage>546</lpage>. doi: <pub-id pub-id-type="doi">10.3892/ijmm.2020.4806</pub-id>, PMID: <pub-id pub-id-type="pmid">33416118</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M.</given-names></name><name><surname>Weaver</surname><given-names>D. F.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 as a trigger of brain autoimmunity</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>12</volume>, <fpage>2558</fpage>&#x02013;<lpage>2561</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acschemneuro.1c00403</pub-id>, PMID: <pub-id pub-id-type="pmid">34213312</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutmann</surname><given-names>C.</given-names></name><name><surname>Khamina</surname><given-names>K.</given-names></name><name><surname>Theofilatos</surname><given-names>K.</given-names></name><name><surname>Diendorfer</surname><given-names>A. B.</given-names></name><name><surname>Burnap</surname><given-names>S. A.</given-names></name><name><surname>Nabeebaccus</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Association of cardiometabolic microRNAs with COVID-19 severity and mortality</article-title>. <source>Cardiovasc. Res.</source>
<volume>118</volume>, <fpage>461</fpage>&#x02013;<lpage>474</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvab338</pub-id>, PMID: <pub-id pub-id-type="pmid">34755842</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haidar</surname><given-names>M. A.</given-names></name><name><surname>Jourdi</surname><given-names>H.</given-names></name><name><surname>Haj Hassan</surname><given-names>Z.</given-names></name><name><surname>Ashekyan</surname><given-names>O.</given-names></name><name><surname>Fardoun</surname><given-names>M.</given-names></name><name><surname>Wehbe</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Neurological and neuropsychological changes associated with SARS-CoV-2 infection: new observations, new mechanisms</article-title>. <source>Neuroscientist</source>. doi: <pub-id pub-id-type="doi">10.1177/1073858420984106</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroun</surname><given-names>R. A.</given-names></name><name><surname>Osman</surname><given-names>W. H.</given-names></name><name><surname>Amin</surname><given-names>R. E.</given-names></name><name><surname>Hassan</surname><given-names>A. K.</given-names></name><name><surname>Abo-Shanab</surname><given-names>W. S.</given-names></name><name><surname>Eessa</surname><given-names>A. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Circulating plasma miR-155 is a potential biomarker for the detection of SARS-CoV-2 infection</article-title>. <source>Pathology</source>
<volume>54</volume>, <fpage>104</fpage>&#x02013;<lpage>110</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pathol.2021.09.006</pub-id>, PMID: <pub-id pub-id-type="pmid">34838331</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasankhani</surname><given-names>A.</given-names></name><name><surname>Bahrami</surname><given-names>A.</given-names></name><name><surname>Sheybani</surname><given-names>N.</given-names></name><name><surname>Aria</surname><given-names>B.</given-names></name><name><surname>Hemati</surname><given-names>B.</given-names></name><name><surname>Fatehi</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Differential co-expression network analysis reveals key hub-high traffic genes as potential therapeutic targets for COVID-19 pandemic</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>:<fpage>789317</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.789317</pub-id>, PMID: <pub-id pub-id-type="pmid">34975885</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hascup</surname><given-names>E. R.</given-names></name><name><surname>Hascup</surname><given-names>K. N.</given-names></name></person-group> (<year>2020</year>). <article-title>Does SARS-CoV-2 infection cause chronic neurological complications?</article-title>
<source>Geroscience</source>
<volume>42</volume>, <fpage>1083</fpage>&#x02013;<lpage>1087</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11357-020-00207-y</pub-id>, PMID: <pub-id pub-id-type="pmid">32451846</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneka</surname><given-names>M. T.</given-names></name><name><surname>Golenbock</surname><given-names>D.</given-names></name><name><surname>Latz</surname><given-names>E.</given-names></name><name><surname>Morgan</surname><given-names>D.</given-names></name><name><surname>Brown</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Immediate and long-term consequences of COVID-19 infections for the development of neurological disease</article-title>. <source>Alzheimers Res. Ther.</source>
<volume>12</volume>:<fpage>69</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-020-00640-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32498691</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>K.</given-names></name><name><surname>Danekas</surname><given-names>A.</given-names></name><name><surname>Farrell</surname><given-names>W.</given-names></name><name><surname>Garcia</surname><given-names>T.</given-names></name><name><surname>Mehboob</surname><given-names>W.</given-names></name><name><surname>White</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>At the intersection of sulfur redox chemistry, cellular signal transduction and proteostasis: a useful perspective from which to understand and treat neurodegeneration</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>178</volume>, <fpage>161</fpage>&#x02013;<lpage>173</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.11.039</pub-id>, PMID: <pub-id pub-id-type="pmid">34863876</pub-id></mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A. F.</given-names></name></person-group> (<year>2019</year>). <article-title>Extracellular vesicles and neurodegenerative diseases</article-title>. <source>J. Neurosci.</source>
<volume>39</volume>, <fpage>9269</fpage>&#x02013;<lpage>9273</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0147-18.2019</pub-id>, PMID: <pub-id pub-id-type="pmid">31748282</pub-id></mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name><name><surname>Qin</surname><given-names>X. Y.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>:<fpage>9094</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-09097-1</pub-id><pub-id pub-id-type="pmid">28831083</pub-id></mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Dong</surname><given-names>X. P.</given-names></name></person-group> (<year>2021</year>). <article-title>Impact of COVID-19 pandemic on patients with neurodegenerative diseases</article-title>. <source>Front. Aging Neurosci.</source>
<volume>13</volume>:<fpage>664965</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2021.664965</pub-id>, PMID: <pub-id pub-id-type="pmid">33897410</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang da</surname><given-names>W.</given-names></name><name><surname>Sherman</surname><given-names>B. T.</given-names></name><name><surname>Lempicki</surname><given-names>R. A.</given-names></name></person-group> (<year>2009a</year>). <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source>Nat. Protoc.</source>
<volume>4</volume>, <fpage>44</fpage>&#x02013;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id>, PMID: <pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang da</surname><given-names>W.</given-names></name><name><surname>Sherman</surname><given-names>B. T.</given-names></name><name><surname>Lempicki</surname><given-names>R. A.</given-names></name></person-group> (<year>2009b</year>). <article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title>. <source>Nucleic Acids Res.</source>
<volume>37</volume>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id>, PMID: <pub-id pub-id-type="pmid">19033363</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H. Y.</given-names></name><name><surname>Lin</surname><given-names>Y. C.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>K. Y.</given-names></name><name><surname>Shrestha</surname><given-names>S.</given-names></name><name><surname>Hong</surname><given-names>H. C.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database</article-title>. <source>Nucleic Acids Res.</source>
<volume>48</volume>, <fpage>D148</fpage>&#x02013;<lpage>d54</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkz896</pub-id>, PMID: <pub-id pub-id-type="pmid">31647101</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Lv</surname><given-names>Q.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Triggering receptor expressed on myeloid cells 2 protects dopaminergic neurons by promoting autophagy in the inflammatory pathogenesis of Parkinson's disease</article-title>. <source>Front. Neurosci.</source>
<volume>15</volume>:<fpage>745815</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2021.745815</pub-id>, PMID: <pub-id pub-id-type="pmid">34867158</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>HMDD v3.0: a database for experimentally supported human microRNA-disease associations</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume>, <fpage>D1013</fpage>&#x02013;<lpage>D1017</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gky1010</pub-id>, PMID: <pub-id pub-id-type="pmid">30364956</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islas-Hernandez</surname><given-names>A.</given-names></name><name><surname>Aguilar-Talamantes</surname><given-names>H. S.</given-names></name><name><surname>Bertado-Cortes</surname><given-names>B.</given-names></name><name><surname>Mejia-delCastillo</surname><given-names>G. J.</given-names></name><name><surname>Carrera-Pineda</surname><given-names>R.</given-names></name><name><surname>Cuevas-Garcia</surname><given-names>C. F.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>BDNF and tau as biomarkers of severity in multiple sclerosis</article-title>. <source>Biomark. Med</source>
<volume>12</volume>, <fpage>717</fpage>&#x02013;<lpage>726</lpage>. doi: <pub-id pub-id-type="doi">10.2217/bmm-2017-0374</pub-id>, PMID: <pub-id pub-id-type="pmid">29865854</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>I. I.</given-names></name><name><surname>Salama</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Association of CNS demyelination and COVID-19 infection: an updated systematic review</article-title>. <source>J. Neurol.</source>
<volume>269</volume>, <fpage>541</fpage>&#x02013;<lpage>576</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-021-10752-x</pub-id>, PMID: <pub-id pub-id-type="pmid">34386902</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafarzadeh</surname><given-names>A.</given-names></name><name><surname>Naseri</surname><given-names>A.</given-names></name><name><surname>Shojaie</surname><given-names>L.</given-names></name><name><surname>Nemati</surname><given-names>M.</given-names></name><name><surname>Jafarzadeh</surname><given-names>S.</given-names></name><name><surname>Bannazadeh Baghi</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>MicroRNA-155 and antiviral immune responses</article-title>. <source>Int. Immunopharmacol.</source>
<volume>101</volume>:<fpage>108188</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2021.108188</pub-id>, PMID: <pub-id pub-id-type="pmid">34626873</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarrahi</surname><given-names>A.</given-names></name><name><surname>Ahluwalia</surname><given-names>M.</given-names></name><name><surname>Khodadadi</surname><given-names>H.</given-names></name><name><surname>da Silva Lopes Salles</surname><given-names>E.</given-names></name><name><surname>Kolhe</surname><given-names>R.</given-names></name><name><surname>Hess</surname><given-names>D. C.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Neurological consequences of COVID-19: what have we learned and where do we go from here?</article-title>
<source>J. Neuroinflammation</source>
<volume>17</volume>:<fpage>286</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-020-01957-4</pub-id><pub-id pub-id-type="pmid">32998763</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>P. K.</given-names></name><name><surname>Vijay</surname><given-names>A.</given-names></name><name><surname>Halu</surname><given-names>A.</given-names></name><name><surname>Uchida</surname><given-names>S.</given-names></name><name><surname>Aikawa</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Gene expression profiling reveals the shared and distinct transcriptional signatures in human lung epithelial cells infected with SARS-CoV-2, MERS-CoV, or SARS-CoV: potential implications in cardiovascular complications of COVID-19</article-title>. <source>Front. Cardiovasc. Med.</source>
<volume>7</volume>:<fpage>623012</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcvm.2020.623012</pub-id>, PMID: <pub-id pub-id-type="pmid">33521069</pub-id></mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jian</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>miR-34a knockout attenuates cognitive deficits in APP/PS1 mice through inhibition of the amyloidogenic processing of APP</article-title>. <source>Life Sci.</source>
<volume>182</volume>, <fpage>104</fpage>&#x02013;<lpage>111</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2017.05.023</pub-id>, PMID: <pub-id pub-id-type="pmid">28533191</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>E. C. B.</given-names></name><name><surname>Carter</surname><given-names>E. K.</given-names></name><name><surname>Dammer</surname><given-names>E. B.</given-names></name><name><surname>Duong</surname><given-names>D. M.</given-names></name><name><surname>Gerasimov</surname><given-names>E. S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level</article-title>. <source>Nat. Neurosci.</source>
<volume>25</volume>, <fpage>213</fpage>&#x02013;<lpage>225</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41593-021-00999-y</pub-id>, PMID: <pub-id pub-id-type="pmid">35115731</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju&#x0017a;wik</surname><given-names>C. A.</given-names></name><name><surname>Drake</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Paradis-Isler</surname><given-names>N.</given-names></name><name><surname>Sylvester</surname><given-names>A.</given-names></name><name><surname>Amar-Zifkin</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>microRNA dysregulation in neurodegenerative diseases: a systematic review</article-title>. <source>Prog. Neurobiol.</source>
<volume>182</volume>:<fpage>101664</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pneurobio.2019.101664</pub-id>, PMID: <pub-id pub-id-type="pmid">31356849</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalia</surname><given-names>L. V.</given-names></name><name><surname>Lang</surname><given-names>A. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Parkinson's disease</article-title>. <source>Lancet</source>
<volume>386</volume>, <fpage>896</fpage>&#x02013;<lpage>912</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61393-3</pub-id>, PMID: <pub-id pub-id-type="pmid">25904081</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamp</surname><given-names>J. C.</given-names></name><name><surname>Neubert</surname><given-names>L.</given-names></name><name><surname>Ackermann</surname><given-names>M.</given-names></name><name><surname>Stark</surname><given-names>H.</given-names></name><name><surname>Werlein</surname><given-names>C.</given-names></name><name><surname>Fuge</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Time-dependent molecular motifs of pulmonary fibrogenesis in COVID-19</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>23</volume>:<fpage>1583</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms23031583</pub-id>, PMID: <pub-id pub-id-type="pmid">35163504</pub-id></mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karuppan</surname><given-names>M. K. M.</given-names></name><name><surname>Devadoss</surname><given-names>D.</given-names></name><name><surname>Nair</surname><given-names>M.</given-names></name><name><surname>Chand</surname><given-names>H. S.</given-names></name><name><surname>Lakshmana</surname><given-names>M. K.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 infection in the central and peripheral nervous system-associated morbidities and their potential mechanism</article-title>. <source>Mol. Neurobiol.</source>
<volume>58</volume>, <fpage>2465</fpage>&#x02013;<lpage>2480</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-020-02245-1</pub-id>, PMID: <pub-id pub-id-type="pmid">33439437</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keikha</surname><given-names>R.</given-names></name><name><surname>Hashemi-Shahri</surname><given-names>S. M.</given-names></name><name><surname>Jebali</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>The relative expression of miR-31, miR-29, miR-126, and miR-17 and their mRNA targets in the serum of COVID-19 patients with different grades during hospitalization</article-title>. <source>Eur. J. Med. Res.</source>
<volume>26</volume>:<fpage>75</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40001-021-00544-4</pub-id><pub-id pub-id-type="pmid">34256840</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khezri</surname><given-names>M. R.</given-names></name><name><surname>Varzandeh</surname><given-names>R.</given-names></name><name><surname>Ghasemnejad-Berenji</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>The probable role and therapeutic potential of the PI3K/AKT signaling pathway in SARS-CoV-2 induced coagulopathy</article-title>. <source>Cell. Mol. Biol. Lett.</source>
<volume>27</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s11658-022-00308-w</pub-id><pub-id pub-id-type="pmid">35016612</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. M.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>J. S.</given-names></name><name><surname>Park</surname><given-names>K. S.</given-names></name><name><surname>Jeon</surname><given-names>G. S.</given-names></name><name><surname>Shon</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Intermittent hypoxia can aggravate motor neuronal loss and cognitive dysfunction in ALS mice</article-title>. <source>PLoS One</source>
<volume>8</volume>:<fpage>e81808</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0081808</pub-id>, PMID: <pub-id pub-id-type="pmid">24303073</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kmetzsch</surname><given-names>V.</given-names></name><name><surname>Anquetil</surname><given-names>V.</given-names></name><name><surname>Saracino</surname><given-names>D.</given-names></name><name><surname>Rinaldi</surname><given-names>D.</given-names></name><name><surname>Camuzat</surname><given-names>A.</given-names></name><name><surname>Gareau</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>92</volume>, <fpage>485</fpage>&#x02013;<lpage>493</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2020-324647</pub-id>, PMID: <pub-id pub-id-type="pmid">33239440</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasemann</surname><given-names>S.</given-names></name><name><surname>Haferkamp</surname><given-names>U.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Woo</surname><given-names>M. S.</given-names></name><name><surname>Heinrich</surname><given-names>F.</given-names></name><name><surname>Schweizer</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2</article-title>. <source>Stem Cell Reports</source>
<volume>17</volume>, <fpage>307</fpage>&#x02013;<lpage>320</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.stemcr.2021.12.011</pub-id>, PMID: <pub-id pub-id-type="pmid">35063125</pub-id></mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Dezso</surname><given-names>Z.</given-names></name><name><surname>MacKenzie</surname><given-names>C.</given-names></name><name><surname>Oestreicher</surname><given-names>J.</given-names></name><name><surname>Agoulnik</surname><given-names>S.</given-names></name><name><surname>Byrne</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Circulating miRNA biomarkers for Alzheimer's disease</article-title>. <source>PLoS One</source>
<volume>8</volume>:<fpage>e69807</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0069807</pub-id>, PMID: <pub-id pub-id-type="pmid">23922807</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>M. C.</given-names></name><name><surname>Liu</surname><given-names>S. C.</given-names></name><name><surname>Hsu</surname><given-names>Y. F.</given-names></name><name><surname>Wu</surname><given-names>R. M.</given-names></name></person-group> (<year>2021</year>). <article-title>The role of noncoding RNAs in Parkinson's disease: biomarkers and associations with pathogenic pathways</article-title>. <source>J. Biomed. Sci.</source>
<volume>28</volume>:<fpage>78</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12929-021-00775-x</pub-id><pub-id pub-id-type="pmid">34794432</pub-id></mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagos</surname><given-names>D.</given-names></name><name><surname>Pollara</surname><given-names>G.</given-names></name><name><surname>Henderson</surname><given-names>S.</given-names></name><name><surname>Gratrix</surname><given-names>F.</given-names></name><name><surname>Fabani</surname><given-names>M.</given-names></name><name><surname>Milne</surname><given-names>R. S.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator</article-title>. <source>Nat. Cell Biol.</source>
<volume>12</volume>, <fpage>513</fpage>&#x02013;<lpage>519</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ncb2054</pub-id>, PMID: <pub-id pub-id-type="pmid">20418869</pub-id></mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>K. S. P.</given-names></name><name><surname>Liu</surname><given-names>C. S.</given-names></name><name><surname>Rau</surname><given-names>A.</given-names></name><name><surname>Lanct&#x000f4;t</surname><given-names>K. L.</given-names></name><name><surname>K&#x000f6;hler</surname><given-names>C. A.</given-names></name><name><surname>Pakosh</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>88</volume>, <fpage>876</fpage>&#x02013;<lpage>882</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2017-316201</pub-id>, PMID: <pub-id pub-id-type="pmid">28794151</pub-id></mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>P.</given-names></name><name><surname>Bossers</surname><given-names>K.</given-names></name><name><surname>Janky</surname><given-names>R.</given-names></name><name><surname>Salta</surname><given-names>E.</given-names></name><name><surname>Frigerio</surname><given-names>C. S.</given-names></name><name><surname>Barbash</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Alteration of the microRNA network during the progression of Alzheimer's disease</article-title>. <source>EMBO Mol. Med.</source>
<volume>5</volume>, <fpage>1613</fpage>&#x02013;<lpage>1634</lpage>. doi: <pub-id pub-id-type="doi">10.1002/emmm.201201974</pub-id>, PMID: <pub-id pub-id-type="pmid">24014289</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lest&#x000f3;n Pinilla</surname><given-names>L.</given-names></name><name><surname>Ugun-Klusek</surname><given-names>A.</given-names></name><name><surname>Rutella</surname><given-names>S.</given-names></name><name><surname>De Girolamo</surname><given-names>L. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Hypoxia signaling in Parkinson's disease: there is use in asking "what HIF?"</article-title>. <source>Biology</source>
<volume>10</volume>:<fpage>723</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biology10080723</pub-id>, PMID: <pub-id pub-id-type="pmid">34439955</pub-id></mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Bedlack</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis</article-title>. <source>Muscle Nerve</source>
<volume>64</volume>, <fpage>E13</fpage>&#x02013;<lpage>e5</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.27351</pub-id>, PMID: <pub-id pub-id-type="pmid">34131925</pub-id></mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q. S.</given-names></name><name><surname>Cai</surname><given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Integrated miRNA-Seq and mRNA-Seq study to identify miRNAs associated with Alzheimer's disease using post-mortem brain tissue samples</article-title>. <source>Front. Neurosci.</source>
<volume>15</volume>:<fpage>620899</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2021.800560</pub-id>, PMID: <pub-id pub-id-type="pmid">33833661</pub-id></mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C. X.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Lv</surname><given-names>S. K.</given-names></name><name><surname>Li</surname><given-names>J. H.</given-names></name><name><surname>Li</surname><given-names>L. L.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name></person-group> (<year>2021</year>). <article-title>Whole-transcriptome RNA sequencing reveals significant differentially expressed mRNAs, miRNAs, and lncRNAs and related regulating biological pathways in the peripheral blood of COVID-19 patients</article-title>. <source>Mediat. Inflamm.</source>
<volume>2021</volume>:<fpage>6635925</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2021/6635925</pub-id>, PMID: <pub-id pub-id-type="pmid">33833618</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Eteleeb</surname><given-names>A.</given-names></name><name><surname>Buchser</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Xiong</surname><given-names>C.</given-names></name><name><surname>Payne</surname><given-names>P. R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Weakly activated core inflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer's disease</article-title>. <source>bioRxiv</source>. doi: <pub-id pub-id-type="doi">10.1101/2021.12.23.473930</pub-id>, PMID: <pub-id pub-id-type="pmid">34981055</pub-id></mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Differential microRNA expression in the peripheral blood from human patients with COVID-19</article-title>. <source>J. Clin. Lab. Anal.</source>
<volume>34</volume>:<fpage>e23590</fpage>. doi: <pub-id pub-id-type="doi">10.1002/jcla.23590</pub-id>, PMID: <pub-id pub-id-type="pmid">32960473</pub-id></mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>P. H.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Ou</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling</article-title>. <source>Biochim. Biophys. Acta Mol. basis Dis.</source>
<volume>1867</volume>:<fpage>166260</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbadis.2021.166260</pub-id>, PMID: <pub-id pub-id-type="pmid">34461258</pub-id></mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Du</surname><given-names>D.</given-names></name><name><surname>Zhan</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>The comprehensive landscape of miR-34a in cancer research</article-title>. <source>Cancer Metastasis Rev.</source>
<volume>40</volume>, <fpage>925</fpage>&#x02013;<lpage>948</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10555-021-09973-3</pub-id>, PMID: <pub-id pub-id-type="pmid">33959850</pub-id></mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>miR-34a-5p and miR-125b-5p attenuate A&#x003b2;-induced neurotoxicity through targeting BACE1</article-title>. <source>J. Neurol. Sci.</source>
<volume>413</volume>:<fpage>116793</fpage><pub-id pub-id-type="pmid">32251872</pub-id></mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Inflamma-MicroRNAs in Alzheimer's disease: from disease pathogenesis to therapeutic potentials</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>15</volume>:<fpage>785433</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2021.785433</pub-id>, PMID: <pub-id pub-id-type="pmid">34776873</pub-id></mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liguori</surname><given-names>M.</given-names></name><name><surname>Nuzziello</surname><given-names>N.</given-names></name><name><surname>Introna</surname><given-names>A.</given-names></name><name><surname>Consiglio</surname><given-names>A.</given-names></name><name><surname>Licciulli</surname><given-names>F.</given-names></name><name><surname>D'Errico</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Dysregulation of MicroRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis</article-title>. <source>Front. Mol. Neurosci.</source>
<volume>11</volume>:<fpage>288</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2018.00288</pub-id>, PMID: <pub-id pub-id-type="pmid">30210287</pub-id></mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>Y. Y.</given-names></name><name><surname>Maruff</surname><given-names>P.</given-names></name><name><surname>Barth&#x000e9;lemy</surname><given-names>N. R.</given-names></name><name><surname>Goate</surname><given-names>A.</given-names></name><name><surname>Hassenstab</surname><given-names>J.</given-names></name><name><surname>Sato</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Association of BDNF Val66Met with tau hyperphosphorylation and cognition in dominantly inherited Alzheimer disease</article-title>. <source>JAMA Neurol.</source>, <volume>79(3)</volume>, <fpage>261</fpage>&#x02013;<lpage>270</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2021.5181</pub-id>, PMID: <pub-id pub-id-type="pmid">35099506</pub-id></mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>A.</given-names></name><name><surname>Domingues</surname><given-names>R.</given-names></name><name><surname>Setz</surname><given-names>C.</given-names></name><name><surname>Outeiro</surname><given-names>T. F.</given-names></name><name><surname>Krisko</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2: at the crossroad between aging and neurodegeneration</article-title>. <source>Mov. Disord.</source>
<volume>35</volume>, <fpage>716</fpage>&#x02013;<lpage>720</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.28084</pub-id>, PMID: <pub-id pub-id-type="pmid">32291797</pub-id></mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>T.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Guan</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>miRNAs and target genes in the blood as biomarkers for the early diagnosis of Parkinson's disease</article-title>. <source>BMC Syst. Biol.</source>
<volume>13</volume>:<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12918-019-0680-4</pub-id><pub-id pub-id-type="pmid">30665415</pub-id></mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Hossinger</surname><given-names>A.</given-names></name><name><surname>Heum&#x000fc;ller</surname><given-names>S. E.</given-names></name><name><surname>Hornberger</surname><given-names>A.</given-names></name><name><surname>Buravlova</surname><given-names>O.</given-names></name><name><surname>Konstantoulea</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>:<fpage>5739</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-021-25855-2</pub-id><pub-id pub-id-type="pmid">34667166</pub-id></mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wen</surname><given-names>Y. Z.</given-names></name><name><surname>Huang</surname><given-names>Z. L.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J. H.</given-names></name><name><surname>Luo</surname><given-names>Y. H.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>SARS-CoV-2 causes a significant stress response mediated by small RNAs in the blood of COVID-19 patients</article-title>. <source>Mol. Ther. Nucleic Acids</source>
<volume>27</volume>, <fpage>751</fpage>&#x02013;<lpage>762</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.omtn.2021.12.034</pub-id>, PMID: <pub-id pub-id-type="pmid">35003892</pub-id></mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Ot&#x000ed;n</surname><given-names>C.</given-names></name><name><surname>Blasco</surname><given-names>M. A.</given-names></name><name><surname>Partridge</surname><given-names>L.</given-names></name><name><surname>Serrano</surname><given-names>M.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>The hallmarks of aging</article-title>. <source>Cells</source>
<volume>153</volume>, <fpage>1194</fpage>&#x02013;<lpage>1217</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2013.05.039</pub-id>, PMID: <pub-id pub-id-type="pmid">23746838</pub-id></mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Ramirez</surname><given-names>M. A.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Pryce</surname><given-names>G.</given-names></name><name><surname>Simpson</surname><given-names>J. E.</given-names></name><name><surname>Reijerkerk</surname><given-names>A.</given-names></name><name><surname>King-Robson</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation</article-title>. <source>FASEB J.</source>
<volume>28</volume>, <fpage>2551</fpage>&#x02013;<lpage>2565</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.13-248880</pub-id>, PMID: <pub-id pub-id-type="pmid">24604078</pub-id></mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorente</surname><given-names>L.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>M. M.</given-names></name><name><surname>Gonz&#x000e1;lez-Rivero</surname><given-names>A. F.</given-names></name><name><surname>P&#x000e9;rez-Cejas</surname><given-names>A.</given-names></name><name><surname>Argueso</surname><given-names>M.</given-names></name><name><surname>Perez</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Blood concentrations of proapoptotic sFas and antiapoptotic Bcl2 and COVID-19 patient mortality</article-title>. <source>Expert. Rev. Mol. Diagn.</source>
<volume>21</volume>, <fpage>837</fpage>&#x02013;<lpage>844</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14737159.2021.1941880</pub-id>, PMID: <pub-id pub-id-type="pmid">34128765</pub-id></mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>S. S.</given-names></name><name><surname>Wang</surname><given-names>Z. H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Day</surname><given-names>J. X.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Akt phosphorylates NQO1 and triggers its degradation, abolishing its Antioxidative activities in Parkinson's disease</article-title>. <source>J. Neurosci.</source>
<volume>39</volume>, <fpage>7291</fpage>&#x02013;<lpage>7305</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0625-19.2019</pub-id>, PMID: <pub-id pub-id-type="pmid">31358653</pub-id></mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>). <article-title>MicroRNA-34/449 family and viral infections</article-title>. <source>Virus Res.</source>
<volume>260</volume>, <fpage>1</fpage>&#x02013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.virusres.2018.11.001</pub-id>, PMID: <pub-id pub-id-type="pmid">30412711</pub-id></mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Mu</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Expression, regulation and function of microRNAs in multiple sclerosis</article-title>. <source>Int. J. Med. Sci.</source>
<volume>11</volume>, <fpage>810</fpage>&#x02013;<lpage>818</lpage>. doi: <pub-id pub-id-type="doi">10.7150/ijms.8647</pub-id>, PMID: <pub-id pub-id-type="pmid">24936144</pub-id></mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammana</surname><given-names>S.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Cavalli</surname><given-names>E.</given-names></name><name><surname>Basile</surname><given-names>M. S.</given-names></name><name><surname>Fagone</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis</article-title>. <source>Oncotarget</source>
<volume>9</volume>, <fpage>8263</fpage>&#x02013;<lpage>8277</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.23862</pub-id>, PMID: <pub-id pub-id-type="pmid">29492193</pub-id></mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandolesi</surname><given-names>G.</given-names></name><name><surname>De Vito</surname><given-names>F.</given-names></name><name><surname>Musella</surname><given-names>A.</given-names></name><name><surname>Gentile</surname><given-names>A.</given-names></name><name><surname>Bullitta</surname><given-names>S.</given-names></name><name><surname>Fresegna</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>miR-142-3p is a key regulator of IL-1&#x003b2;-dependent synaptopathy in neuroinflammation</article-title>. <source>J. Neurosci.</source>
<volume>37</volume>, <fpage>546</fpage>&#x02013;<lpage>561</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0851-16.2016</pub-id>, PMID: <pub-id pub-id-type="pmid">28100738</pub-id></mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China</article-title>. <source>JAMA Neurol.</source>
<volume>77</volume>, <fpage>683</fpage>&#x02013;<lpage>690</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.1127</pub-id>, PMID: <pub-id pub-id-type="pmid">32275288</pub-id></mixed-citation></ref><ref id="ref150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>March-Diaz</surname><given-names>R.</given-names></name><name><surname>Lara-Ure&#x000f1;a</surname><given-names>N.</given-names></name><name><surname>Romero-Molina</surname><given-names>C.</given-names></name><name><surname>Heras-Garvin</surname><given-names>A.</given-names></name><name><surname>Ortega-de San Luis</surname><given-names>C.</given-names></name><name><surname>Alvarez-Vergara</surname><given-names>M. I.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Hypoxia compromises the mitochondrial metabolism of Alzheimer&#x02019;s disease microglia via HIF1. Nature</article-title>. <source>Aging</source>
<volume>1</volume>, <fpage>385</fpage>&#x02013;<lpage>399</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s43587-021-00054-2</pub-id></mixed-citation></ref><ref id="ref151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-Fleta</surname><given-names>P.</given-names></name><name><surname>Vera-Tom&#x000e9;</surname><given-names>P.</given-names></name><name><surname>Jim&#x000e9;nez-Fern&#x000e1;ndez</surname><given-names>M.</given-names></name><name><surname>Requena</surname><given-names>S.</given-names></name><name><surname>Roy-Vallejo</surname><given-names>E.</given-names></name><name><surname>Sanz-Garc&#x000ed;a</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>A differential signature of circulating miRNAs and cytokines between COVID-19 and community-acquired pneumonia uncovers novel physiopathological mechanisms of COVID-19</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>:<fpage>815651</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.815651</pub-id>, PMID: <pub-id pub-id-type="pmid">35087533</pub-id></mixed-citation></ref><ref id="ref152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matamala</surname><given-names>J. M.</given-names></name><name><surname>Arias-Carrasco</surname><given-names>R.</given-names></name><name><surname>Sanchez</surname><given-names>C.</given-names></name><name><surname>Uhrig</surname><given-names>M.</given-names></name><name><surname>Bargsted</surname><given-names>L.</given-names></name><name><surname>Matus</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Genome-wide circulating microRNA expression profiling reveals potential biomarkers for amyotrophic lateral sclerosis</article-title>. <source>Neurobiol. Aging</source>
<volume>64</volume>, <fpage>123</fpage>&#x02013;<lpage>138</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.12.020</pub-id>, PMID: <pub-id pub-id-type="pmid">29458840</pub-id></mixed-citation></ref><ref id="ref153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>J. T.</given-names></name><name><surname>Enguita</surname><given-names>F. J.</given-names></name><name><surname>Taylor</surname><given-names>D.</given-names></name><name><surname>Griffin</surname><given-names>R. J.</given-names></name><name><surname>Priebe</surname><given-names>W.</given-names></name><name><surname>Emmett</surname><given-names>M. R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Role of miR-2392 in driving SARS-CoV-2 infection</article-title>. <source>Cell Rep.</source>
<volume>37</volume>:<fpage>109839</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2021.109839</pub-id>, PMID: <pub-id pub-id-type="pmid">34624208</pub-id></mixed-citation></ref><ref id="ref154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGettrick</surname><given-names>A. F.</given-names></name><name><surname>O'Neill</surname><given-names>L. A. J.</given-names></name></person-group> (<year>2020</year>). <article-title>The role of HIF in immunity and inflammation</article-title>. <source>Cell Metab.</source>
<volume>32</volume>, <fpage>524</fpage>&#x02013;<lpage>536</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2020.08.002</pub-id>, PMID: <pub-id pub-id-type="pmid">32853548</pub-id></mixed-citation></ref><ref id="ref155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>C. N.</given-names></name><name><surname>Broihier</surname><given-names>H. T.</given-names></name></person-group> (<year>2018</year>). <article-title>Keeping neurons young and foxy: FoxOs promote neuronal plasticity</article-title>. <source>Trends Genet.</source>
<volume>34</volume>, <fpage>65</fpage>&#x02013;<lpage>78</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tig.2017.10.002</pub-id>, PMID: <pub-id pub-id-type="pmid">29102406</pub-id></mixed-citation></ref><ref id="ref156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meidert</surname><given-names>A. S.</given-names></name><name><surname>Hermann</surname><given-names>S.</given-names></name><name><surname>Brandes</surname><given-names>F.</given-names></name><name><surname>Kirchner</surname><given-names>B.</given-names></name><name><surname>Buschmann</surname><given-names>D.</given-names></name><name><surname>Billaud</surname><given-names>J. N.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Extracellular vesicle associated miRNAs regulate signaling pathways involved in COVID-19 pneumonia and the progression to severe acute respiratory corona virus-2 syndrome</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>:<fpage>784028</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.784028</pub-id>, PMID: <pub-id pub-id-type="pmid">34956213</pub-id></mixed-citation></ref><ref id="ref157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercado</surname><given-names>N. M.</given-names></name><name><surname>Stancati</surname><given-names>J. A.</given-names></name><name><surname>Sortwell</surname><given-names>C. E.</given-names></name><name><surname>Mueller</surname><given-names>R. L.</given-names></name><name><surname>Boezwinkle</surname><given-names>S. A.</given-names></name><name><surname>Duffy</surname><given-names>M. F.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats</article-title>. <source>Neurobiol. Dis.</source>
<volume>148</volume>:<fpage>105175</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2020.105175</pub-id>, PMID: <pub-id pub-id-type="pmid">33188920</pub-id></mixed-citation></ref><ref id="ref158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>B.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>SARS-CoV-2-induced overexpression of miR-4485 suppresses osteogenic differentiation and impairs fracture healing</article-title>. <source>Int. J. Biol. Sci.</source>
<volume>17</volume>, <fpage>1277</fpage>&#x02013;<lpage>1288</lpage>. doi: <pub-id pub-id-type="doi">10.7150/ijbs.56657</pub-id>, PMID: <pub-id pub-id-type="pmid">33867845</pub-id></mixed-citation></ref><ref id="ref159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Rezk</surname><given-names>A.</given-names></name><name><surname>Misirliyan</surname><given-names>H.</given-names></name><name><surname>Moore</surname><given-names>C.</given-names></name><name><surname>Farooqi</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected]</article-title>. <source>PLoS One</source>
<volume>9</volume>:<fpage>e105421</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0105421</pub-id>, PMID: <pub-id pub-id-type="pmid">25136908</pub-id></mixed-citation></ref><ref id="ref160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanta</surname><given-names>T. K.</given-names></name><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Arina</surname><given-names>P.</given-names></name><name><surname>Defilippi</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Molecular insights into the MAPK Cascade during viral infection: potential crosstalk between HCQ and HCQ analogues</article-title>. <source>Biomed. Res. Int.</source>
<volume>2020</volume>:<fpage>8827752</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2020/8827752</pub-id>, PMID: <pub-id pub-id-type="pmid">33426074</pub-id></mixed-citation></ref><ref id="ref161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagu</surname><given-names>P.</given-names></name><name><surname>Parashar</surname><given-names>A.</given-names></name><name><surname>Behl</surname><given-names>T.</given-names></name><name><surname>Mehta</surname><given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>CNS implications of COVID-19: a comprehensive review</article-title>. <source>Rev. Neurosci.</source>
<volume>32</volume>, <fpage>219</fpage>&#x02013;<lpage>234</lpage>. doi: <pub-id pub-id-type="doi">10.1515/revneuro-2020-0070</pub-id><pub-id pub-id-type="pmid">33550782</pub-id></mixed-citation></ref><ref id="ref162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>R. R.</given-names></name><name><surname>Shakya</surname><given-names>A. K.</given-names></name><name><surname>Aladwan</surname><given-names>S. M.</given-names></name><name><surname>El-Tanani</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Kinase inhibitors as potential therapeutic agents in the treatment of COVID-19</article-title>. <source>Front. Pharmacol.</source>
<volume>13</volume>:<fpage>806568</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2022.806568</pub-id>, PMID: <pub-id pub-id-type="pmid">35444538</pub-id></mixed-citation></ref><ref id="ref163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwald</surname><given-names>M.</given-names></name><name><surname>Migdalska-S&#x00119;k</surname><given-names>M.</given-names></name><name><surname>Brzezia&#x00144;ska-Lasota</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Evaluation of selected MicroRNAs expression in remission phase of multiple sclerosis and their potential link to cognition, depression, and disability</article-title>. <source>J. Mol. Neurosci.</source>
<volume>63</volume>, <fpage>275</fpage>&#x02013;<lpage>282</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12031-017-0977-y</pub-id>, PMID: <pub-id pub-id-type="pmid">29043654</pub-id></mixed-citation></ref><ref id="ref164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunomura</surname><given-names>A.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>RNA and oxidative stress in Alzheimer's disease: focus on microRNAs</article-title>. <source>Oxidative Med. Cell. Longev.</source>
<volume>2020</volume>:<fpage>2638130</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2020/2638130</pub-id>, PMID: <pub-id pub-id-type="pmid">33312335</pub-id></mixed-citation></ref><ref id="ref165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oli&#x000e8;re</surname><given-names>S.</given-names></name><name><surname>Douville</surname><given-names>R.</given-names></name><name><surname>Sze</surname><given-names>A.</given-names></name><name><surname>Belgnaoui</surname><given-names>S. M.</given-names></name><name><surname>Hiscott</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis</article-title>. <source>Cytokine Growth Factor Rev.</source>
<volume>22</volume>, <fpage>197</fpage>&#x02013;<lpage>210</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cytogfr.2011.08.002</pub-id>, PMID: <pub-id pub-id-type="pmid">21924945</pub-id></mixed-citation></ref><ref id="ref166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>S. R.</given-names></name><name><surname>Dion&#x000ed;sio</surname><given-names>P. A.</given-names></name><name><surname>Correia Guedes</surname><given-names>L.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>N.</given-names></name><name><surname>Coelho</surname><given-names>M.</given-names></name><name><surname>Rosa</surname><given-names>M. M.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Circulating inflammatory miRNAs associated with Parkinson's disease pathophysiology</article-title>. <source>Biomol. Ther.</source>
<volume>10</volume>:<fpage>945</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biom10060945</pub-id>, PMID: <pub-id pub-id-type="pmid">32585840</pub-id></mixed-citation></ref><ref id="ref167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakpoor</surname><given-names>J.</given-names></name><name><surname>Noyce</surname><given-names>A.</given-names></name><name><surname>Goldacre</surname><given-names>R.</given-names></name><name><surname>Selkihova</surname><given-names>M.</given-names></name><name><surname>Mullin</surname><given-names>S.</given-names></name><name><surname>Schrag</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Viral hepatitis and Parkinson disease: a national record-linkage study</article-title>. <source>Neurology</source>
<volume>88</volume>, <fpage>1630</fpage>&#x02013;<lpage>1633</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000003848</pub-id>, PMID: <pub-id pub-id-type="pmid">28356465</pub-id></mixed-citation></ref><ref id="ref168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panda</surname><given-names>M.</given-names></name><name><surname>Kalita</surname><given-names>E.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>K.</given-names></name><name><surname>Rao</surname><given-names>A.</given-names></name><name><surname>Prajapati</surname><given-names>V. K.</given-names></name></person-group> (<year>2022</year>). <article-title>MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies</article-title>. <source>Life Sci.</source>
<volume>305</volume>:<fpage>120761</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2022.120761</pub-id>, PMID: <pub-id pub-id-type="pmid">35787998</pub-id></mixed-citation></ref><ref id="ref169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parray</surname><given-names>A.</given-names></name><name><surname>Mir</surname><given-names>F. A.</given-names></name><name><surname>Doudin</surname><given-names>A.</given-names></name><name><surname>Iskandarani</surname><given-names>A.</given-names></name><name><surname>Danjuma</surname><given-names>M. M.</given-names></name><name><surname>Kuni</surname><given-names>R. A. T.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>SnoRNAs and miRNAs networks underlying COVID-19 disease severity</article-title>. <source>Vaccines</source>
<volume>9</volume>:<fpage>1056</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9101056</pub-id>, PMID: <pub-id pub-id-type="pmid">34696164</pub-id></mixed-citation></ref><ref id="ref170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>T.</given-names></name><name><surname>Meyer</surname><given-names>K.</given-names></name><name><surname>Geerling</surname><given-names>L.</given-names></name><name><surname>Isbell</surname><given-names>T. S.</given-names></name><name><surname>Hoft</surname><given-names>D. F.</given-names></name><name><surname>Brien</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells</article-title>. <source>PLoS Pathog.</source>
<volume>16</volume>:<fpage>e1009128</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1009128</pub-id>, PMID: <pub-id pub-id-type="pmid">33284859</pub-id></mixed-citation></ref><ref id="ref171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S.</given-names></name><name><surname>Bravo V&#x000e1;zquez</surname><given-names>L. A.</given-names></name><name><surname>Reyes-P&#x000e9;rez</surname><given-names>P. R.</given-names></name><name><surname>Estrada-Meza</surname><given-names>C.</given-names></name><name><surname>Aponte Alburquerque</surname><given-names>R. A.</given-names></name><name><surname>Pathak</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: a mini-review</article-title>. <source>Virus Res.</source>
<volume>308</volume>:<fpage>198631</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.virusres.2021.198631</pub-id>, PMID: <pub-id pub-id-type="pmid">34788642</pub-id></mixed-citation></ref><ref id="ref172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname><given-names>A. E.</given-names></name><name><surname>Sandeep</surname><given-names>B. V.</given-names></name><name><surname>Rao</surname><given-names>B. G.</given-names></name><name><surname>Kalpana</surname><given-names>V. L.</given-names></name></person-group> (<year>2020</year>). <article-title>Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>:<fpage>583777</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2020.583777</pub-id>, PMID: <pub-id pub-id-type="pmid">33708109</pub-id></mixed-citation></ref><ref id="ref173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichler</surname><given-names>S.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Hartl</surname><given-names>D.</given-names></name><name><surname>Gasparoni</surname><given-names>G.</given-names></name><name><surname>Leidinger</surname><given-names>P.</given-names></name><name><surname>Keller</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>The miRNome of Alzheimer's disease: consistent downregulation of the miR-132/212 cluster</article-title>. <source>Neurobiol. Aging</source>
<volume>50</volume>, <fpage>167.e1</fpage>&#x02013;<lpage>167.e10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.09.019</pub-id>, PMID: <pub-id pub-id-type="pmid">27816213</pub-id></mixed-citation></ref><ref id="ref174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrasik</surname><given-names>S.</given-names></name><name><surname>Dziedzic</surname><given-names>A.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name><name><surname>Starosta</surname><given-names>M.</given-names></name><name><surname>Saluk-Bijak</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Circulating miRNAs as potential biomarkers distinguishing relapsing-remitting from secondary progressive multiple sclerosis. A review</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>22</volume>. doi: <pub-id pub-id-type="doi">10.3390/ijms222111887</pub-id>, PMID: <pub-id pub-id-type="pmid">34769314</pub-id></mixed-citation></ref><ref id="ref175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimenta</surname><given-names>R.</given-names></name><name><surname>Viana</surname><given-names>N. I.</given-names></name><name><surname>Dos Santos</surname><given-names>G. A.</given-names></name><name><surname>Candido</surname><given-names>P.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>V. R.</given-names></name><name><surname>Rom&#x000e3;o</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>MiR-200c-3p expression may be associated with worsening of the clinical course of patients with COVID-19</article-title>. <source>Mol. Biol. Res. Commun.</source>
<volume>10</volume>, <fpage>141</fpage>&#x02013;<lpage>147</lpage>. doi: <pub-id pub-id-type="doi">10.22099/mbrc.2021.40555.1631</pub-id>, PMID: <pub-id pub-id-type="pmid">34476267</pub-id></mixed-citation></ref><ref id="ref176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Single-cell RNA sequencing analysis of the Immunometabolic rewiring and Immunopathogenesis of coronavirus disease 2019</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>:<fpage>651656</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.651656</pub-id>, PMID: <pub-id pub-id-type="pmid">33936072</pub-id></mixed-citation></ref><ref id="ref177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Ge</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Dysregulated microRNA expression in serum of non-vaccinated children with varicella</article-title>. <source>Viruses</source>
<volume>6</volume>, <fpage>1823</fpage>&#x02013;<lpage>1836</lpage>. doi: <pub-id pub-id-type="doi">10.3390/v6041823</pub-id>, PMID: <pub-id pub-id-type="pmid">24759212</pub-id></mixed-citation></ref><ref id="ref178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>X. Y.</given-names></name><name><surname>Zhang</surname><given-names>S. P.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name><name><surname>Loh</surname><given-names>Y. P.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis</article-title>. <source>JAMA Neurol.</source>
<volume>73</volume>, <fpage>1316</fpage>&#x02013;<lpage>1324</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2016.2742</pub-id>, PMID: <pub-id pub-id-type="pmid">27668667</pub-id></mixed-citation></ref><ref id="ref179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Hujie</surname><given-names>G.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>MicroRNA-132-3p alleviates neuron apoptosis and impairments of learning and memory abilities in Alzheimer's disease by downregulation of HNRNPU stabilized BACE1</article-title>. <source>Cell Cycle</source>
<volume>20</volume>, <fpage>2309</fpage>&#x02013;<lpage>2320</lpage>. doi: <pub-id pub-id-type="doi">10.1080/15384101.2021.1982507</pub-id>, PMID: <pub-id pub-id-type="pmid">34585626</pub-id></mixed-citation></ref><ref id="ref180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raheja</surname><given-names>R.</given-names></name><name><surname>Regev</surname><given-names>K.</given-names></name><name><surname>Healy</surname><given-names>B. C.</given-names></name><name><surname>Mazzola</surname><given-names>M. A.</given-names></name><name><surname>Beynon</surname><given-names>V.</given-names></name><name><surname>Von Glehn</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis</article-title>. <source>Muscle Nerve</source>
<volume>58</volume>, <fpage>261</fpage>&#x02013;<lpage>269</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.26106</pub-id>, PMID: <pub-id pub-id-type="pmid">29466830</pub-id></mixed-citation></ref><ref id="ref181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram&#x000ed;rez-de-Arellano</surname><given-names>A.</given-names></name><name><surname>Guti&#x000e9;rrez-Franco</surname><given-names>J.</given-names></name><name><surname>Sierra-Diaz</surname><given-names>E.</given-names></name><name><surname>Pereira-Su&#x000e1;rez</surname><given-names>A. L.</given-names></name></person-group> (<year>2021</year>). <article-title>The role of estradiol in the immune response against COVID-19</article-title>. <source>Hormones (Athens)</source>
<volume>20</volume>, <fpage>657</fpage>&#x02013;<lpage>667</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s42000-021-00300-7</pub-id>, PMID: <pub-id pub-id-type="pmid">34142358</pub-id></mixed-citation></ref><ref id="ref182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M.</given-names></name><name><surname>Brito-Zer&#x000f3;n</surname><given-names>P.</given-names></name><name><surname>Mariette</surname><given-names>X.</given-names></name></person-group> (<year>2021</year>). <article-title>Systemic and organ-specific immune-related manifestations of COVID-19</article-title>. <source>Nat. Rev. Rheumatol.</source>
<volume>17</volume>, <fpage>315</fpage>&#x02013;<lpage>332</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41584-021-00608-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33903743</pub-id></mixed-citation></ref><ref id="ref183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastegar-Moghaddam</surname><given-names>S. H.</given-names></name><name><surname>Ebrahimzadeh-Bideskan</surname><given-names>A.</given-names></name><name><surname>Shahba</surname><given-names>S.</given-names></name><name><surname>Malvandi</surname><given-names>A. M.</given-names></name><name><surname>Mohammadipour</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Roles of the miR-155 in Neuroinflammation and neurological disorders: a potent biological and therapeutic target</article-title>. <source>Cell. Mol. Neurobiol.</source>, <volume>43(2)</volume>, <fpage>455</fpage>&#x02013;<lpage>467</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10571-022-01200-z</pub-id>, PMID: <pub-id pub-id-type="pmid">35107690</pub-id></mixed-citation></ref><ref id="ref184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravnik-Glava&#x0010d;</surname><given-names>M.</given-names></name><name><surname>Glava&#x0010d;</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Circulating RNAs as potential biomarkers in amyotrophic lateral sclerosis</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume>. doi: <pub-id pub-id-type="doi">10.3390/ijms21051714</pub-id>, PMID: <pub-id pub-id-type="pmid">32138249</pub-id></mixed-citation></ref><ref id="ref185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razani</surname><given-names>E.</given-names></name><name><surname>Pourbagheri-Sigaroodi</surname><given-names>A.</given-names></name><name><surname>Safaroghli-Azar</surname><given-names>A.</given-names></name><name><surname>Zoghi</surname><given-names>A.</given-names></name><name><surname>Shanaki-Bavarsad</surname><given-names>M.</given-names></name><name><surname>Bashash</surname><given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>The PI3K/Akt signaling axis in Alzheimer's disease: a valuable target to stimulate or suppress?</article-title>
<source>Cell Stress Chaperones</source>
<volume>26</volume>, <fpage>871</fpage>&#x02013;<lpage>887</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12192-021-01231-3</pub-id>, PMID: <pub-id pub-id-type="pmid">34386944</pub-id></mixed-citation></ref><ref id="ref186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recabarren-Leiva</surname><given-names>D.</given-names></name><name><surname>Alarc&#x000f3;n</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>New insights into the gene expression associated to amyotrophic lateral sclerosis</article-title>. <source>Life Sci.</source>
<volume>193</volume>, <fpage>110</fpage>&#x02013;<lpage>123</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2017.12.016</pub-id>, PMID: <pub-id pub-id-type="pmid">29241710</pub-id></mixed-citation></ref><ref id="ref187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regev</surname><given-names>K.</given-names></name><name><surname>Healy</surname><given-names>B. C.</given-names></name><name><surname>Khalid</surname><given-names>F.</given-names></name><name><surname>Paul</surname><given-names>A.</given-names></name><name><surname>Chu</surname><given-names>R.</given-names></name><name><surname>Tauhid</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Association between serum MicroRNAs and magnetic resonance imaging measures of multiple sclerosis severity</article-title>. <source>JAMA Neurol.</source>
<volume>74</volume>, <fpage>275</fpage>&#x02013;<lpage>285</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2016.5197</pub-id>, PMID: <pub-id pub-id-type="pmid">28114622</pub-id></mixed-citation></ref><ref id="ref188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regev</surname><given-names>K.</given-names></name><name><surname>Healy</surname><given-names>B. C.</given-names></name><name><surname>Paul</surname><given-names>A.</given-names></name><name><surname>Diaz-Cruz</surname><given-names>C.</given-names></name><name><surname>Mazzola</surname><given-names>M. A.</given-names></name><name><surname>Raheja</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Identification of MS-specific serum miRNAs in an international multicenter study</article-title>. <source>Neurol. Neuroimmunol. Neuroinflamm.</source>
<volume>5</volume>:<fpage>e491</fpage>. doi: <pub-id pub-id-type="doi">10.1212/NXI.0000000000000491</pub-id>, PMID: <pub-id pub-id-type="pmid">30175165</pub-id></mixed-citation></ref><ref id="ref189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regev</surname><given-names>K.</given-names></name><name><surname>Paul</surname><given-names>A.</given-names></name><name><surname>Healy</surname><given-names>B.</given-names></name><name><surname>von Glenn</surname><given-names>F.</given-names></name><name><surname>Diaz-Cruz</surname><given-names>C.</given-names></name><name><surname>Gholipour</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis</article-title>. <source>Neurol. Neuroimmunol. Neuroinflamm.</source>
<volume>3</volume>:<fpage>e267</fpage>. doi: <pub-id pub-id-type="doi">10.1212/NXI.0000000000000267</pub-id>, PMID: <pub-id pub-id-type="pmid">27606352</pub-id></mixed-citation></ref><ref id="ref190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichardt</surname><given-names>L. F.</given-names></name></person-group> (<year>2006</year>). <article-title>Neurotrophin-regulated signalling pathways</article-title>. <source>Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.</source>
<volume>361</volume>, <fpage>1545</fpage>&#x02013;<lpage>1564</lpage>. doi: <pub-id pub-id-type="doi">10.1098/rstb.2006.1894</pub-id>, PMID: <pub-id pub-id-type="pmid">16939974</pub-id></mixed-citation></ref><ref id="ref191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>R. H.</given-names></name><name><surname>Petersen</surname><given-names>M. H.</given-names></name><name><surname>Willert</surname><given-names>C. W.</given-names></name><name><surname>Heinrich</surname><given-names>M.</given-names></name><name><surname>Nymann</surname><given-names>N.</given-names></name><name><surname>Dall</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model</article-title>. <source>Mol. Cell. Neurosci.</source>
<volume>88</volume>, <fpage>118</fpage>&#x02013;<lpage>129</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mcn.2017.12.009</pub-id>, PMID: <pub-id pub-id-type="pmid">29289683</pub-id></mixed-citation></ref><ref id="ref192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzuti</surname><given-names>M.</given-names></name><name><surname>Filosa</surname><given-names>G.</given-names></name><name><surname>Melzi</surname><given-names>V.</given-names></name><name><surname>Calandriello</surname><given-names>L.</given-names></name><name><surname>Dioni</surname><given-names>L.</given-names></name><name><surname>Bollati</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>MicroRNA expression analysis identifies a subset of downregulated miRNAs in ALS motor neuron progenitors</article-title>. <source>Sci. Rep.</source>
<volume>8</volume>:<fpage>10105</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-28366-1</pub-id><pub-id pub-id-type="pmid">29973608</pub-id></mixed-citation></ref><ref id="ref193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzuti</surname><given-names>M.</given-names></name><name><surname>Melzi</surname><given-names>V.</given-names></name><name><surname>Gagliardi</surname><given-names>D.</given-names></name><name><surname>Resnati</surname><given-names>D.</given-names></name><name><surname>Meneri</surname><given-names>M.</given-names></name><name><surname>Dioni</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>79</volume>:<fpage>189</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-022-04217-1</pub-id><pub-id pub-id-type="pmid">35286466</pub-id></mixed-citation></ref><ref id="ref194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>B.</given-names></name><name><surname>Kurtishi</surname><given-names>A.</given-names></name><name><surname>Vazquez-Jimenez</surname><given-names>G. R.</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>S. G.</given-names></name></person-group> (<year>2021</year>). <article-title>The intersection of Parkinson's disease, viral infections, and COVID-19</article-title>. <source>Mol. Neurobiol.</source>, <volume>58</volume>, <fpage>4477</fpage>&#x02013;<lpage>4486</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-021-02408-8</pub-id><pub-id pub-id-type="pmid">34033061</pub-id></mixed-citation></ref><ref id="ref195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names>C. M.</given-names></name><name><surname>Podyminogin</surname><given-names>R. L.</given-names></name><name><surname>Diercks</surname><given-names>A. H.</given-names></name><name><surname>Treuting</surname><given-names>P. M.</given-names></name><name><surname>Peschon</surname><given-names>J. J.</given-names></name><name><surname>Rodriguez</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>miR-144 attenuates the host response to influenza virus by targeting the TRAF6-IRF7 signaling axis</article-title>. <source>PLoS Pathog.</source>
<volume>13</volume>:<fpage>e1006305</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1006305</pub-id>, PMID: <pub-id pub-id-type="pmid">28380049</pub-id></mixed-citation></ref><ref id="ref196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roshani</surname><given-names>F.</given-names></name><name><surname>Delavar Kasmaee</surname><given-names>H.</given-names></name><name><surname>Falahati</surname><given-names>K.</given-names></name><name><surname>Arabzade</surname><given-names>G.</given-names></name><name><surname>Sohan Forooshan Moghadam</surname><given-names>A.</given-names></name><name><surname>Sanati</surname><given-names>M. H.</given-names></name></person-group> (<year>2021</year>). <article-title>Analysis of micro-RNA-144 expression profile in patients with multiple sclerosis in comparison with healthy individuals</article-title>. <source>Rep. Biochem. Mol. Biol.</source>
<volume>10</volume>, <fpage>396</fpage>&#x02013;<lpage>401</lpage>. doi: <pub-id pub-id-type="doi">10.52547/rbmb.10.3.396</pub-id>, PMID: <pub-id pub-id-type="pmid">34981016</pub-id></mixed-citation></ref><ref id="ref197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruganzu</surname><given-names>J. B.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>Q.</given-names></name><name><surname>Ding</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Downregulation of TREM2 expression exacerbates neuroinflammatory responses through TLR4-mediated MAPK signaling pathway in a transgenic mouse model of Alzheimer's disease</article-title>. <source>Mol. Immunol.</source>
<volume>142</volume>, <fpage>22</fpage>&#x02013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2021.12.018</pub-id>, PMID: <pub-id pub-id-type="pmid">34959070</pub-id></mixed-citation></ref><ref id="ref198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbatinelli</surname><given-names>J.</given-names></name><name><surname>Giuliani</surname><given-names>A.</given-names></name><name><surname>Matacchione</surname><given-names>G.</given-names></name><name><surname>Latini</surname><given-names>S.</given-names></name><name><surname>Laprovitera</surname><given-names>N.</given-names></name><name><surname>Pomponio</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients</article-title>. <source>Mech. Ageing Dev.</source>
<volume>193</volume>:<fpage>111413</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mad.2020.111413</pub-id>, PMID: <pub-id pub-id-type="pmid">33307107</pub-id></mixed-citation></ref><ref id="ref199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Buttari</surname><given-names>B.</given-names></name><name><surname>Profumo</surname><given-names>E.</given-names></name><name><surname>Tucci</surname><given-names>P.</given-names></name><name><surname>Saso</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>A perspective on Nrf2 signaling pathway for Neuroinflammation: a potential therapeutic target in Alzheimer's and Parkinson's diseases</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>15</volume>:<fpage>787258</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2021.787258</pub-id>, PMID: <pub-id pub-id-type="pmid">35126058</pub-id></mixed-citation></ref><ref id="ref200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salta</surname><given-names>E.</given-names></name><name><surname>De Strooper</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease</article-title>. <source>FASEB J.</source>
<volume>31</volume>, <fpage>424</fpage>&#x02013;<lpage>433</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.201601308</pub-id>, PMID: <pub-id pub-id-type="pmid">28148775</pub-id></mixed-citation></ref><ref id="ref201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santo</surname><given-names>E. E.</given-names></name><name><surname>Paik</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>FOXO in neural cells and diseases of the nervous system</article-title>. <source>Curr. Top. Dev. Biol.</source>
<volume>127</volume>, <fpage>105</fpage>&#x02013;<lpage>118</lpage>. doi: <pub-id pub-id-type="doi">10.1016/bs.ctdb.2017.10.002</pub-id>, PMID: <pub-id pub-id-type="pmid">29433734</pub-id></mixed-citation></ref><ref id="ref202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>S.</given-names></name><name><surname>Jun</surname><given-names>S.</given-names></name><name><surname>Rellick</surname><given-names>S.</given-names></name><name><surname>Quintana</surname><given-names>D. D.</given-names></name><name><surname>Cavendish</surname><given-names>J. Z.</given-names></name><name><surname>Simpkins</surname><given-names>J. W.</given-names></name></person-group> (<year>2016</year>). <article-title>Expression of microRNA-34a in Alzheimer's disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity</article-title>. <source>Brain Res.</source>
<volume>1646</volume>, <fpage>139</fpage>&#x02013;<lpage>151</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainres.2016.05.026</pub-id>, PMID: <pub-id pub-id-type="pmid">27235866</pub-id></mixed-citation></ref><ref id="ref203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saulle</surname><given-names>I.</given-names></name><name><surname>Garziano</surname><given-names>M.</given-names></name><name><surname>Fenizia</surname><given-names>C.</given-names></name><name><surname>Cappelletti</surname><given-names>G.</given-names></name><name><surname>Parisi</surname><given-names>F.</given-names></name><name><surname>Clerici</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>MiRNA profiling in plasma and placenta of SARS-CoV-2-infected pregnant women</article-title>. <source>Cells</source>
<volume>10</volume>. doi: <pub-id pub-id-type="doi">10.3390/cells10071788</pub-id>, PMID: <pub-id pub-id-type="pmid">34359957</pub-id></mixed-citation></ref><ref id="ref204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarraj</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>E. S.</given-names></name><name><surname>Colpo</surname><given-names>G. D.</given-names></name><name><surname>Hinds</surname><given-names>S. N.</given-names></name><name><surname>Morales</surname><given-names>D.</given-names></name><name><surname>Ahnstedt</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Brain injury, endothelial injury and inflammatory markers are elevated and express sex-specific alterations after COVID-19</article-title>. <source>J. Neuroinflammation</source>
<volume>18</volume>:<fpage>277</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-021-02323-8</pub-id><pub-id pub-id-type="pmid">34838058</pub-id></mixed-citation></ref><ref id="ref205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepramaniam</surname><given-names>S.</given-names></name><name><surname>Armugam</surname><given-names>A.</given-names></name><name><surname>Lim</surname><given-names>K. Y.</given-names></name><name><surname>Karolina</surname><given-names>D. S.</given-names></name><name><surname>Swaminathan</surname><given-names>P.</given-names></name><name><surname>Tan</surname><given-names>J. R.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia</article-title>. <source>J. Biol. Chem.</source>
<volume>285</volume>, <fpage>29223</fpage>&#x02013;<lpage>29230</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M110.144576</pub-id>, PMID: <pub-id pub-id-type="pmid">20628061</pub-id></mixed-citation></ref><ref id="ref206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serpente</surname><given-names>M.</given-names></name><name><surname>Fenoglio</surname><given-names>C.</given-names></name><name><surname>D'Anca</surname><given-names>M.</given-names></name><name><surname>Arcaro</surname><given-names>M.</given-names></name><name><surname>Sorrentino</surname><given-names>F.</given-names></name><name><surname>Visconte</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>MiRNA profiling in plasma neural-derived small extracellular vesicles from patients with Alzheimer's disease</article-title>. <source>Cells</source>
<volume>9</volume>. doi: <pub-id pub-id-type="doi">10.3390/cells9061443</pub-id>, PMID: <pub-id pub-id-type="pmid">32531989</pub-id></mixed-citation></ref><ref id="ref207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfera</surname><given-names>A.</given-names></name><name><surname>Osorio</surname><given-names>C.</given-names></name><name><surname>Maguire</surname><given-names>G.</given-names></name><name><surname>Rahman</surname><given-names>L.</given-names></name><name><surname>Afzaal</surname><given-names>J.</given-names></name><name><surname>Cummings</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>COVID-19, ferrosenescence and neurodegeneration, a mini-review</article-title>. <source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source>
<volume>109</volume>:<fpage>110230</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pnpbp.2020.110230</pub-id></mixed-citation></ref><ref id="ref208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X. N.</given-names></name><name><surname>Niu</surname><given-names>L. D.</given-names></name><name><surname>Wang</surname><given-names>Y. J.</given-names></name><name><surname>Cao</surname><given-names>X. P.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Tan</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>90</volume>, <fpage>590</fpage>&#x02013;<lpage>598</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2018-319148</pub-id>, PMID: <pub-id pub-id-type="pmid">30630955</pub-id></mixed-citation></ref><ref id="ref209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>A.</given-names></name><name><surname>Mukhametshina</surname><given-names>R. T.</given-names></name><name><surname>Taghizadeh</surname><given-names>S.</given-names></name><name><surname>V&#x000e1;squez-Pacheco</surname><given-names>E.</given-names></name><name><surname>Cabrera-Fuentes</surname><given-names>H.</given-names></name><name><surname>Rizvanov</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>MicroRNA-142 is a multifaceted regulator in organogenesis, homeostasis, and disease</article-title>. <source>Dev. Dyn.</source>
<volume>246</volume>, <fpage>285</fpage>&#x02013;<lpage>290</lpage>. doi: <pub-id pub-id-type="doi">10.1002/dvdy.24477</pub-id>, PMID: <pub-id pub-id-type="pmid">27884048</pub-id></mixed-citation></ref><ref id="ref210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Y.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Aberrant expression of microRNA-132-3p and microRNA-146a-5p in Parkinson's disease patients</article-title>. <source>Open Life Sci.</source>
<volume>15</volume>, <fpage>647</fpage>&#x02013;<lpage>653</lpage>. doi: <pub-id pub-id-type="doi">10.1515/biol-2020-0060</pub-id>, PMID: <pub-id pub-id-type="pmid">33817253</pub-id></mixed-citation></ref><ref id="ref211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidiropoulos</surname><given-names>K.</given-names></name><name><surname>Viteri</surname><given-names>G.</given-names></name><name><surname>Sevilla</surname><given-names>C.</given-names></name><name><surname>Jupe</surname><given-names>S.</given-names></name><name><surname>Webber</surname><given-names>M.</given-names></name><name><surname>Orlic-Milacic</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Reactome enhanced pathway visualization</article-title>. <source>Bioinformatics</source>
<volume>33</volume>, <fpage>3461</fpage>&#x02013;<lpage>3467</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btx441</pub-id>, PMID: <pub-id pub-id-type="pmid">29077811</pub-id></mixed-citation></ref><ref id="ref212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siedlecki-Wullich</surname><given-names>D.</given-names></name><name><surname>Mi&#x000f1;ano-Molina</surname><given-names>A. J.</given-names></name><name><surname>Rodr&#x000ed;guez-&#x000c1;lvarez</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>microRNAs as early biomarkers of Alzheimer's disease: a synaptic perspective</article-title>. <source>Cells</source>
<volume>10</volume>. doi: <pub-id pub-id-type="doi">10.3390/cells10010113</pub-id>, PMID: <pub-id pub-id-type="pmid">33435363</pub-id></mixed-citation></ref><ref id="ref213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slota</surname><given-names>J. A.</given-names></name><name><surname>Booth</surname><given-names>S. A.</given-names></name></person-group> (<year>2019</year>). <article-title>MicroRNAs in Neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications. Noncoding</article-title>. <source>RNA</source>
<volume>5</volume>. doi: <pub-id pub-id-type="doi">10.3390/ncrna5020035</pub-id>, PMID: <pub-id pub-id-type="pmid">31022830</pub-id></mixed-citation></ref><ref id="ref214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>P. Y.</given-names></name><name><surname>Hernandez-Rapp</surname><given-names>J.</given-names></name><name><surname>Jolivette</surname><given-names>F.</given-names></name><name><surname>Lecours</surname><given-names>C.</given-names></name><name><surname>Bisht</surname><given-names>K.</given-names></name><name><surname>Goupil</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo</article-title>. <source>Hum. Mol. Genet.</source>
<volume>24</volume>, <fpage>6721</fpage>&#x02013;<lpage>6735</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddv377</pub-id>, PMID: <pub-id pub-id-type="pmid">26362250</pub-id></mixed-citation></ref><ref id="ref215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>Y. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Identification of the role of miR-142-5p in Alzheimer's disease by comparative bioinformatics and cellular analysis</article-title>. <source>Front. Mol. Neurosci.</source>
<volume>10</volume>:<fpage>227</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2017.00227</pub-id><pub-id pub-id-type="pmid">28769761</pub-id></mixed-citation></ref><ref id="ref216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J. E.</given-names></name></person-group> (<year>2015</year>). <article-title>miR-155 is involved in Alzheimer's disease by regulating T lymphocyte function</article-title>. <source>Front. Aging Neurosci.</source>
<volume>7</volume>:<fpage>61</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2015.00061</pub-id>, PMID: <pub-id pub-id-type="pmid">25983691</pub-id></mixed-citation></ref><ref id="ref217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y. J.</given-names></name><name><surname>Li</surname><given-names>S. R.</given-names></name><name><surname>Li</surname><given-names>X. W.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>Z. X.</given-names></name><name><surname>Liu</surname><given-names>Q. S.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>The effect of estrogen replacement therapy on Alzheimer's disease and Parkinson's disease in postmenopausal women: a meta-analysis</article-title>. <source>Front. Neurosci.</source>
<volume>14</volume>:<fpage>157</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2020.00157</pub-id>, PMID: <pub-id pub-id-type="pmid">32210745</pub-id></mixed-citation></ref><ref id="ref218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;rensen</surname><given-names>S. S.</given-names></name><name><surname>Nygaard</surname><given-names>A. B.</given-names></name><name><surname>Christensen</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia - an exploratory study</article-title>. <source>Transl. Neurodegener.</source>
<volume>5</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40035-016-0053-5</pub-id>, PMID: <pub-id pub-id-type="pmid">26981236</pub-id></mixed-citation></ref><ref id="ref219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soreq</surname><given-names>H.</given-names></name><name><surname>Wolf</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>NeurimmiRs: microRNAs in the neuroimmune interface</article-title>. <source>Trends Mol. Med.</source>
<volume>17</volume>, <fpage>548</fpage>&#x02013;<lpage>555</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molmed.2011.06.009</pub-id>, PMID: <pub-id pub-id-type="pmid">21813326</pub-id></mixed-citation></ref><ref id="ref220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Tang</surname><given-names>N.</given-names></name><name><surname>Peluso</surname><given-names>M. J.</given-names></name><name><surname>Iyer</surname><given-names>N. S.</given-names></name><name><surname>Torres</surname><given-names>L.</given-names></name><name><surname>Donatelli</surname><given-names>J. L.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations</article-title>. <source>Cells</source>
<volume>10</volume>:<fpage>386</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10020386</pub-id>, PMID: <pub-id pub-id-type="pmid">33668514</pub-id></mixed-citation></ref><ref id="ref221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suo</surname><given-names>N.</given-names></name><name><surname>Guo</surname><given-names>Y. E.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name><name><surname>Gu</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>). <article-title>Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases</article-title>. <source>Glia</source>
<volume>67</volume>, <fpage>1320</fpage>&#x02013;<lpage>1332</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.23606</pub-id>, PMID: <pub-id pub-id-type="pmid">30815939</pub-id></mixed-citation></ref><ref id="ref222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y. J.</given-names></name><name><surname>Wong</surname><given-names>B. Y. X.</given-names></name><name><surname>Vaidyanathan</surname><given-names>R.</given-names></name><name><surname>Sreejith</surname><given-names>S.</given-names></name><name><surname>Chia</surname><given-names>S. Y.</given-names></name><name><surname>Kandiah</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Altered cerebrospinal fluid exosomal microRNA levels in young-onset Alzheimer's disease and frontotemporal dementia</article-title>. <source>J. Alzheimers Dis. Rep.</source>
<volume>5</volume>, <fpage>805</fpage>&#x02013;<lpage>813</lpage>. doi: <pub-id pub-id-type="doi">10.3233/ADR-210311</pub-id><pub-id pub-id-type="pmid">34870106</pub-id></mixed-citation></ref><ref id="ref223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Miao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19</article-title>. <source>Clin. Transl. Med.</source>
<volume>10</volume>:<fpage>e200</fpage>. doi: <pub-id pub-id-type="doi">10.1002/ctm2.200</pub-id>, PMID: <pub-id pub-id-type="pmid">33135345</pub-id></mixed-citation></ref><ref id="ref224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasker</surname><given-names>R.</given-names></name><name><surname>Rowlands</surname><given-names>J.</given-names></name><name><surname>Ahmed</surname><given-names>Z.</given-names></name><name><surname>Di Pietro</surname><given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>Co-expression network analysis of micro-RNAs and proteins in the Alzheimer's brain: a systematic review of studies in the last 10 years</article-title>. <source>Cells</source>
<volume>10</volume>:<fpage>3479</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10123479</pub-id>, PMID: <pub-id pub-id-type="pmid">34943987</pub-id></mixed-citation></ref><ref id="ref225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ten Bosch</surname><given-names>G. J. A.</given-names></name><name><surname>Bolk</surname><given-names>J.</given-names></name><name><surname>t Hart</surname><given-names>B. A.</given-names></name><name><surname>Laman</surname><given-names>J. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Multiple sclerosis is linked to MAPK(ERK) overactivity in microglia</article-title>. <source>J. Mol. Med.</source>
<volume>99</volume>, <fpage>1033</fpage>&#x02013;<lpage>1042</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00109-021-02080-4</pub-id>, PMID: <pub-id pub-id-type="pmid">33948692</pub-id></mixed-citation></ref><ref id="ref226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thome</surname><given-names>A. D.</given-names></name><name><surname>Harms</surname><given-names>A. S.</given-names></name><name><surname>Volpicelli-Daley</surname><given-names>L. A.</given-names></name><name><surname>Standaert</surname><given-names>D. G.</given-names></name></person-group> (<year>2016</year>). <article-title>microRNA-155 regulates alpha-Synuclein-induced inflammatory responses in models of Parkinson disease</article-title>. <source>J. Neurosci.</source>
<volume>36</volume>, <fpage>2383</fpage>&#x02013;<lpage>2390</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3900-15.2016</pub-id>, PMID: <pub-id pub-id-type="pmid">26911687</pub-id></mixed-citation></ref><ref id="ref227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Shereen</surname><given-names>M. A.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>HIF-1&#x003b1; promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19</article-title>. <source>Signal Transduct. Target. Ther.</source>
<volume>6</volume>:<fpage>308</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00726-w</pub-id>, PMID: <pub-id pub-id-type="pmid">34408131</pub-id></mixed-citation></ref><ref id="ref228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torii</surname><given-names>Y.</given-names></name><name><surname>Kawada</surname><given-names>J. I.</given-names></name><name><surname>Horiba</surname><given-names>K.</given-names></name><name><surname>Okumura</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>MicroRNA expression profiling of cerebrospinal fluid/serum exosomes in children with human herpesvirus 6-associated encephalitis/encephalopathy by high-throughput sequencing</article-title>. <source>J. Neurovirol.</source>
<volume>28</volume>, <fpage>151</fpage>&#x02013;<lpage>157</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13365-022-01058-3</pub-id>, PMID: <pub-id pub-id-type="pmid">35212942</pub-id></mixed-citation></ref><ref id="ref229"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>UGent</surname><given-names>V.</given-names></name></person-group> (<year>n.d.</year>). Bioinformatics &#x00026; Evolutionary Genomics Available at: <ext-link xlink:href="http://bioinformatics.psb.ugent.be/webtools/Venn/" ext-link-type="uri">http://bioinformatics.psb.ugent.be/webtools/Venn/</ext-link> (Accessed September 11, 2022).</mixed-citation></ref><ref id="ref230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usai</surname><given-names>C.</given-names></name><name><surname>Gibbons</surname><given-names>J. M.</given-names></name><name><surname>Pade</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Jacobs</surname><given-names>S. R. M.</given-names></name><name><surname>McKnight</surname><given-names>&#x000c1;.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>The &#x003b2;-NGF/TrkA signalling pathway is associated with the production of anti-nucleoprotein IgG in convalescent COVID-19</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>:<fpage>813300</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.813300</pub-id>, PMID: <pub-id pub-id-type="pmid">35095908</pub-id></mixed-citation></ref><ref id="ref231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varma-Doyle</surname><given-names>A. V.</given-names></name><name><surname>Lukiw</surname><given-names>W. J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Lovera</surname><given-names>J.</given-names></name><name><surname>Devier</surname><given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways</article-title>. <source>J. Neurol. Sci.</source>
<volume>420</volume>:<fpage>117202</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2020.117202</pub-id><pub-id pub-id-type="pmid">33183778</pub-id></mixed-citation></ref><ref id="ref232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavougios</surname><given-names>G. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Human coronaviruses in idiopathic Parkinson's disease: implications of SARS-CoV-2's modulation of the host's transcriptome</article-title>. <source>Infect. Genet. Evol.</source>
<volume>89</volume>:<fpage>104733</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.meegid.2021.104733</pub-id>, PMID: <pub-id pub-id-type="pmid">33516970</pub-id></mixed-citation></ref><ref id="ref233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verkhratsky</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Melino</surname><given-names>S.</given-names></name><name><surname>Melino</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases?</article-title>
<source>Biol. Direct</source>
<volume>15</volume>:<fpage>28</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13062-020-00282-3</pub-id>, PMID: <pub-id pub-id-type="pmid">33246479</pub-id></mixed-citation></ref><ref id="ref234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrabec</surname><given-names>K.</given-names></name><name><surname>Bo&#x00161;tjan&#x0010d;i&#x0010d;</surname><given-names>E.</given-names></name><name><surname>Koritnik</surname><given-names>B.</given-names></name><name><surname>Leonardis</surname><given-names>L.</given-names></name><name><surname>Dolenc Gro&#x00161;elj</surname><given-names>L.</given-names></name><name><surname>Zidar</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Differential expression of several miRNAs and the host genes AATK and DNM2 in leukocytes of sporadic ALS patients</article-title>. <source>Front. Mol. Neurosci.</source>
<volume>11</volume>:<fpage>106</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2018.00106</pub-id><pub-id pub-id-type="pmid">29670510</pub-id></mixed-citation></ref><ref id="ref235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>K.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center retrospective cohort study</article-title>. <source>Front. Med.</source>, <fpage>1</fpage>&#x02013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00716-y</pub-id><pub-id pub-id-type="pmid">32789731</pub-id></mixed-citation></ref><ref id="ref236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Qiu</surname><given-names>Z.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</article-title>. <source>Cell Res.</source>
<volume>31</volume>, <fpage>126</fpage>&#x02013;<lpage>140</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41422-020-00460-y</pub-id>, PMID: <pub-id pub-id-type="pmid">33420426</pub-id></mixed-citation></ref><ref id="ref237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>X. M.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients</article-title>. <source>Signal Transduct. Target. Ther.</source>
<volume>6</volume>:<fpage>300</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s11684-021-0854-5</pub-id><pub-id pub-id-type="pmid">34381015</pub-id></mixed-citation></ref><ref id="ref238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weckbach</surname><given-names>L. T.</given-names></name><name><surname>Schweizer</surname><given-names>L.</given-names></name><name><surname>Kraechan</surname><given-names>A.</given-names></name><name><surname>Bieber</surname><given-names>S.</given-names></name><name><surname>Ishikawa-Ankerhold</surname><given-names>H.</given-names></name><name><surname>Hausleiter</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Association of Complement and MAPK activation with SARS-CoV-2-associated myocardial inflammation</article-title>. <source>JAMA Cardiol.</source>
<volume>7</volume>, <fpage>286</fpage>&#x02013;<lpage>297</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamacardio.2021.5133</pub-id>, PMID: <pub-id pub-id-type="pmid">34910083</pub-id></mixed-citation></ref><ref id="ref239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>P. A. C.</given-names></name><name><surname>Keeley</surname><given-names>T. P.</given-names></name><name><surname>Zhuang</surname><given-names>X.</given-names></name><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Prange-Barczynska</surname><given-names>M.</given-names></name><name><surname>Tsukuda</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells</article-title>. <source>Cell Rep.</source>
<volume>35</volume>:<fpage>109020</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2021.109020</pub-id>, PMID: <pub-id pub-id-type="pmid">33852916</pub-id></mixed-citation></ref><ref id="ref240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wissler Gerdes</surname><given-names>E. O.</given-names></name><name><surname>Vanichkachorn</surname><given-names>G.</given-names></name><name><surname>Verdoorn</surname><given-names>B. P.</given-names></name><name><surname>Hanson</surname><given-names>G. J.</given-names></name><name><surname>Joshi</surname><given-names>A. Y.</given-names></name><name><surname>Murad</surname><given-names>M. H.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Role of senescence in the chronic health consequences of COVID-19</article-title>. <source>Transl. Res.</source>
<volume>241</volume>, <fpage>96</fpage>&#x02013;<lpage>108</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.trsl.2021.10.003</pub-id>, PMID: <pub-id pub-id-type="pmid">34695606</pub-id></mixed-citation></ref><ref id="ref241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Shao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Xue</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Expression of plasma IFN signaling-related miRNAs during acute SARS-CoV-2 infection and its association with RBD-IgG antibody response</article-title>. <source>Virol. J.</source>
<volume>18</volume>:<fpage>244</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12985-021-01717-7</pub-id><pub-id pub-id-type="pmid">34876159</pub-id></mixed-citation></ref><ref id="ref242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S. Y.</given-names></name><name><surname>Pan</surname><given-names>B. S.</given-names></name><name><surname>Tsai</surname><given-names>S. F.</given-names></name><name><surname>Chiang</surname><given-names>Y. T.</given-names></name><name><surname>Huang</surname><given-names>B. M.</given-names></name><name><surname>Mo</surname><given-names>F. E.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>BDNF reverses aging-related microglial activation</article-title>. <source>J. Neuroinflammation</source>
<volume>17</volume>:<fpage>210</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-020-01887-1</pub-id><pub-id pub-id-type="pmid">32664974</pub-id></mixed-citation></ref><ref id="ref243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y. F.</given-names></name><name><surname>Yu</surname><given-names>W. J.</given-names></name><name><surname>Jiang</surname><given-names>Y. H.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhen</surname><given-names>R. B.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: a case report</article-title>. <source>World J. Clin. Cases</source>
<volume>9</volume>, <fpage>5266</fpage>&#x02013;<lpage>5269</lpage>. doi: <pub-id pub-id-type="doi">10.12998/wjcc.v9.i19.5266</pub-id>, PMID: <pub-id pub-id-type="pmid">34307577</pub-id></mixed-citation></ref><ref id="ref244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>R. X.</given-names></name><name><surname>Li</surname><given-names>L. G.</given-names></name><name><surname>Liu</surname><given-names>X. W.</given-names></name><name><surname>Tian</surname><given-names>B. X.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Down regulation of miR-218, miR-124, and miR-144 relates to Parkinson's disease via activating NF-&#x003ba;B signaling</article-title>. <source>Kaohsiung J. Med. Sci.</source>
<volume>36</volume>, <fpage>786</fpage>&#x02013;<lpage>792</lpage>. doi: <pub-id pub-id-type="doi">10.1002/kjm2.12241</pub-id>, PMID: <pub-id pub-id-type="pmid">32492291</pub-id></mixed-citation></ref><ref id="ref245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B.</given-names></name><name><surname>Lei</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>SOD1 is a possible predictor of COVID-19 progression as revealed by plasma proteomics</article-title>. <source>ACS Omega</source>
<volume>6</volume>, <fpage>16826</fpage>&#x02013;<lpage>16836</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acsomega.1c01375</pub-id>, PMID: <pub-id pub-id-type="pmid">34250342</pub-id></mixed-citation></ref><ref id="ref246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>R. K.</given-names></name><name><surname>Minz</surname><given-names>E.</given-names></name><name><surname>Mehan</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Understanding abnormal c-JNK/p38MAPK signaling in amyotrophic lateral sclerosis: potential drug targets and influences on neurological disorders</article-title>. <source>CNS Neurol. Disord. Drug Targets</source>
<volume>20</volume>, <fpage>417</fpage>&#x02013;<lpage>429</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1871527320666210126113848</pub-id>, PMID: <pub-id pub-id-type="pmid">33557726</pub-id></mixed-citation></ref><ref id="ref247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>M.</given-names></name><name><surname>Qi</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Altered expression levels of MicroRNA-132 and Nurr1 in peripheral blood of Parkinson's disease: potential disease biomarkers</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>10</volume>, <fpage>2243</fpage>&#x02013;<lpage>2249</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acschemneuro.8b00460</pub-id>, PMID: <pub-id pub-id-type="pmid">30817108</pub-id></mixed-citation></ref><ref id="ref248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Lin</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Long non-coding RNA ANRIL interacts with microRNA-34a and microRNA-125a, and they all correlate with disease risk and severity of Parkinson's disease</article-title>. <source>J. Clin. Lab. Anal.</source>
<volume>36</volume>:<fpage>e24037</fpage>. doi: <pub-id pub-id-type="doi">10.1002/jcla.24037</pub-id>, PMID: <pub-id pub-id-type="pmid">34921567</pub-id></mixed-citation></ref><ref id="ref249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/IL-6R-associated cytokine storms in COVID-19 patients</article-title>. <source>Cell. Mol. Immunol.</source>
<volume>18</volume>, <fpage>1064</fpage>&#x02013;<lpage>1066</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41423-021-00652-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33637960</pub-id></mixed-citation></ref><ref id="ref250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yapasert</surname><given-names>R.</given-names></name><name><surname>Khaw-On</surname><given-names>P.</given-names></name><name><surname>Banjerdpongchai</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Coronavirus infection-associated cell death signaling and potential therapeutic targets</article-title>. <source>Molecules</source>
<volume>26</volume>:<fpage>7459</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules26247459</pub-id>, PMID: <pub-id pub-id-type="pmid">34946543</pub-id></mixed-citation></ref><ref id="ref251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Mao</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>The pathogenesis and treatment of the &#x02018;cytokine storm&#x02019; in COVID-19</article-title>. <source>J. Infect.</source>
<volume>80</volume>, <fpage>607</fpage>&#x02013;<lpage>613</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.037</pub-id>, PMID: <pub-id pub-id-type="pmid">32283152</pub-id></mixed-citation></ref><ref id="ref252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Du</surname><given-names>Q.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>X. G.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Liver injury in COVID-19: clinical features and treatment management</article-title>. <source>Virol. J.</source>
<volume>18</volume>:<fpage>121</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12985-021-01593-1</pub-id><pub-id pub-id-type="pmid">34108015</pub-id></mixed-citation></ref><ref id="ref253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zago</surname><given-names>E.</given-names></name><name><surname>Dal Molin</surname><given-names>A.</given-names></name><name><surname>Dimitri</surname><given-names>G. M.</given-names></name><name><surname>Xumerle</surname><given-names>L.</given-names></name><name><surname>Pirazzini</surname><given-names>C.</given-names></name><name><surname>Bacalini</surname><given-names>M. G.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Early downregulation of hsa-miR-144-3p in serum from drug-na&#x000ef;ve Parkinson's disease patients</article-title>. <source>Sci. Rep.</source>
<volume>12</volume>:<fpage>1330</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-022-05227-6</pub-id>, PMID: <pub-id pub-id-type="pmid">35079043</pub-id></mixed-citation></ref><ref id="ref254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>F. R.</given-names></name><name><surname>Tang</surname><given-names>L. J.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Garcia</surname><given-names>R. C.</given-names></name></person-group> (<year>2015</year>). <article-title>An update on the role of miRNA-155 in pathogenic microbial infections</article-title>. <source>Microbes Infect.</source>
<volume>17</volume>, <fpage>613</fpage>&#x02013;<lpage>621</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micinf.2015.05.007</pub-id>, PMID: <pub-id pub-id-type="pmid">26072128</pub-id></mixed-citation></ref><ref id="ref255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Bian</surname><given-names>Z.</given-names></name></person-group> (<year>2021</year>). <article-title>Alzheimer's disease and microRNA-132: a widespread pathological factor and potential therapeutic target</article-title>. <source>Front. Neurosci.</source>
<volume>15</volume>:<fpage>687973</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2021.799526</pub-id>, PMID: <pub-id pub-id-type="pmid">34108863</pub-id></mixed-citation></ref><ref id="ref256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>MicroRNA-132-3p suppresses type I IFN response through targeting IRF1 to facilitate H1N1 influenza a virus infection</article-title>. <source>Biosci. Rep.</source>
<volume>39</volume>. doi: <pub-id pub-id-type="doi">10.1042/BSR20192769</pub-id>, PMID: <pub-id pub-id-type="pmid">31746331</pub-id></mixed-citation></ref><ref id="ref257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H. T.</given-names></name></person-group> (<year>2002</year>). <article-title>MAPK signal pathways in the regulation of cell proliferation in mammalian cells</article-title>. <source>Cell Res.</source>
<volume>12</volume>, <fpage>9</fpage>&#x02013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.cr.7290105</pub-id>, PMID: <pub-id pub-id-type="pmid">11942415</pub-id></mixed-citation></ref><ref id="ref258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Tellgren-Roth</surname><given-names>C.</given-names></name><name><surname>Pettersson</surname><given-names>U.</given-names></name></person-group> (<year>2015</year>). <article-title>Fluctuating expression of microRNAs in adenovirus infected cells</article-title>. <source>Virology</source>
<volume>478</volume>, <fpage>99</fpage>&#x02013;<lpage>111</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.virol.2015.01.033</pub-id>, PMID: <pub-id pub-id-type="pmid">25744056</pub-id></mixed-citation></ref><ref id="ref259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H. Y.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>C. X.</given-names></name><name><surname>Tian</surname><given-names>R. R.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J. J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19</article-title>. <source>Signal Transduct. Target. Ther.</source>
<volume>5</volume>:<fpage>294</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-020-00457-4</pub-id><pub-id pub-id-type="pmid">33361761</pub-id></mixed-citation></ref><ref id="ref260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zha</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>MicroRNA-144: a novel biological marker and potential therapeutic target in human solid cancers</article-title>. <source>J. Cancer</source>
<volume>11</volume>, <fpage>6716</fpage>&#x02013;<lpage>6726</lpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.46293</pub-id>, PMID: <pub-id pub-id-type="pmid">33046994</pub-id></mixed-citation></ref><ref id="ref261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zingale</surname><given-names>V. D.</given-names></name><name><surname>Gugliandolo</surname><given-names>A.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>MiR-155: an important regulator of Neuroinflammation</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>23</volume>:<fpage>90</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms23010090</pub-id>, PMID: <pub-id pub-id-type="pmid">35008513</pub-id></mixed-citation></ref><ref id="ref262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>Z.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>The intersection of COVID-19 and cancer: signaling pathways and treatment implications</article-title>. <source>Mol. Cancer</source>
<volume>20</volume>:<fpage>76</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-021-01363-1</pub-id><pub-id pub-id-type="pmid">34001144</pub-id></mixed-citation></ref></ref-list><sec id="sec27"><title>Glossary</title><table-wrap position="anchor" id="tab3"><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">A&#x003b2;</td><td align="left" valign="top" rowspan="1" colspan="1">Amyloid-&#x003b2;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACHE</td><td align="left" valign="top" rowspan="1" colspan="1">Acetylcholinesterase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AD</td><td align="left" valign="top" rowspan="1" colspan="1">Alzheimer&#x02019;s disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ADAM10</td><td align="left" valign="top" rowspan="1" colspan="1">ADAM metallopeptidase domain 10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AKT</td><td align="left" valign="top" rowspan="1" colspan="1">Protein kinase B</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALS</td><td align="left" valign="top" rowspan="1" colspan="1">Amyotrophic lateral sclerosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AQP1</td><td align="left" valign="top" rowspan="1" colspan="1">Aquaporin 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AP-1</td><td align="left" valign="top" rowspan="1" colspan="1">Activator protein 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APP</td><td align="left" valign="top" rowspan="1" colspan="1">Amyloid precursor protein</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AT1</td><td align="left" valign="top" rowspan="1" colspan="1">Angiotensin II receptor type 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BACE1</td><td align="left" valign="top" rowspan="1" colspan="1">Beta-secretase 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BCL2</td><td align="left" valign="top" rowspan="1" colspan="1">BCL2 apoptosis regulator</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BDNF</td><td align="left" valign="top" rowspan="1" colspan="1">Brain-derived neurotrophic factor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003b2;-NGF</td><td align="left" valign="top" rowspan="1" colspan="1">&#x003b2;-Nerve growth factor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS</td><td align="left" valign="top" rowspan="1" colspan="1">Central nervous system</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DAVID</td><td align="left" valign="top" rowspan="1" colspan="1">Database for Annotation, Visualization and Integrated Discovery</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ERK1/2</td><td align="left" valign="top" rowspan="1" colspan="1">Extracellular signal-regulated kinase 1 and 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FDR</td><td align="left" valign="top" rowspan="1" colspan="1">False discovery rate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FOXO</td><td align="left" valign="top" rowspan="1" colspan="1">Class O of forkhead box transcription factors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GFAP</td><td align="left" valign="top" rowspan="1" colspan="1">Glial fibrillary acidic protein</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HD</td><td align="left" valign="top" rowspan="1" colspan="1">Huntington&#x02019;s disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIF-1</td><td align="left" valign="top" rowspan="1" colspan="1">Hypoxia-inducible factor 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HMDD</td><td align="left" valign="top" rowspan="1" colspan="1">Human microRNA Disease Database</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HO-1</td><td align="left" valign="top" rowspan="1" colspan="1">Haem oxygenase 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HTLV-1</td><td align="left" valign="top" rowspan="1" colspan="1">Human T-cell leukemia virus type I</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-1&#x003b2;</td><td align="left" valign="top" rowspan="1" colspan="1">Interleukin 1&#x003b2;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-2</td><td align="left" valign="top" rowspan="1" colspan="1">Interleukin 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-4</td><td align="left" valign="top" rowspan="1" colspan="1">Interleukin 4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-5</td><td align="left" valign="top" rowspan="1" colspan="1">Interleukin 5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-6</td><td align="left" valign="top" rowspan="1" colspan="1">Interleukin 6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL6ST</td><td align="left" valign="top" rowspan="1" colspan="1">IL-6 Signal transducer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-10</td><td align="left" valign="top" rowspan="1" colspan="1">Interleukin 10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL13RA1</td><td align="left" valign="top" rowspan="1" colspan="1">Interleukin 13 receptor subunit alpha 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IRF1</td><td align="left" valign="top" rowspan="1" colspan="1">Interferon regulatory factor 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JNK</td><td align="left" valign="top" rowspan="1" colspan="1">c-Jun N-terminal kinase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KEAP1</td><td align="left" valign="top" rowspan="1" colspan="1">Kelch-like ECH-associated protein 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KEGG</td><td align="left" valign="top" rowspan="1" colspan="1">Kyoto Encyclopedia of Genes and Genomes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAPK1</td><td align="left" valign="top" rowspan="1" colspan="1">Mitogen-activated protein kinase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MMP9</td><td align="left" valign="top" rowspan="1" colspan="1">Matrix metallopeptidase 9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">mRNA</td><td align="left" valign="top" rowspan="1" colspan="1">Messenger RNA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MS</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple sclerosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">mTOR</td><td align="left" valign="top" rowspan="1" colspan="1">Mammalian target of rapamycin</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NF-&#x003ba;B</td><td align="left" valign="top" rowspan="1" colspan="1">Nuclear factor kappa-light-chain-enhancer of activated B cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NfL</td><td align="left" valign="top" rowspan="1" colspan="1">Neurofilament light chain</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NLRP3</td><td align="left" valign="top" rowspan="1" colspan="1">NLR family pyrin domain containing 3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NOS1</td><td align="left" valign="top" rowspan="1" colspan="1">Nitric oxide synthase 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NRF2</td><td align="left" valign="top" rowspan="1" colspan="1">Nuclear factor erythroid 2-related factor 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD</td><td align="left" valign="top" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PS-1</td><td align="left" valign="top" rowspan="1" colspan="1">Presenilin-1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PI3K</td><td align="left" valign="top" rowspan="1" colspan="1">Phosphatidyl-inositol-3-kinase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PICALM</td><td align="left" valign="top" rowspan="1" colspan="1">phosphatidylinositol binding clathrin assembly protein</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">p-tau<sub>181</sub></td><td align="left" valign="top" rowspan="1" colspan="1">Phosphorylated tau-181</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PTEN</td><td align="left" valign="top" rowspan="1" colspan="1">Phosphatase and tensin homolog</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ROS</td><td align="left" valign="top" rowspan="1" colspan="1">Reactive oxygen species</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SIRT1</td><td align="left" valign="top" rowspan="1" colspan="1">Sirtuin 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SHC3</td><td align="left" valign="top" rowspan="1" colspan="1">SHC-transforming protein 3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SHIP1</td><td align="left" valign="top" rowspan="1" colspan="1">Inositol polyphosphate-5-phosphatase D</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOCS1</td><td align="left" valign="top" rowspan="1" colspan="1">Suppressor of cytokine signaling 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SORL1</td><td align="left" valign="top" rowspan="1" colspan="1">Sortilin related receptor 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TDP-43</td><td align="left" valign="top" rowspan="1" colspan="1">TAR DNA-binding protein 43</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TMPRSS2</td><td align="left" valign="top" rowspan="1" colspan="1">Transmembrane protease, serine 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR</td><td align="left" valign="top" rowspan="1" colspan="1">Toll-like receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TNF&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Tumor necrosis factor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TREM2</td><td align="left" valign="top" rowspan="1" colspan="1">Triggering receptor expressed on myeloid cells 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-tau</td><td align="left" valign="top" rowspan="1" colspan="1">Total tau</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UCHL1</td><td align="left" valign="top" rowspan="1" colspan="1">Ubiquitin carboxyterminal hydrolase L1</td></tr></tbody></table></table-wrap></sec></back></article>